TWI376367B - An amine derivative as a npy y5 receptor antagonist - Google Patents
An amine derivative as a npy y5 receptor antagonist Download PDFInfo
- Publication number
- TWI376367B TWI376367B TW096114901A TW96114901A TWI376367B TW I376367 B TWI376367 B TW I376367B TW 096114901 A TW096114901 A TW 096114901A TW 96114901 A TW96114901 A TW 96114901A TW I376367 B TWI376367 B TW I376367B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- substituent
- compound
- nmr
- dmso
- Prior art date
Links
- 150000001412 amines Chemical class 0.000 title claims description 20
- 102000028582 Neuropeptide Y5 receptor Human genes 0.000 title claims description 10
- 108010046593 Neuropeptide Y5 receptor Proteins 0.000 title claims description 10
- 239000002464 receptor antagonist Substances 0.000 title claims description 7
- 229940044551 receptor antagonist Drugs 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 486
- 125000001424 substituent group Chemical group 0.000 claims description 249
- 125000000217 alkyl group Chemical group 0.000 claims description 103
- -1 piperidinyldiyl Chemical group 0.000 claims description 71
- 229910052736 halogen Inorganic materials 0.000 claims description 55
- 125000000623 heterocyclic group Chemical group 0.000 claims description 53
- 150000002367 halogens Chemical class 0.000 claims description 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 33
- 239000012453 solvate Substances 0.000 claims description 31
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 14
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 230000008485 antagonism Effects 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 claims description 5
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000005493 quinolyl group Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 2
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000005248 alkyl aryloxy group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000003106 haloaryl group Chemical group 0.000 claims 1
- 125000004996 haloaryloxy group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 228
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 60
- 238000005481 NMR spectroscopy Methods 0.000 description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 239000000126 substance Substances 0.000 description 43
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 239000002904 solvent Substances 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 31
- 125000003545 alkoxy group Chemical group 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 239000002585 base Substances 0.000 description 26
- 238000002844 melting Methods 0.000 description 25
- 230000008018 melting Effects 0.000 description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 18
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 13
- 239000000460 chlorine Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 125000004414 alkyl thio group Chemical group 0.000 description 11
- 125000003277 amino group Chemical group 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 125000001624 naphthyl group Chemical group 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000012046 mixed solvent Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 101710151321 Melanostatin Proteins 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- 102400000064 Neuropeptide Y Human genes 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 6
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
- 125000005530 alkylenedioxy group Chemical group 0.000 description 5
- 230000003579 anti-obesity Effects 0.000 description 5
- 150000001540 azides Chemical class 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 229940126208 compound 22 Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 4
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 4
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 4
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 150000001602 bicycloalkyls Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940125961 compound 24 Drugs 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- GJPCTAKRQZKVCR-UHFFFAOYSA-N [Cl-].C(C)(C)[SH2+] Chemical compound [Cl-].C(C)(C)[SH2+] GJPCTAKRQZKVCR-UHFFFAOYSA-N 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 150000003973 alkyl amines Chemical class 0.000 description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 description 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 229940125710 antiobesity agent Drugs 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 125000005059 halophenyl group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000006307 alkoxy benzyl group Chemical group 0.000 description 2
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 2
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 125000006612 decyloxy group Chemical group 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- YWWNNLPSZSEZNZ-UHFFFAOYSA-N n,n-dimethyldecan-1-amine Chemical compound CCCCCCCCCCN(C)C YWWNNLPSZSEZNZ-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000004032 porphyrins Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 239000012748 slip agent Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 125000004149 thio group Chemical group *S* 0.000 description 2
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- CGVQNDZUWCSFFT-UHFFFAOYSA-N $l^{1}-oxidanyloxyethane Chemical group CCO[O] CGVQNDZUWCSFFT-UHFFFAOYSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- RZFDLDWSAAUYFW-UHFFFAOYSA-N 1,2,3,4,21,23-hexahydroporphyrin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)CCC1C=C1C=CC4=N1 RZFDLDWSAAUYFW-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- WAKJZPDCSCIDLD-UHFFFAOYSA-N 1-[6-(2-oxoimidazolidin-1-yl)hexyl]imidazolidin-2-one Chemical compound O=C1NCCN1CCCCCCN1C(=O)NCC1 WAKJZPDCSCIDLD-UHFFFAOYSA-N 0.000 description 1
- WMASLRCNNKMRFP-UHFFFAOYSA-N 1-fluoro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(F)=C1 WMASLRCNNKMRFP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- JFZJMSDDOOAOIV-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)N=C1 JFZJMSDDOOAOIV-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- UECUPGFJVNJNQA-UHFFFAOYSA-N 2-phenylbenzenethiol Chemical group SC1=CC=CC=C1C1=CC=CC=C1 UECUPGFJVNJNQA-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- IDWRJRPUIXRFRX-UHFFFAOYSA-N 3,5-dimethylpiperidine Chemical compound CC1CNCC(C)C1 IDWRJRPUIXRFRX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KGQDKWOOKMSBEF-UHFFFAOYSA-N C(C)(C)N(CC)C(C)C.[Os] Chemical compound C(C)(C)N(CC)C(C)C.[Os] KGQDKWOOKMSBEF-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
- 101000633401 Homo sapiens Neuropeptide Y receptor type 5 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- FCVHBUFELUXTLR-UHFFFAOYSA-N [Li].[AlH3] Chemical class [Li].[AlH3] FCVHBUFELUXTLR-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005138 alkoxysulfonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- JGVDBODXXHHCJH-UHFFFAOYSA-N butyl acetate;ethyl acetate Chemical compound CCOC(C)=O.CCCCOC(C)=O JGVDBODXXHHCJH-UHFFFAOYSA-N 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- 229960005286 carbaryl Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000002366 halogen compounds Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000000879 imine group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- VSPPONOIKZXUBJ-UHFFFAOYSA-N n,n-diethylethanamine;oxolane Chemical compound C1CCOC1.CCN(CC)CC VSPPONOIKZXUBJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010043412 neuropeptide Y-Y1 receptor Proteins 0.000 description 1
- 108010089579 neuropeptide Y2 receptor Proteins 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940025656 proin Drugs 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/43—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
1376367 九、發明說明: 【發明所屬之技術領域】 本發明爲有關具有ΝΡΥ Y5受體拮抗作用而作爲醫藥, 尤其抗肥胖藥有用之新穎化合物。 【先前技術】 神經胜肽Y(以下稱NPY)爲由36個胺基酸殘基而成之胜 肽,於1982年由猪腦分離。ΝΡΥ於人及動物之中樞神經 系及末梢組織廣泛分布。
於以往之報告,得知ΝΡΥ於中樞神經系中具有攝食促進 作用、抗痙攣作用、學習促進作用、抗焦慮作用、抗壓力 作用等,更有與憂鬱病、阿滋海黙型痴呆、巴金森病等中 樞神經系疾病深深關連之可能性。又於末梢組織中,ΝΡΥ 因引起血管等平滑肌或心肌之收縮,故認爲與循環器系障 礙也有關連。更知與肥胖症、糖尿病、激素異常等代謝性 疾病也有關連(參照非專利文獻1)。故ΝΡΥ受體拮抗劑對 如上述ΝΡΥ受體關連之種種疾病有成爲預防或治療藥之可 能性。 ΝΡΥ受體至今發現Υ1、Υ2、Υ3、Υ4、Υ5及Υ6之亞型( 參照非專利文獻2)。Υ5受體至少與攝食機能關連,其拮 抗劑暗示成爲抗肥胖藥(參照非專利文獻3)。 與本發明化合物類似之構造而具有ΝΡΥ Υ5受體拮抗作 用之具有磺醯基之胺衍生物記載於專利文獻1、專利文獻 2 '專利文獻3、專利文獻4等。此外,於專利文獻5、專 利文獻8、專利文獻9、專利文獻1 〇及專利文獻1 1記載 1376367 【專利文獻13】美國專利申請公開第2007/060598 冊 【專利文獻14】國際公開第2005/1 2 1 1 07號小冊 【發明內容】 發明欲解泱夕課題 本發明之目的爲提供具有優異NPY Y5受體拮抗作 新穎化合物。令專利文獻1、2記載之化合物試驗之 ,確認藥物代謝酵素之強力誘導》試驗專利文獻10 之一部分化合物之結果,有貧血誘發作用等毒性。 解決課顆:> 丰跺 本發明者致力硏究之結果,成功合成如下具有優異 Y5受體拮抗作用之新穎化合物。具有磺醯基之醯胺 物於專利文獻5公知爲具有NPY Y5受體拮抗作用之 物。但本發明者令醯胺衍生物作成胺衍生物之化合物 現與取代前之化合物相較其腦移行性大爲改善。又確 發明之化合物與專利文獻1、2之化合物相較,爲不 起藥物代謝酵素之誘導之化合物,終於完成本發明。 也即本發明爲有關: (1)如下式(I)化合物、其製藥容許鹽或這些之溶劑合物 【化1】 R1—Y—N-X-N—Z (I) I / R2 R7 [式中R1爲可有取代基之低烷基, Y 爲-s(0)n-(n 爲 1 或 2)或-CO-, 號小
用之 結果 記載 NP Y 衍生 化合 ,發 認本 易引 1376367 R2爲氫或可有取代基之低烷基, R1及R2可一起形成低伸烷基, R7爲氫或可有取代基之低烷基, X爲 可有取代基之低伸烷基, 可有取代基之低伸烯基, 可有取代基之-C0-低伸烷基, 可有取代基之- C0-低伸烯基或 【化2】
(CR3R4)p— (式中R3、R4、R5及R6各自獨立爲氫或可有取代基之低烷 基, 【化3】
爲可有取代基之環伸烷基、可有取代基之環伸烯基、可有 取代基之雙環伸烷基、可有取代基之伸芳基或可有取代基 之雜環二基’P及q各自獨立爲〇〜2之整數,p及q之任 一方不爲〇, 但 【化4】
不爲 -9- 1376367
[式中R14爲可有取代基之苯基]), -nr2-x-爲 【化6】
(式中 【化
-N
可爲哌啶二基、哌畊二基、吡啶二基、吡阱 二基或吡咯二基,U爲低伸烷基或低伸烯基) Z爲可有取代基之低烷基 '可有取代基之低 代基之胺基、可有取代基之低烷氧基、可有 式基、可有取代基之雜環式基, (但Z不爲3環之稠合雜環式基、可有取代 可有取代基之喹唑啉基)] (但X爲 【化8】 一 (CR3R4)p—(CR5R6)q— 【化9】 -0- 爲可有取代基之環伸烷基,q爲1,q爲0, 二基、吡咯啶 > 嫌基、可有取 取代基之烴環 基之噻唑基或 且Z爲可有取 -10- 1376367 【化1 7】 R1—Y—Ν-Χ-Ν—Ζ (I) R2 R7 [式中R1爲可有取代基之低烷基, Υ 爲-S(0)2-, R2爲氫或可有取代基之低烷基, R7爲氫或可有取代基之低烷基, X爲
【化1 8】 —(CR3R4)p—(^}—(CR5R6)q- (式中R3及R4各自獨立爲氫, 【化1 9】 -0- 爲可有取代基之環伸烷基,P爲1或2,q爲0, 但
【化20】 "Θ' 不爲 【化2 1】
[式中R14爲可有取代基之苯基]), Z爲可有取代基之烴環式基或可有取代基之雜環式基] (但Z爲3環之稠合雜環式基、可有取代基之噻唑基或可 -14- 1376367 有取代基之喹唑啉基之化合物除外), (16) Z爲可有取代基之苯基、可有取代基之吡啶基、可有 取代基之嗒阱基、可有取代基之吡阱基、可有取代基之嘧 啶基、可有取代基之喹啉基、可有取代基之異喹啉基、可 有取代基之苯并噻唑基、可有取代基之苯并咪唑基、可有 取代基之苯并噚唑基、可有取代基之噻唑并吡啶基或可有 取代基之噚唑并吡啶基之(15)記載之化合物、其製藥容許 鹽或這些之溶劑合物,
(17) 如下式(I)化合物、其鹽或這些之溶劑合物, 【化22】 R1—Y—N-X-N—Z (I) I / R2 R7 [式中R1爲可有取代基之低烷基, Y 爲-S(0)2_, R2爲氫或可有取代基之低烷基, R7爲氫或可有取代基之低烷基,
X爲 【化23】 —(CR3R4)p—(CR5R6)q- (式中R3及R4各自獨立爲氫, 【化24】 -0- 爲可有取代基之環伸烷基,P爲1或2,q爲0), Z爲可有取代基之苯基、可有取代基之吡啶基 '可有%# -15- 1376367 基之嗒阱基、可有取代基之吡畊基、可有取代基之嘧啶基 、可有取代基之喹啉基、可有取代基之異喹啉基、可有取 代基之苯并噻唑基、可有取代基之苯并咪唑基、可有取代 基之苯并噚唑基、可有取代基之噻唑并吡啶基或可有取代 基之噚唑并吡啶基], (18) 如(1)〜(17)中任一項之化合物、其製藥容許鹽或這 些之溶劑合物爲有效成分之醫藥組成物,
(19) 如(1)〜(I7)中任一項之化合物、其製藥容許鹽或這 些之溶劑合物爲有效成分之NPY Y5受體拮抗劑, (2 0)如下式化合物、其鹽或這些之溶劑合物, 【化25】 V^^T)-NH2 U2 (式中R1爲乙基或第三丁基), (21)如下式化合物、其鹽或這些之溶劑合物,
【化26】 0
ΝΗ 0——tert-Bu (式中R1爲乙基、異丙基或第三丁基), (22)如下式化合物、其鹽或這些之溶劑合物, 1376367 【實施方式】 實施發明之最佳形態 以下說明本說明書中使用之各用語。本說明書中,各用 語於單獨使用之場合,或與其他用語一起使用之場合也爲 同一意義。 「鹵素」爲氟、氯、溴及碘。尤以氟及氯較佳。
「可被保護之羥基」、「可被保護之羥低烷基」之保護 基包含所有通常使用之羥基保護基。例如醢基(乙醯基、 三氯乙醯基、苄醯基等)、低烷氧羰基(第三丁氧羰基等)、 低烷磺醯基(甲磺醯基等)、低烷氧基低烷基(甲氧甲基等) 、三烷基矽烷基(第三丁基二甲基矽烷基等)等。
「低烷基」包含碳數1〜10之直鏈或分枝狀之烷基,例 如甲基、乙基、正丙基、異丙基、正丁基、異丁基、第二 丁基、第三丁基、正戊基、異戊基、新戊基、己基、異己 基、正庚基、異庚基、正辛基、異辛基、正壬基及正癸基 等。 R1中「低烷基」宜碳數2〜10,尤宜碳數2〜6,最好爲 乙基、異丙基或第三丁基。 其他場合中「低烷基」宜碳數1〜6,尤宜碳數1〜4。 Z中「可有取代基之低烷基」之取代基可爲例如(1)鹵素 ;(2)氰基;(3)可有由各如下定義之取代基群β選擇之1 以上取代可能之基取代之(i)羥基、(Π)低烷氧基、(iii)氫 硫基、(iv)低院硫基、(v)醯基、(vi)醯氧基、(vii)羧基、 -18- 1376367 (νίΠ)低烷氧羰基、(ix)亞胺基、(x)胺甲醯基、(xi)硫胺甲 醯基、(xii)低烷胺甲醯基' (xiii)低烷硫胺甲醯基、(xiv) 胺基、(xv)低烷胺基或(xvi)雜環羰基;或 (4)如下式基: 【化2 9】 —W—(CR10R11)s -(J) (式中R1C)及R11各自獨立爲氫或低烷基,若有2以上之 R1()及/或R11存在時,各Rl()及R11可相異,
W爲單鍵、〇、S或NR12, R12爲氫、低烷基或苯基, 【化30】 爲各如下定義之取代基群α選擇之1以上取代可能之基取 代之環烷基、雙環烷基、環烯基、芳基或雜環式基, s爲0〜4之整數)等。
於此取代基群α爲(1)鹵素;(2)氧基;(3)氰基;(4)硝基 ;(5)可有低烷基或羥基取代之亞胺基; (6)各可有由取代基群β選擇之1以上取代可能之基取代之 (i)羥基、(ii)低烷基、(iii)低烯基、(iv)低烷氧基、(ν)羧基 、(vi)低烷氧羰基、(vii)醯基、(viii)醯氧基、(ix)亞胺基 、(X)氫硫基、(xi)低烷硫基、(xii)胺甲醯基、(xiii)低烷胺 甲醯基、(xiv)環烷胺甲醯基、(xv)硫胺甲醯基、(xvi)低烷 硫胺甲醯基、(xvii)低烷亞磺醯基、(xviii)低烷磺醯基、 (xix)胺磺醯基、(XX)低烷胺磺醯基及(xxi)環烷胺磺醯基; -19- 1376367 (7) 各可有取代基群β、低烷基、低烷氧基低烷基、可被保 護之羥低烷基、鹵低烷基、低烷磺醯基及/或芳磺醯取代之 ⑴環烷基、(ii)環烯基、(iii)環烷氧基、(iv)胺基及(V)伸烷 二氧基:及
(8) 各可有取代基群β、低烷基、鹵低烷基及/或氧基取代之 (i)苯基、(ii)萘基、(iii)苯氧基、(iv)苯低烷氧基、(ν)苯硫 基、(vi)苯低烷硫基、(vii)苯偶氮基、(viii)雜環式基、 (ix)雜環氧基、(X)雜環硫基、(xi)雜環羰基及(xii)雜環磺 醯而成群。 作爲B環中取代基之取代基群α之適例爲鹵素;硝基; 羥基; 可有取代基之低烷基(於此取代基爲鹵素、氰基、苯基、 羧基及/或低烷氧羰基); 低烯基:低烷氧羰低烯基: 可有取代基之低烷氧基(於此取代基爲鹵素、羥基、低烷 氧基、羧基、低烷氧羰基、低烷胺基及/或氰基);
醯基;羥亞胺基;低烷硫基;低烷亞磺醯基;胺磺醯基; 可有取代基之胺基(於此取代基爲低烷基、可被保護之羥 低烷基、苯基及/或醯基); 伸烷二氧基;氰苯基;雜環取代苯基;聯苯基;苯氧基; 可有低烷基取代之苯偶氮基; 可有取代基之雜環式基(於此取代基爲可被保護之羥基; 氫硫基;鹵素;低烷基:環烷基;低烷氧羰基;胺基;低 烷氧羰胺基:胺甲醯基:氧基:苯基:低烷氧苯基;或雜 -20· 1376367 環式基)、尤宜鹵素;可有鹵素取代之低烷基:可有鹵素 取代之低烷氧基。 取代基群β爲鹵素、可被保護之羥基、氫硫基、低烷氧 基、低烯基、胺基、低烷胺基、低烷氧羰胺基、低烷硫基 、醯基、羧基、低烷氧羰基、胺甲醯基、氰基、環烷基、 苯基、苯氧基、低烷苯基、低烷氧苯基、鹵苯基、萘基及 雜環式基而成群。
Ζ以外中「可有取代基之低烷基」(例如於R1中場合等) 之取代基可爲由取代基群β選擇之1以上之基而任意之位 置可有這些取代基取代。 「低烷氧基」、「低烷氧羰基」、「低烷氧羰低烷基」
、「低烷苯基」、「低烷氧苯基」、「低烷胺甲醯基」、 「低烷硫胺甲醯基」、「低烷胺基」、「鹵低烷基」、「 羥低烷基」、「苯低烷氧基」、「低烷硫基」、「苯低烷 硫基」、「低烷氧羰胺基」、「低烷氧羰低烯基」、「低 烷亞磺醯基」、「低烷磺醯基」、「芳低烷氧羰基」、「 低烷苄醯基」及「低烷氧苄醯基」之低烷基部分與上述「 低烷基」同樣》 「可有取代基之低烷氧基」之取代基爲由取代基群Ρ選 擇之1以上之基,宜苯基、低烷苯基、低烷氧苯基、萘基 或雜環式基。 「環烷基」包含碳數3〜8、宜5或6之環狀之烷基。具 體而言,爲環丙基、環丁基、環戊基、環己基、環庚基及 環辛基等》 -21 - 1376367 「可有取代基之環烷基」之取代基爲由取代基群α選擇 之1以上之基等而可於任意之位置取代。 「雙環烷基」包含由2環共有2個或其以上之原子之碳 數5〜8之脂肪族環去除1個氫之基。具體而言,爲雙環 [2.1_0]戊基、雙環[2_2.1]庚基、雙環[2·2.2]辛基及雙環 [3.2.1]辛基等。
「低稀基」爲於任意位置有1以上雙鍵之碳數2〜10, 宜碳數2〜8’尤宜碳數3〜6之直鏈或分枝狀之烯基。具 體而言’包含乙烯基、丙烯基、異丙烯基、丁烯基、異丁 烯基、異戊二烯基、丁二烯基、戊烯基、異戊烯基、戊二 烯基、己烯基、異己烯基、己二烯基、庚烯基、辛烯基、 壬烯基及癸烯基等。 「低烷氧羰低烯基」中「低烯基」部分與上述「低烯基 」同樣。
「可有取代基之低烯基」之取代基可爲鹵素、低烷氧基 、低烯基、胺基、低烷胺基、低烷氧羰胺基、低烷硫基、 醯基、羧基、低烷氧羰基、胺甲醯基、氰基、環烷基、苯 基、低烷苯基、低烷氧苯基、萘基及/或雜環式基等。 「醯基」包含(1)碳數1〜10,尤宜碳數1〜6,最好碳數 1〜4之直鏈或分枝狀之烷羰基或烯羰基,(2)碳數4〜9, 宜碳數4〜7之環烷羰基及(3)碳數7〜11之芳羰基。具體 而言’包含甲醯基、乙醯基、丙醯基、丁醯基、異丁醯基 、戊醯基、特戊醯基、己醯基、丙烯醯基、丙炔醯基、甲 基丙烯醯基、巴豆醯基、環丙羰基、環己羰基、環辛羰基 -22- 1376367 及节酿基等。 F醯氧基」之醯基部分與上述同樣。 「環烯基」包含於上述環烷基之環中任意位置有1以上 之雙鍵者,具體而言,可爲環丙烯基、環丁烯基、環戊烯 基、環己烯基及環己二烯基等。 「可有取代基之環烯基」之取代基爲由取代基群β選擇 之1以上之基。
「可有取代基之胺基」之取代基爲取代基群卩、可有取 代基之苄醯基及/或可有取代基之雜環羰基(於此取代基爲 羥基、低烷基、低烷氧基及/或低烷硫基)。 「芳基」爲單環或多環之芳香族碳環式基,包含苯基、 萘基、蒽基及菲基等》又包含與其他非芳香族烴環式基稠 合之芳基,具體而言,氫茚基、茚基、聯苯基、苊基、四 氫萘基及莽基等。尤以苯基較佳。 「芳低烷氧羰基」之芳基部分也同樣。
Ζ中「可有取代基之芳基」及「可有取代基之苯基」包 含可有取代基群α、由取代基群α選擇之取代可能之1以 上之基取代之低烷基等取代之「芳基」、「苯基」。 Ζ以外之「可有取代基之芳基」及「可有取代基之苯基 」之取代基爲由取代基群Ρ選擇之1以上之基。 「烴環式基」包含上述「環烷基J 、「環烯基」、「雙 環烷基」及「芳基J 。 「非芳香族烴環式基」包含上述「環烷基」、「環烯基 」及「雙環烷基」。 -23 - 1376367 唑啉基、哌啶基、哌阱基、嗎啉基、嗎啉基、硫嗎啉基、 硫嗎啉基、二硫氫吡啶基、四氫呋喃基、四氫吡喃基、四 氫噻唑基、四氫異噻唑基等非芳香族雜環式基。 與雜環以外之環稠合之稠合雜環式基(例如苯并噻唑基等 )爲可於任一環有鍵結。 「可有取代基之雜環式基」及「可有取代基之2環之稠 合雜環式基」之取代基與上述「可有取代基之芳基」同樣
「雜環羰基」、「雜環氧基」、「雜環硫基」及「雜環 取代苯基」之雜環式基部分與上述「雜環式基」同樣。 「低伸烷基」包含亞甲基1〜6個,宜2〜6個,尤宜3 〜6個連續之2價基,具體而言,亞甲基、伸乙基、三亞 甲基、四亞甲基、五亞甲基及六亞甲基等。尤宜四亞甲基 R1及R2 —起形成低伸烷基之場合包含
。宜 【化3 2】
「低伸烷二氧基」之低伸烷基部分與上述「低伸院基」 同樣,宜亞甲基二氧基或伸乙基二氧基》
-25- 1376367 群β選擇之1以上取代可能之基,宜鹵素、羥基、低烷基 、鹵低烷基、低烷氧基、胺基、低烷胺基、醯基、羧基或 低烷氧羰基等。任意之位置可有這些基取代。 -NR2-X-爲 【化3 3】
之場合,宜U爲亞甲基、伸乙基,尤宜 【化34】
H2
本發明化合物包含各化合物之生成可能之製藥容許鹽。
「其製藥容許鹽」可爲例如鹽酸、硫酸、硝酸或磷酸等無 機酸之鹽;對甲苯磺酸、甲磺酸、草酸或檸檬酸等有機酸 之鹽;銨、三甲胺或三乙胺等有機鹼之鹽;鈉或鉀等鹼金 屬之鹽;及鈣或錶等鹼土金屬之鹽等。 本發明化合物包含對化合物(I)之溶劑合物,宜水合物。 本發明化合物1分子可與任意數之水分子配位。 本發明化合物(I)若有不對稱碳原子時,包括消旋體、兩 對掌體及所有立體異構物(幾何異構物、表異構物、鏡像 異構物等)。又本發明化合物⑴若有雙鍵之場合可有E體 及Z體存在時,包括其任一方。又X爲環伸烷基時,包括 順體及反體之任一方。 本發明之化合物(I)可例如依如下方法合成。以下以X爲-
-27- 1376367 CH2-G-或-G-CH2-說明。 [Y = S(0)n之場合] 【化35.】
R ^02^81 2 HN _ ,C02R13 -- 工锃A
;02R13
工锃D R2
^^ο2η 6
(式中Hal爲鹵素,-G-CH2-與式(I)之-X-同義,R13爲低烷 基,其他與前述同義)
工程A 化合物1和具有對應目的化合物之取代基R1之磺醯鹵2 於適當溶劑中,於0 °C〜5 (TC反應數分〜數小時,則得η 爲2之化合物3。溶劑可使用四氫呋喃、二甲基甲醯胺、 乙醚、二氯甲烷、甲苯、苯、二甲苯、環己烷、己烷、氯 仿、乙酸乙酯、乙酸丁酯、戊烷、庚烷、二噚烷、丙酮、 乙腈、水及這些之混合溶劑等。 -28- 1376367
工程B 化合物1和具有取代基R1之亞磺醯鹵4反應,得n=i之 化合物5。反應條件與上述工程A同樣。
工程C
工程B所得化合物5依常法來氧化反應,則得n = 2之化 合物3。氧化劑可用間氯苯甲酸、過乙酸、過氧化氫、過 三氟乙酸、過碘酸鈉 '次亞氯酸鈉、過錳酸鉀等,反應可 於0°C〜50°C施行。溶劑可用四氫呋喃、二甲基甲醯胺、 乙醚、二氯甲烷、甲苯 '苯、二甲苯、環己烷、己烷、氯 仿、乙酸乙酯、乙酸丁酯、戊烷、庚烷、二曙烷、丙酮、 乙腈、水、甲醇、乙醇、異丙醇及這些之混合溶劑等。
工程D
工程A或C所得化合物3於適當溶劑中以鹼處理,得化 合物6。鹼可用氫氧化鈀、氫氧化鈉、氫氧化鉀、肼、丙 烷硫醇鋰鹽等,溶劑可用四氫呋喃、二甲基甲醯胺、二噚 院、丙酮、乙腈、甲醇、乙醇、丙醇、水及這些之混合溶 劑等。可於0°c〜100°c反應數分〜數十小時。
工程E 工程D所得化合物6和具有對應目的化合物之取代基z 及R7之胺基化合物7於適當溶劑中,於〇它〜5〇。(:反應數 分〜數小時而得化合物8。溶劑可用四氫呋喃、二甲基甲 醯胺、乙醚、二氯甲烷、甲苯、苯、二甲苯、環己烷、己 烷、氯仿、乙酸乙酯、乙酸丁酯、戊烷、庚烷、二噚烷、 丙酮、乙腈、水及這些之混合溶劑等,必要時也可用亞磺 -29- 1376367 醯氯、醯鹵、酸酐、活性化酯等活性化劑。
工程F 所得化合物8於適當溶劑中,以適當還原劑處理,得化 合物(Ι-A)。還原劑可用硼氫化鈉、硼氫化鋰、氫化鋰鋁等 、溶劑可用四氫呋喃、二甲基甲醯胺、二噚烷、乙腈、甲 醇、乙醇、丙醇、乙酸及這些之混合溶劑等。可於0-c〜 l〇〇C反應數分〜數十小時。
工程G
工程D所得化合物6於適當溶劑中,以還原劑處理而得 化合物9。還原劑可用硼氫化鈉、硼氫化鋰、氫化鋰鋁、 二硼烷等,溶劑可用四氫呋喃 '二甲基甲醯胺、二噚烷、 乙腈、甲醇 '乙醇 '丙醇及這些之混合溶劑等。可於〇°C 〜1 0 0 °c反應數分〜數十小時,必要時也可經由醯齒、酸 酐、活性化酯等中間體。 工程Η
工程G所得化合物9可依常法氧化反應,則得化合物1 0 。氧化劑可用間氯苯甲酸、過乙酸、過氧化氫、過三氟乙 酸、過碘酸鈉、次亞氯酸鈉、過錳酸鉀、Dess-Martin過 碘酸、二甲亞颯/草醯氯(Swern氧化)、釕觸媒等,反應於-8 0°C〜5 0°C施行。溶劑可用四氫呋喃、二甲基甲醯胺、乙 醚、二氯甲烷、甲苯、苯、二甲苯、環己烷、己烷、氯仿 、乙酸乙酯'乙酸丁酯、戊烷、庚烷、二噚烷、丙酮、乙 腈、水、甲醇、乙醇、異丙醇及這些之混合溶劑等。
工程J
-30- 1376367 所得化合物10與具有對應目的化合物之取代基Z及R7 之胺基化合物7依常法還原地施行胺基化反應,得化合物 (Ι-A)。還原劑可用硼氫化鈉、三乙醯氧基硼氫化鈉、氰基 硼氫化鈉等,反應在〇°C〜50°C施行》溶劑可用四氫呋喃 、二甲基甲醯胺、二噚烷、乙腈、甲醇、乙醇、丙醇、乙 酸、鹽酸及這些之混合溶劑等。 [Y = CO之場合]
【化36】 R2 HN, ^COjR R'-CO-Hal 11
工程K R2 R1. .N^^COsR1
Ύ O
工程D 12 R2 R^N^^COjH ° 13
工程G
RJ
RYN
工程H RVN o
,CHO R7HN-Z 7
工程J 15
R2
R7 (l-B) (式中各符號與前述同義,-G-CHy與式(I)之-X-同義)
工程K
化合物1和具有對應目的化合物之取代基R1之醯鹵11 於適當溶劑,-2(TC〜50 °C反應數分〜數小時而得化合物 12。溶劑可用四氫呋喃、二甲基甲醯胺、乙醚、二氯甲烷 、甲苯、苯、二甲苯、環己烷、己烷、氯仿、乙酸乙酯' 乙酸丁酯、戊烷、庚烷、二噚烷、丙酮、乙腈、水及這些 之混合溶劑等。 工程D、工程〇、工程Η及工程J 所得化合物12依上述工程D、工程G、工程Η及工程j 同樣方法可得本發明之化合物(Ι_Β)。
-31 - 1376367 【化37】 ο
Η
工程L
0 H RO
工裎M 〇
11 ’rq/^g
16 17 i, 工程N I 工程o z 工程p ^ HO’^G’N'R7 N3/^G,N、R7 19
z 21
工程Q 20z R1 人
22
工程R ---► r〆丫、r R2 Z I 、G 、R7 (I-C) (式中各符號與前述同義,-CH2_G-與式⑴之-x-同義,R爲 院基)
工程L
於化合物16導入取代基R7之工程。例如r7Xi(x1爲鹵 素)於鹼之存在下反應,得化合物17。溶劑可用四気咲喃 、二甲基甲酿胺。反應可於室溫施行。鹼可用三乙胺、p比 啶、二甲胺基吡啶等。式(Ι-C)中,R7爲氫之化合物不施行 本工程。 工程Μ 於化合物17導入取代基Ζ之工程。可例如ΖΧ'Χ1爲鹵 素)於鹼之存在下反應,而得化合物18。溶劑可用甲醇、 乙醇' 異丙醇、二甲基甲醯胺等。反應於室溫下或加溫下 -32- 1376367 施行。可例如封管而用微波爐反應裝置施行。鹼可用Ν,Ν· 二異丙基乙胺等。 工程Ν 令化合物18還原而得化合物19之工程。還原劑可用氫 化鋰鋁。溶劑可用四氫呋喃等。反應於室溫施行。 工程〇
令化合物19疊氮化而誘導爲化合物20之工程。例如於 化合物19以三乙胺爲鹼,與甲磺醯氯反應,使化合物19 誘導爲甲磺酸酯。予以甲磺醯基化時之溶劑可用氯仿。所 得化合物與疊氮化鈉反應,於二甲基甲醯胺中等,室溫下 或加溫下施行疊氮化,得化合物20。 工程Ρ 令化合物20還原而得化合物21之工程。以接觸還原施 行。觸媒可用10%鈀碳等。溶劑可用乙醇等》
工程Q
化合物21與式:F^-Y-X'X1爲鹵素等,γ爲s、SO、so2 或CO)化合物反應而得化合物22之工程。式:R^-Y-X1所 示化合物可爲各種之磺醯氯、醯氯等。溶劑可用四氫呋喃 、二甲基醯胺等。反應可於室溫下或加溫下施行。以鹼之 存在下施行較佳,鹼可用吡啶、三乙胺等。式(Ι-C)中,R2 爲氫之化合物不施行以下之工程R,化合物22成爲最終目 的化合物。也可用Y=S或SO之式:Ri-Y-X1所示化合物來 反應而得化合物22,其後氧化而變換成γ爲S〇2之化合 物,而供其次之工程。 -33- 1376367
工程R 於化合物22導入取代基R2之工程。令R2xi(xi爲鹵素 等)於鹼之存在下與化合物22反應而得化合*(I_C)。鹼可 用氫化鈉等。溶劑可用二甲基甲醯胺等。 上述之工程中,可用以下之中間體❶· 化38 O Z R0
Z
N 、R7 、R7
18
Z
19 Z N3/^tG/N、R7 H2n/^G’N、R7 21 20 (式中R爲可有取代基之低烷基,r7爲氫或可有取代基之 低烷基’ G爲1,4·環伸烷基,Z爲可有取代基之烴環式基 或可有取代基之雜環式基)
R尤其可用低烷基,更以甲基、乙基較佳。尤以乙基較 佳。 R以氮較佳。 Z以可有取代基之雜環式基較佳。 尤其以下之化合物較佳。 式: 【化3 9】
N—Z
{ C -34- 1376367 (式中各符號與前述同義,-CH2-G-與式(I)之-X-同義,r爲 烷基,Pro爲胺基保護基)
工程S 於化合物17導入保護基之工程。保護基可廣泛用 Protective Groups in Organic Synthesis(Theodra W. Greene
著)等記載之保護基。以可於酸性條件下去除之胺基保護 基較佳。可爲苄氧羰基、第三丁氧羰基等。例如令 ProX'X1爲鹵素等,Pro爲苄氧羰基、第三丁氧羰基等), pr〇-〇-pr〇(pro爲苄氧羰基、第三丁氧羰基等)於鹼之存在 下反應而得化合物23。溶劑可用四氫呋喃、二甲基甲醯胺 。反應於室溫施行》鹼可用三乙胺、吡啶、二甲胺基吡啶 等。R7爲氫之化合物也可同樣反應。
工程T 令化合物23還原而得化合物24之工程。還原劑可用氫 化鋰鋁。溶劑可用四氫呋喃等。反應於室溫施行。
工程U
令化合物2 4疊氮化來誘導爲化合物2 5之工程》例如於 化合物24以三乙胺爲鹼,與甲磺醯氯反應,使化合物24 誘導爲甲磺酸酯。甲磺醯基化時之溶劑可用氯仿。所得化 合物與疊氮化鈉反應,於二甲基甲醯胺中等,室溫下或加 溫下施行疊氮化,也可得化合物2 5。
工程V 令化合物25還原而得化合物26之工程。化合物25用三 苯滕及水來還原而得化合物26。反應於加溫下施行。溶劑
-36- 1376367 可用四氫呋喃。除用三苯膦之還原法以外,可施行接觸還 原。接觸還原之場合,觸媒可用10%鈀碳等。溶劑可用乙 醇等。使用何種還原法,可依使用保護基而適宜選擇。 工程w
化合物26與式:Ι^-Υ-Χ'Χ1爲鹵素等,Y爲S、SO、S02 或CO)所示化合物反應而得化合物27而工程。式:W-Y-χ^χ1爲鹵素等)所示化合物可爲各種之磺醯氯、醯氯等。 溶劑可用四氫呋喃、二甲基醯胺等。反應在室溫下或加溫 下施行。以鹼之存在下施行較佳,鹼可用吡啶、三乙胺等 。又也可用Y = S或SO之式:W-Y-X1所示化合物來反應而 得化合物27後,氧化而變換成Y爲S02之化合物而供其 次之工程。
工程X 爲去除化合物27之保護基之工程。保護基之去除可依保 護基而選用各種條件。例如第三丁氧羰基可以酸去除。苄 氧羰基可以接觸還原等去除。
工程Y 爲於化合物28導入取代基Z之工程。可例如ZX^X1爲 鹵素)於鹼之存在下反應而得化合物(I-D) »溶劑可用甲醇 、乙醇、異丙醇、二甲基甲醯胺等。反應可於室溫下或加 溫下施行。例如封管而用微波爐反應裝置來施行。鹼可用 N,N-二異丙基乙胺等。 上述之工程中,可用以下之中間體。 -37- 1376367 化 /GΠΟΛ 4 〇
ProIN、
7 R
Ho ΡΓΟΙΝ R7
PrIN
R 23 fj>ro h2n^^g/N、r7 R1 人[| 26 24 25
ProI ,N 27 R7 R1/Y、N〆 I R2 HI ,N. 'R/ 28 (式中R爲可有取代基之低烷基,Pro爲保護基,R7爲氫或 可有取代基之低烷基,G爲1,4-環伸烷基,Y爲S02或SO ,R1爲可有取代基之低烷基,R2爲氫或可有取代基之低 烷基) R尤以低烷基,更以甲基、乙基較佳。尤以乙基較佳。 Pro以可於酸性條件下去除之胺基保護基較佳。例如Pro 以式:-(C = 0)-O-R(R爲可有取代基之低烷基、可有取代基 之低烯基)所示基較佳。尤其第三丁氧羰基較佳β R7以氫較佳。 Υ以S02較佳。 R1以尤其低烷基 更爲異丙基、乙基較佳。尤以乙基較 佳 R2以氫較佳。 尤其以下之化合物較佳 式: -38- 1376367 【化42】
NH2 (式中R1爲乙基或第三丁基)所示化合物。 式:
(式中R1爲乙基、異丙基或第三丁基)所示化合物。 式: 【化44】
(式中Z爲可有取代基之烴環式基或可有取代基之雜 基)所示化合物。 本發明之化合物皆具有NPY Y5受體拮抗作用’尤 合物爲以下之化合物。 式(I)中 R1爲可有取代基之低烷基(以下稱R1爲R1-1)化合物, R1爲各可有鹵素取代之碳數1〜10之烷基(以下稱] R1 -2)化合物, R1爲可有鹵素取代之碳數1〜10之烷基(以下稱R1爲 3)化合物, R1爲異丙基或第三丁基(以下稱R1爲R1-4)化合物, 環式 宜化 ^爲 R1- -39- 1376367
(以下稱Z爲Ζ·2)化合物, ζ 爲-(CH2)r-W-(CH2)s-V
[式中W爲單鍵、0、S或NR12,R12爲氫或低烷基,V爲 各可有取代基之芳基或雜環式基(於此取代基爲鹵素、羥 基、低烷基、鹵低烷基、低烷氧基、低烯基、胺基、低烷 胺基、醯基、羧基、低烷氧羰基、苯基或單環之雜芳基) ,r爲1〜4之整數,s爲0〜4之整數] (以下稱Z爲Z-3)化合物,
Z 爲-(CH2)r-W-(CH2)s-V
[式中W爲單鍵、0、S、NH或NMe,V爲各可有取代基 之苯基或雜芳基(於此取代基爲鹵素、低烷基、鹵低烷基 、低烷氧基、胺基或低烷胺基),r爲1〜3之整數,s爲〇 或1] (以下稱Z爲Z-4)化合物, Z爲可有取代基之烴環式基 [於此取代基爲鹵素;羥基;
可有取代基之低烷基(於此取代基爲鹵素、羥基、羧基、 低烷氧羰基、氰基及/或苯基); 可有低烷氧羰基取代之低烯基; 可有取代基之低烷氧基(於此取代基爲鹵素、羥基、低院 氧基、羧基、低烷氧羰基、低烷胺基、環烷基、氰基及/或 雜環式基); 環烷基:環烷氧基;醯基;低烷硫基;胺甲醯基;低烷胺 甲醯基;環烷胺甲醯基;羥亞胺基: -42- 1376367 可有取代基之胺基(於此取代基爲低烷基、可被保護之羥 低烷基、低烷氧基低烷基、醯基、低烷磺醯基、芳磺醯及/ 或苯基); 可有鹵素、氰基、苯基及/或雜環式基取代之苯基; 低烷亞磺醯基;低烷胺磺醯基:環烷胺磺醯基; 硝基;氰基;伸烷二氧基;可有低烷基取代之苯偶氮基: 苯氧基;氧基;
可有取代基之雜環式基(於此取代基爲可被保護之羥基; 氫硫基;鹵素;低烷基;環烷基;低烷氧羰基:醯基;胺 基;低烷氧羰胺基:胺甲醯基:氧基:苯基:低烷氧苯基 :鹵苯基;雜環式基及/或氧基); 可有低烷基取代之雜環磺醯基;雜環氧基;可有低烷基取 代之雜環羰基] (以下稱z爲Z-5)化合物, Z爲可有取代基之苯基
(於此取代基爲鹵素;羥基;可有鹵素、羥基、低烷氧羰 基、氰基及/或苯基取代之低烷基;低烷氧羰低烯基;可有 鹵素、低烷氧基、低烷氧羰基、環烷基及/或雜環式基取代 之低烷氧基;環烷基;環烷氧基;醯基;低烷硫基;胺甲 醯基;低烷胺甲醯基:可有低烷基、羥低烷基、醯基、低 院擴酸基及/或苯基取代之胺基;可有_素、氰基、苯基及 /或雜環式基取代之苯基; 低烷胺磺醯基;環烷胺磺醯基;硝基;伸烷二氧基;可有 低烷基取代之苯偶氮基;苯氧基;氧基;可有羥基、鹵素
{ C -43- 1376367 、低烷基、低烷氧羰基、胺基、胺甲醯基、苯基、鹵苯基 、雜環式基及/或氧基取代之雜環式基;雜環氧基:及/或 可有低烷基取代之雜環磺醯基)(以下稱Z爲Z-6)化合物, Z爲可有取代基之苯基
(於此取代基爲鹵素;可有鹵素、羥基、低烷氧羰基及/或 苯基取代之低烷基;可有鹵素及/或環烷基取代之低烷氧基 :環烷基;環烷氧基;醯基;低烷硫基;低烷胺甲醯基; 可有低烷基、羥低烷基、醯基及/或苯基取代之胺基;可有 哌啶基取代之苯基;環烷胺磺醯基;伸烷二氧基;苯氧基
可有低烷基取代之嗎啉基或嗎啉基;羥基、可有低烷基、 低烷氧羰基、苯基、鹵苯基及/或氧基取代之哌啶基;可有 羥基、胺甲醯基及/或氧基取代之吡咯啶基;可有苯基或嘧 啶基取代之哌畊基;二硫氫吡啶基;吡咯基;吡咯啉基; 可有鹵素及/或低烷基取代之咪唑基;吡唑基;噻吩基;噻 二唑基;呋喃基;噚唑基;異噚唑基;可有低烷基及/或苯 基取代之四唑基;吲哚啉基;吲哚基;四氫唾啉基;可有 低烷基取代之苯并噻唑基;可有氧基取代之四氫異噻唑基 :可有氧基取代之苯并吡喃基;四氫吡喃氧基;四氫呋喃 氧基;可有低院基取代之嗎啉基擴酿基;及/或可有低院基 取代之哌啶基磺醯基)(以下稱z爲Z-7)化合物, Z爲可有取代基之苯基(於此取代基爲鹵素、低烷基、鹵低 烷基、低烷氧基、環烷氧基、低烷胺甲醯基、苯基、低烷 基嗎啉基及/或四氫吡喃氧基)(以下稱Z爲Z-8)化合物, -44- 1376367 z爲可有取代基之雜環式基(於此取代基爲鹵素、羥基、低 烷基、鹵低烷基、低烷氧基、氫硫基、低烷硫基、醯基、 羧基、低烷氧羰基、胺基、低烷胺基、苯基、萘基、可有 鹵素取代之苯硫基、可有鹵素取代之苯氧基、可有氧基及/ 或低烷基取代之雜環式基)(以下稱z爲Z-9)化合物,
Z爲各可有取代基之噻吩基、吡唑基、唾唑基、噻二唑基 、吡啶基、嘧啶基、吡畊基、嗒阱基、三畊基、吲哚基、 異吲哚基、吲哚啉基、異吲哚啉基、吲唑基、苯并吡喃基 、苯并噚唑基、苯并噻吩基、苯并唾唑基、苯并噻唑啉基 、苯并噻二唑基、苯并咪唑基、喹啉基、異唾啉基、二硫 氫苯并呋喃基、咔唑基、吖啶基、二苯并呋喃基或噻唑并 吡啶基(於此取代基爲低烷基;鹵低烷基;低烷氧基:低 烷氧羰基;醯基;低烷氧羰低烷基;氫硫基;各可有鹵素 取代之苯基、萘基、苯硫基或苯氧基;呋喃基;硝基;氧. 基;及/或可有低烷基取代之嗎啉基)(以下稱Z爲Z-10)化 合物,
Z爲各可有取代基之噻吩基、噻唑基、噻二唑基、吡啶基 、吡阱基、吲哚基、異吲哚啉基、苯并吡喃基、唾啉基、 咔唑基、二苯并呋喃基、苯并吡喃基、苯并噻吩基或苯并 噻唑基(於此取代基爲低烷基、鹵低烷基、低烷氧基、低 烷氧羰基、醯基、苯基、萘基、苯硫基、低烷基嗎啉基及 氧基而成群選擇之1以上之基) (以下稱Z爲Z-1 1)化合物, R1 爲 R1-2,R2 爲 R2-2,η 爲 2,X、Y 及 z 之組合(X,Y,Z) -45- 1376367 爲以下之組合之化合物, (Χ,Υ,Ζ) = (Χ-3,Υ-2,Ζ-1),(Χ-3,Υ-2,Ζ-2),(Χ-3,Υ-2,Ζ-3),(Χ- 3,Υ-2,Ζ-4),(Χ-3,Υ-2,Ζ-5),(Χ·3,Υ-2,Ζ-6),(Χ-3,Υ-2,Ζ-7),(Χ- 3,Υ-2,Ζ-8),(Χ-3,Υ-2,Ζ·9),(Χ-3,Υ-2,Ζ-10),(Χ-3,Υ-2,Ζ-11), (Χ-3,Υ-3,Ζ-1),(Χ·3,Υ-3,Ζ-2),(Χ-3,Υ-3,Ζ-3),(Χ-3,Υ-3,Ζ- 4),(Χ-3,Υ-3,Ζ-5),(Χ-3,Υ-3,Ζ-6),(Χ-3,Υ-3,Ζ-7),(Χ-3,Υ-3,Ζ- 8),(Χ-3,Υ-3,Ζ-9),(Χ-3,Υ-3,Ζ-10),(Χ-3,Υ-3,Ζ-11), (Χ-4,Υ-2,Ζ-1),(Χ-4,Υ-2,Ζ-2),(Χ-4,Υ-2,Ζ-3),(Χ·4,Υ-2,Ζ-
4),(Χ-4,Υ-2,Ζ-5),(Χ-4,Υ-2,Ζ-6),(Χ-4,Υ-2,Ζ-7),(Χ-4,Υ-2,Ζ- 8),(Χ-4,Υ-2,Ζ-9),(Χ-4,Υ-2,Ζ-10),(Χ-4,Υ-2,Ζ-1 1), (Χ-4,Υ-3,Ζ-1),(Χ-4,Υ-3,Ζ-2),(Χ-4,Υ-3,Ζ-3),(Χ-4,Υ-3,Ζ- 4),(Χ-4,Υ·3,Ζ-5),(Χ-4,Υ-3,Ζ-6),(Χ-4,Υ-3,Ζ-7),(Χ-4,Υ-3,Ζ- 8),(Χ-4,Υ-3,Ζ-9),(Χ-4,Υ-3,Ζ·10),(Χ-4,Υ-3,Ζ-1 1), (Χ-5,Υ-2,Ζ-1),(Χ-5,Υ-2,Ζ-2),(Χ-5,Υ-2,Ζ-3),(Χ-5,Υ-2,Ζ- 4),(Χ-5,Υ-2,Ζ-5),(Χ-5,Υ-2,Ζ-6),(Χ-5,Υ-2,Ζ-7),(Χ-5,Υ-2,Ζ- 8),(Χ-5,Υ-2,Ζ-9),(Χ-5,Υ-2,Ζ_10),(Χ-5,Υ-2,Ζ-1 1),
(Χ-5,Υ-3,Ζ-1),(Χ-5,Υ·3,Ζ-2),(Χ-5,Υ-3,Ζ-3),(Χ-5,Υ-3,Ζ- 4),(Χ-5,Υ-3,Ζ-5),(Χ-5,Υ-3,Ζ-6),(Χ-5,Υ-3,Ζ-7),(Χ-5,Υ-3,Ζ- 8),(又-5,丫-3,乙-9),(又-5,丫-3,乙-10)或(又-5,丫-3,2-11) 或其製藥容許鹽、或這些之溶劑合物。 本發明之ΝΡΥ Υ5受體拮抗劑對ΝΡΥ Υ5關連疾病全般有 效地作用,尤其對肥胖之預防及/或治療及攝食抑制有用。 又對肥胖成爲危險因子之疾病,例如糖尿病、高血壓、高 脂血症、動脈硬化、急性冠狀動脈症候群等預防/及或治療
-46- 1376367 也有效。 更本發明化合物不僅有ΝΡΥ Y5受體拮抗作用,且具備 醫藥之有用性,具有下述任一或所有優異特徵。 a) CYP酵素抑制弱。 b) 不易引起藥物代謝酵素之誘導。 c) 呈高生物利用性等良好之藥物動態。 d) 貧血誘發作用等毒性低。 e) 代謝安定性高。
f) 具有高Y5受體選擇性。 g) 水溶性高。 h) 腦移行性高。 且本發明之ΝΡΥ Y5受體拮抗劑對ΝΡΥ Y1及Y2受體之 親和性低,具有高Y5受體選擇性。NPY於末梢惹起持續 性之缺陷收縮作用,但此作用主要仲介Y1受體。Y5受!| 與如此作用完全無關連,故基於末梢血管收縮而誘發副作 用之可能性低,可視爲安全之醫藥而適合使用。
ΝΡΥ Y5受體拮抗劑抑制攝食而呈抗肥胖效果。故無見諸 抑制消化吸收而呈抗肥胖效果之藥劑之消化不良等副作用 ’和呈抗肥胖效果之如血清素轉運蛋白抑制劑之抗鬱作用 等中樞性副作用爲本藥劑之特色之一。 本發明之化合物作爲抗肥胖藥或攝食抑制劑來投與時, 經口或非經口之任一方法皆可投與。經口投與可依常法調 製成錠劑、顆粒劑、散劑、膠囊劑、九劑、液劑、糖漿劑 、口含劑或舌下劑等通常使用之劑型來投與。非經口投與 -47- 1376367 可以例如肌肉內投與、靜脈內投與等注射劑、坐劑、經皮 吸收劑 '吸入劑等通常使用之任一劑型皆可適宜投與。本 發明之化合物因經口吸收性高,適合以經口劑使用。 於本發明之化合物之有效量令適合其劑型之賦形劑、結 合劑、濕潤劑、崩壞劑、滑澤劑、稀釋劑等各種醫藥用添 加劑依必要而混合作爲醫藥製劑。注射劑時與適當載體一 起滅菌處理作成製劑。
具體而言,賦形劑可用乳糖、白糖、葡萄糖、澱粉、碳 酸鈣或結晶纖維素等、結合劑可用甲基纖維素、羧甲基纖 維素、羥丙基纖維素、明膠或聚乙烯基吡咯啶酮等、崩壞 劑可用羧甲基纖維素、羧甲基纖維素鈉、澱粉、藻酸鈉、 洋菜末或十二基硫酸鈉等、滑澤劑可用滑石、硬脂酸鎂或 聚乙二醇等。坐劑之基劑可用可可脂、聚乙二醇或甲基纖 維素等。又作爲液劑或乳濁性、懸浮性之注射劑可令調製 時通常使用之助溶劑、懸浮化劑、乳化劑、安定化劑、保 存劑、等張劑等適宜添加,經口投與時也可加矯味劑、芳 香劑等。 作爲本發明化合物之抗肥胖藥或攝食抑制劑之投與量宜 考慮患者之年齡、體重、疾病之種類和程度、投與經路等 而設定,成人經口投與時,通常爲0.05〜100mg/kg/曰, 宜0.1〜10m g/kg/日之範圍內。非經口投與之時,依投與 經路而大爲相異,通常爲0.005〜10mg/kg/日,宜0.01〜 lmg/kg/日之範圍內。可分1日1回〜數回投與。 以下舉實施例更詳細說明本發明,但發明不受此限定。
-48- 1376367 又本說明書中所用縮寫如下。 M e :甲基 Et:乙基 i-Pr:異丙基 DMSO:二甲亞碾 Pd-C:鈀碳 THF:四氫呋喃
DMF:N,N·二甲基甲醯胺 mCPBA:間氯苯甲酸 【實施例】 實施例1化合物(Ii-Ι)之合成 第1工程
〇2N^j-
o2n
C6H4FN〇2 Mol. Wt. : 141.1
C13H18N202 Mol. Wt. : 234.29 3-氟硝苯(2.00 g,14.2 mmol)溶解於二甲亞颯15 ml’加 3,5-二甲基哌啶(3.21 g,28.4 mmol)和碳酸鉀(3.92 g,28·4 mmol)於15 (TC攪拌3小時。反應液注入水而以乙酸乙醋萃 取》令有機層水洗而以無水硫酸鈉乾燥。減壓蒸除溶劑 殘渣加乙酸乙酯及己烷,濾取析出之結晶而得目的物取代 硝苯2.05 g,産率62%。 'H-NMR (CDCI3) δρριη: 0.76 (q,1H,J = 12.0 Hz), 0 96 (d, 6H, J = 6.3 Hz), 1.70-1.91 (m, 3H), 2.32 (t, 2H, j ^ -49- 1376367 12.0 Hz), 3.62-3.72 (m, 2H), 7.17-7.25 (m, 1H), 7.34 (t, 1H, J = 8.1 Hz), 7.59 (d, 1H, J = 8.1 Hz), 7.71 (s, 1H). 第2工程 【化52】
c13h18n2o2 MoL Wt.: 234.29
M〇.C^°2N024.31
第1工程所得化合物(2.05 g,8.75 mmol)溶解於乙醇25 ml,加入10°/。Pd-C( 0.20g )來氫添加反應12小時。以矽 藻土濾除Pd-C,令濾液減壓濃縮。殘渣以矽膠柱層析精製 而得目的物苯胺1.62 g,産率90%。 ^-NMR (CDC13) δρριη: 0.69 (q, 1H, J = 12.0 Hz), 0.92 (d, 6H, J = 6.3 Hz), 1.75 - 1.9 8 (m, 3H), 2.22 (t, 2H, J = 12.0 Hz), 3.5 3 -3.62 (m, 2H), 6.21 (d, 1H, J = 7.5 Hz), 6.38 (s, 1H)., 6.42 (d, 1H, J = 8.1 Hz), 7.04 (t, 1H, J = 8.1 Hz). 第3工程
【化53】 co2h L1AIH4
THF
C11H23NO3S Mol. Wt :249.37 C11H21NO4S Mol. Wt :263.35 原料羧酸(合成法記載於國際公開第01/037826號小冊 )(5.04 g,19.1 mmol)懸浮於四氫呋喃50 ml,於冰冷下加 氫化鋰鋁 (0.726 g,1 9.1 mmol),於室溫攪拌1小時。反 應液再冰冷攪泮,小心滴下水(1 . 5 m L )。滴下後,於室溫 攪拌5分,濾除生成之沈澱,令濾液減壓濃縮。殘渣加乙 -50- 1376367 酸乙酯及己烷,濾取析出之結晶而得目的物醇3.15 g,産 率 66% » ^-NMR (DMS0-d6) Sppm: Ο· 8 8 (q,2Η,J = 1 1 ·6 Ηz), 1.25 (s, 9H), 1.15-1.30 (m, 3H), 1.67- 1.76 (m, 2H), 1.83-1.92 (m, 2H), 2.97 (m, 1H), 3.13-3.20 (m, 2H), 4.35 (t5 1H, J = 5.2 Hz), 6.71 (d, 1H, J = 8.8 Hz). 第4工程 【化54】
C11H23NO3S Mol.Wt.: 249.37 Μ ΧΗΟ C11H21N03S Mol. Wt. :247.35 第3工程所得化合物(5 00 mg, 2.01 mmol)溶解於氯仿5 ml,力Π Dess-Martin 過澳酸(893 mg,2.11 mmol),於室溫 攪拌1小時。濾除沈澱,令濾液減壓濃縮。殘渣以矽膠柱 層析精製而得目的物醛385 mg,産率77%。 'H-NMR (DMSO-d6) δ p p m : 1.2 6 (s,9 Η),1.1 3 -1 . 3 8 (m,
4H), 1.8 5 - 1.9 8 (m, 4H), 2.16 (m, 1H), 3.01 (m, 1H), 6.80 (d, 1H, J = 8.0 Hz), 9.54 (s, 1H). 第5工程 【化5 5】
Mol.Wl.: 247.35
第2工程所得苯胺(107 mg,0.523 mmol)溶解於四氫呋喃 -51 - 1376367 3 ml ’加第4工程所得醛(130 mg,0.523 mmol)、於室溫攪 拌1小時。反應液加硼氫化鈉(23.7mg,0.628 mmol),更於 室溫攪拌3小時。反應液以乙酸乙酯萃取。令有機層水洗 、以無水硫酸鈉乾燥。減壓蒸除溶劑,殘渣以矽膠柱層析 精製而得目的物99.3 mg,産率43%。 iH-NMR (DMSO-d6) δρριη: 0.64 (q, 1H, J = 11.6 Hz), 0 87 (d, 6H, J = 6.0 Hz), 0.92- 1.08 (m, 2H), 1.25 (s, 9H), 1.15-1.32 (m5 2H), 1.41 (m, 1H), 1.5 8- 1.95 (m, 7H), 2.08
(t, 2H, J = 11.6 Hz), 2.75-2.82 (m, 2H), 3.00 (m, 1H), 3.48-3.5 5 (m, 2H), 5.31 (m, 1H), 5.94 (d, 1H, J = 8.5 Hz),
6.08-6.13 (m, 2H), 6.71 (d, 1H, J = 8.5 Hz), 6.85 (t, 1H, J = 8.5 Hz)·熔點:161-162°C 實施例2化合物(I j -1)之合成 第1工程 【化5 6】
Me02C
C11H21NO4S M〇丨.Wt. :263.35
TsOH :,i?CF: (^Pr)2NEt
i-PrOH
〇F3 C14H17F3N2〇2 Mol. Wt. : 302.29 原料胺(1_20 g,3.64 mmol)和2-氯-5-三氟甲基吡啶 (727 mg,4.0 1 mmol)懸浮於異丙醇4 ml,加N,N-二異丙 基乙胺(1.87 ml, 10.9 mmol)來封管後,用微波爐反應裝置 以1 6(TC之條件反應1小時。反應液注入水而以乙酸乙酯 萃取。令有機層水洗而以無水硫酸鈉乾燥。減壓蒸除溶劑 ’殘渣以矽膠柱層析精製而得目的物酯222 mg,産率20% -52- 1376367 第2工程 【化57】 Me 0 2〇 C F 3 CuHnF3N2〇2 Mol. Wt : 302.29
H
CF3i)MsCI. Et3N CHCl·, iD NaN3/DMF
C13H17F3N20 C|3H16F3Ns Mol. Wt :274.28 WoLWt. :299.29
第1工程所得酯(207 mg,0.68 5 mmol)溶解於四氫呋喃3 ml,冰冷下加入氫化鋰鋁 (31.1 mg,0.822 mmol),於室溫 攪拌0.5小時。反應液注入冰水而以乙酸乙酯萃取後,令 有機層水洗而以無水硫酸鈉乾燥,減壓蒸除溶劑而得醇。 所得醇溶解於氯仿3ml,加三乙胺(0.28 ml,2.04 mmol), 於冰冷下滴下甲磺醯氯 (〇·12 ml,1.64 mmol),於室溫攪 拌1小時。反應液注入水而以乙酸乙酯萃取後,令有機層 水洗而以無水硫酸鈉乾燥,減壓蒸除溶劑而得甲磺酸酯。 所得甲磺酸酯溶解於二甲基甲醯胺3ml,加入疊氮化鈉 (2 21 mg,3.40 mmol),於100°C攪拌3小時。反應液注入 水而以乙酸乙酯萃取。令有機層水洗而以無水硫酸鈉乾燥 。減壓蒸除溶劑,殘渣以矽膠柱層析精製而得目的物疊氮 化物178 mg,産率87%。 第3工程 【化58】
i)Hi, Pd-C EtOH
HaN
ii) J^rSOjCI Et3N THF
H ciBH2iFaN302S Mol.Wl. :379.44
Cia^ ib^jNs
Mol.Wl.: 299.29 第2工程所得疊氮化物(178 mg, 0.595 mmol)溶解於乙 •53- 1376367 醇3 ml,力〇 10% Pd-C( 30 mg )而氫添加反應4小時。令 Pd-C以矽藻土濾除,令濾液減壓濃縮而得胺。 所得胺溶解於四氫呋喃3ml,加三乙胺(0.28 ml,0.714 mmol),於冰冷下滴下異丙磺醯氯 (0.10 ml, 1.64 mmol)而 攪拌1小時。反應液注入水而以乙酸乙酯萃取後,令有機 層水洗而以無水硫酸鈉乾燥。減壓蒸除溶劑,殘渣以矽膠 柱層析精製而得目的物64.8 mg,産率29%。
*H-NMR (DMSO-d6) δ: 0.92- 1.06 (m, 2 Η), 1.10-1.25 (m, 2H,), 1.22 (d, 6H, J = 6.4 Hz), 1.38 (m, 1H), 1.76- 1.84 (m, 2H), 1.93 -2.02 (m, 2H), 2.81 (t, 2H, J = 6.0 H z), 3.0 8 - 3 .1 9 (m, 1H), 3.69 (m, 1H), 6.53 (d, 1H, J = 8.8 Hz), 6.95 (t, 1H, J = 5.6 Hz), 7.16 (d, 1H, J = 7.6 Hz), 7.58 (d, 1H, J = 8.8 Hz), 8.26 (s, 1H)熔點:1 5 5- 1 5 6°C 實施例3化合物(Ij_l)之合成 第1工程 【化5 9】
Me02C
C15H23NO5S M ol.Wt. :329.41
(B〇C)2〇 EtsN
TsOH
ChbCb
Mol. Wt.: 257.33 原料胺(132 g,401 mmol)冰冷下懸浮於二氯甲烷1000 ml,依序加三乙胺(123 ml, 882 mmol)、(Boc)2〇(l〇l ml, 44 0 mmol)而反應1 0分。其後更於室溫反應2小時,蒸除 溶劑。於檸檬酸水(檸檬酸一水合物50g,水400 ml)注入 殘渣而作成pH4,以乙酸乙酯萃取。令有機層水洗,以無 水硫酸鎂乾燥,減壓蒸除溶劑而得目的物,定量》 -54- 1376367 'H-NMR (DMS0-d6) 5ppm: 1 .06- 1.25 (m, 2H), 1.25-1.43 (m, 2H), 1.37 (s, 9H), 1.75- 1.94 (m, 4H), 2.19 (tt, 1H, J = 11.7, 3.9 Hz), 3.07-3.24 (m, 1H), 3.58 (s, 3H), 6.74 (d, 1H, J = 6.6 Hz). 第2工程 【化60】
L1AIH4 THF
C13H23NO4 C12H23NO3
Mol. Wt. :257.33 Mol. Wt.: 229.32
氫化鋰銘 (18.3 g, 483 mmol)懸浮於四氫呋喃800 ml’ 於冰冷攪拌下以1小時徐徐加第l工程所得酯之四氫呋喃 (3 00 ml)溶液。於冰冷下反應10分後,更於室溫反應2.5 小時。令反應液再冰冷,依序加水和四氫呋喃之混合液 (1:1,36 ml)、2N氫氧化鈉水溶液(18 ml)、水(18 ml)而攪 拌20分。其後更於室溫攪拌1.5小時,濾除析出物,令濾 液減壓濃縮》於殘渣加乙酸乙酯及己烷,濾取析出之結晶 而得目的物醇79.5 g,産率87%(第1〜2工程合計)。 iH-NMR (DMSO-d6) δρριη: 0.78-1.00 (m, 2H), 1.00-1.32 (m, 3H), 1.37 (s, 9H), 1.65- 1.84 (m, 4H), 3.04-3.24 (m, 3H), 4.32-4.42 (m, 1H), 6.66 (d, 1H, J = 7.8 Hz). 第3工程 【化6 1】
C12H23NO3 Mol. Wt :229.32
i) MSCI/THF ii) NaN3/DMF
.Boc C12H22N4O2 Mol Wt. : 254.33 -55- 1376367
原料醇 (79.5 g,347 mmol)溶解於四氫呋喃800 ml,冰 冷攪拌下依序加三乙胺(72.5 ml,520 mmol)、甲磺醯氯 (32.2 ml,416 mmol)而反應1.5小時。反應液注入檸檬酸 水(檸檬酸一水合物30g,水500 ml)作成pH4,以乙酸乙 酯萃取後,令有機層水洗而以無水硫酸鎂乾燥。令減壓蒸 除溶劑之途中濾取析出之結晶,以己烷洗淨而得甲磺酸酯 100 g。所得甲磺酸酯溶解於二甲基甲醯胺100 ml,加疊 氮化鈉(63.7 g,980 mmol),於80°C反應2小時。反應液 注入水而以乙酸乙酯萃取。令有機層水洗,以無水硫酸鎂 乾燥,減壓蒸除溶劑而得目的物疊氮化物,定量(粗重量 8 5.4 g)。 'H-NMR (DMSO-d6) 5ppm: 0.90-1.21 (m, 4H), 1.32-1.50 (m, 1H)S 1.37 (s, 9H), 1.65- 1.84 (m, 4H), 3.06-3.24 (m, 3H), 6.71 (d, 1H, J = 8.1 Hz). 第4工程 【化62】
ΆΒί ^12^2^4〇2 Mol. Wt. :254.33 PPh3 H20
THF
Boc ^12^24^2^2 Mol. Wt. : 228.33 第3工程所得疊氮化物室溫溶解於四氫呋喃900 ml,依 序加三苯膦(103 g,392 mmol)、水(90卩1),於80 °C反應 1.5小時》蒸除溶劑770 ml,依序加水300ml、乙酸乙酯 400 ml、2N鹽酸150 ml作成pH2.5,施行分液萃取。有機 層以2N鹽酸萃取,合倂水層而以乙酸乙酯洗淨後,以2N 氫氧化鈉作成鹼性,以乙酸乙酯及氯仿反復萃取。合倂有 -56- 1376367 機層,以無水硫酸鎂乾燥。減壓蒸除溶劑,殘渣加己烷, 濾取析出之結晶,以己烷洗淨而得目的物胺41.7 g,産率 5 3 %(第3〜4工程合計)。 •H-NMR (DMS0-d6) 5ppm: 0.77-0.96 (m, 2H), 1.00-1.18 (m, 3H), 1.37 (s, 9H), 1.67-1.82 (m, 4H), 2.30-2.38 (m, 2H), 2.90-3.60 (m, 2H), 3.05-3.22 (m, 1H), 6.66 (d, 1H, J =7.2 Hz).
第5工程 【化63】 Ο ο
C12H24N202 C15H30N2O4S Μol.wt :228.33 Mol. Wt.: 334.47
原料胺(37.5 g,164 mmol)懸浮於四氫呋喃400 m卜於-55 〜-40°C攪拌下徐徐依序加三乙胺(91.7 ml,656 mmol)、異 丙磺醯氯(32.2 ml, 416 mmol),徐徐昇溫至0°C並反應6 小時。反應液注入冰冷之‘稀酸水溶液,以乙酸乙酯萃取。 令有機層水洗,以無水硫酸鎂乾燥。減壓蒸除溶劑,殘渣 加異丙醚,濾取析出之結晶,以異丙醚洗淨而得目的物磺 酿胺43.1 g,産率79%。 'H-NMR (DMSO-d6) δρριη: 0.79-0.98 (m, 2H), 1.00-1.36 (m, 3H), 1.20 (d, 6H, J = 6.6 Hz), 1.37 (s, 9H), 1.70-1.84 (m, 4H), 2.72-2.80 (m, 2H), 3.04-3.22 (m, 2H), 6.68 (d, 1H, J = 8.1 Hz), 6.94 (t, 1H, J = 6.0 Hz). 第6工程 -57- 1376367 溶劑,殘渣以矽膠柱層析精製而得目的物化合物(Ij-1)158 mg,産率 60% β 又第5工程中異丙磺醯氯代之以乙磺醯氯來反應,得Ri 爲乙基之如下化合物》 【化66】
Cl4H28N2〇4S Mol. Wl. :320.45
^-NMR (DMSO-d6) 6ppm: 0.80-0.98 (m, 2H), 1.02-1.18 (m, 2H), 1.17 (t, 3H, J = 7.2 Hz), 1.22-1.34 (m, 1H), 1.37 (s, 9H), 1.68- 1.82 (m, 4H), 2.68-2.78 (m, 2H), 2.96 (q, 2H, J = 7.2 Hz), 3.04-3.22 (m, 1H), 6.68 (d, 1H, J = 8.1 Hz), 6.94 (t, 1H, J = 6.0 Hz). 第5工程中異丙磺醯氯代之以第三丁亞磺醯氯來反應, 其後用mCPBA來氧化,得R1爲第三丁基之如下化合物( 參照 W02001037826,實施例 3)。
【化67】
CieH32tS|2〇4S Mol. Wt. : 348.5 h-NMR (DMSO-d6) δρριη: 0.79- 1.00 (m,2H),1.01-1.20 (m,2H),1.22-1.34 (m,1H),1.25 (s,9H),1.37 (s,9H), 1.70-1.86 (m,4H),2.81-2.90 (m,2H),3.04-3.22 (m,1H), 6.68 (d, 1H, J = 8.1 Hz), 6.83 (t, 1H, J = 6.0 Hz). -59- 1376367 利用上述化合物,得第6工程中R1爲乙基或第三丁基之 如下化合物。 R 1爲乙基之場合 【化68】
C^H21CIN2〇2S Mol.Wt. : 256.79
H-NMR (DMSO-d6) 5ppm: 0.84- 1.02 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.20- 1.40 (m, 3H), 1.74- 1.82 (m, 2H), 1.90-2.00 (m, 2H), 2.72-2.80 (m, 2H), 2.8 3 -2.96 (m, 1H), 2.97 (q, 2H, J = 7.5 Hz), 7.04 (t, 1H, J = 6.0 Hz), 8.03 (s, 3H). R1爲第三丁基之場合 【化69】
C11H25CIN2O2S Mol. Wt.: 284.85 ίμη2
HCI «
H-NMR (DMSO-d6) 5ppm: 0.84- 1.04 (m, 2H), 1.16-1.38 (m, 3H), 1.26 (s, 9H), 1.74- 1.84 (m, 2H), 1.92-2.02 (m, 2H), 2.82-2.9 8 (m, 3H), 6.90 (d, 1H, J - 6.0 Hz), 8.01 (s, 3H). 同樣合成之以下化合物也包括於本發明。 { e -60- 1376367 【化7 0】
1-1 1-2 1-3 ΙΑ 1-5 1-6 1-7 1-8 1-9 1-10 1-11
1-12 1-13 1-14 1-15 1-16 1-17 1-18 1-19 1-20 1-21 1-22
H
伽
-61 - 1376367 【化7 1】 0 1-23 a Ml 1-24
1-25 y〇.j l~35 ysNj〇^H^XX^ 〇 x-36 xkx^to^ 0 0 1-26
.Ν. 〇。〇 1-27 00 Η 1-38 βχχ a 1-28 OMe 1-39 1-29 鲁 1-30 Η Η ο >· N N 00 U^c, 1-40 Ον- Ο 气|
Ml N0〇 x> N〇〇 1-31 ^08¾ 1-42
H 1-32 0¾ °ΉΧΙ_ 143 〇""t) CLn -Cl 1-33 144
^XX -62- 1376367
1-47 1-48
1-49 1-50
1-61 1-51 1-52 1-53 1-54 1-55
〇MJ〇 〇. Ό
O a Ό
1-56 1-57 1-58 1-59 1-60 1-62 1-63 1-64 1-65 1-66
-63- 1376367 【化7 3】 J-67 1-68 1-69 1-70 1-71 1-72 1-73 1-74 1-75 1-76 1-77 1-78 ^δ〇.^ ^bO.^ OJ ^6〇..s Χ>Λ 1-79 1-80 1-81 h2 1-82 O, nh2
XX >〇 〇 Λ-
〇.2HCI N〇-NH2
O 8 CLg Oy^ NH2 1-83 1-84 1-85 1-86 1-87 1-88 1-89 1-90
^6〇J ^b〇J ^sb〇J ^b〇J Λ ^6〇J
XXN X»
OTBS OTBS a,
XX
〜。H
Ou, 〇2Me
X02H
On- -64- 1376367 【化7 4】 1-91 ^
!.92 C^S^H Η 1-93 1-105 、Ke 1-94 CI^S*^ Η 1-106 ° ^ Cu^ 1-95
XX^ 1-96
t ^i〇N N J^H 0¾ N 人N 1-97 1-98
々iiOJJ 1-99 1-100 1-101 1-102
H do
Cu. 1-103 1-104 1-107 1-108 1-109 1-110 1-111 1-112 1-113
Λ -65- 1376367 【化7 5】 Ι-】]5 "ΐ、 I**l 16 Η 1-127 〇〇/ 1-128 Η ,Ν 1-117 1-118 Η Η °'"〇 ^13° 1-119 ν/ tl Η 1-120 乂兵 1-131 Η …1 1-132 〇-'〇 U,..N^S>^Q.f _ u 1-121 1-122
^s.nn^| H 〇5 认1-133 ¢5¾ 1-134 1-123 CU. 1-135 1-124
H nNX) 1-136 J-125 O:h 1-137 1-126 '耳 丫、h 0 0 ^v.N^.〇cf2chf2 1-138 1376367 【化7 6】 Ι-Ϊ39 1-151
Cl 1-140 〇〇Ό·』 I H CF3 χ-152 ^
j-141 ^£όλ
m3 ms
1-142 OMe
1-154 00 Ά$) 1-143 1-144
H C〇2Me 0。kA-N^cc^MeH ;XrF 1-155 1-156
Hsnvn H s'N^b〇.J
CQ 0 1-145
OJ
1-157 I H 乂 SN 60 1-146 fo. H 0-¾ N-NH 1-158 1-147 ^£oj 以OMe 1-159 Hoy 1-148 Wa, H 广0 1-160 ^b〇.,S0〇^ 1-149 ^o. 』,NJ〇 1-161 0¾ 1-150 h ci 00 1-162 { c <· -67- 1376367 【化7 7]1-163 ^fo. OH 1-173 Η
OJ 1-164
1 XX^CC^Me 1-174 a 〇τ〇〇2η 1-165 06
1-175 Η
1-166
荔OJ ΙΊ76 1-167
A 1-177 O' 〇s^C〇2(V(0
fQ^C〇zH 1-168
^〇OJ 1-178 1-169 1-170 ΝΛα Meφ〇Ό Me 1-179 ΐΊ8〇 混 0 Jqt。〜_e2 ^〇Ό, -N, 1-171 Μη
6%n〇j 1-172 1-182 -N、
)1D -68- 1376367 [化7 8] 1-183 1-193 1-184 1-194 1-185
ΟΌ
Ό-J
N 1-195 ^OJH0〇Me^OJNU H ^^OMi 乂cfoj 4' C02Me 1-186
XO-jS 1-196
Ns^wOEt XX OEt 1-187 I H OMe 1-188 H " OMe 1-198 I- 189 OMe NMe2 i_i99 n_n 1-200 1-191 '0
Xr1 1-201
0¾Woj切 ^N—OH^b〇J^〇.J x> c〇 1-192 1-202
-69- 1376367 【化7 9】 1-203 X?' conh2 1-204 xx> 1-205 CONH^( 1-206
OuGN 1-207 1-208 1-209 1-210 S02NH2
CQ 1-211 1-212 1-213 1-214 1-215 1-216 1-217 1-218 1-219 1-220 1376367 【化8 0】 1-227
Op 1-228
Ο 1-229
Ό0Ο
1-230
1-231
1-232 1-233 1-234 1-235 1-236 1-237
-71 - 1376367 【化8 1】
-72. 1376367 [化8 2] 1-260 1-271 I Η Λ〇νσο"
Me 1-261
XV
OTBS k,〇TBS 1-272 1-262 1-273 1-263 1-264 。’ m 1-274 ,Η Η Ν Ν 1-275 1-265 1-266 1-267
、ΎΜ£ ώ χχ^ C02Me 、n〜oh
A χο2η 1-276 4Sf 00^Κ 1-277 〇〇 1-278 Ο, OMe νλν Η o' OCFoCHFo
1-268
Nu>〇?if 1-279
Η N〇y 1-269 1-280
^ΟΗ 0 SMe 1-270
,Me >SN -73- 1376367 【化8 3】 1-282 1-283 1-284 1-285
1-293 1-294 1-295 1-296 1-297
1-287 1-288 1-289
1-290 1-291 1-292
1-298 1-299
1-300 1-301
1-303 Cl >-sN 〇〇Ή -74- 1376367 【化8 4】 、l Η 1-304 〇〇
1-315
I H >SN cf3 H 一 N -N^S 1-305 00
H 1-316 1-306
A 1-317 1-307 μ 00
1-318
1-308 1-309 ^SN 00 Ή、 ^SN 〇〇 Ί 1-319
0 1-320
1-310 1-311 1-312 1-313 1-314
1-321 1-322 1-323 1-324 1-325
Me
-75- 1376367 【化85】
1-326 1-327 1-328 1-329
1-337
1-338 1-340
1-339 .
OMe 1-330
1-341
ja ΝΜθ2 'Q-0'^NMe2 1-331 1-332
1-342 1-343
1-333
1-344 1-334
1-335
1-336 1-345 1-346 1-347
-76- 1376367
1-351 1-352 1-353 ® 1-354 1-355 1-356 [化8 6] 1-348 1-349 1-350
1-357
CONH-( 1-358 1-359
1-360 1-361 1-362 1-363
1-364
/ C、 v - -77- 1376367 【化8 7】 1-366 1-377
Χ-367 I-37S X-36S 1-379 «χ^ςΡ ; 1-369 ^^ΝηΧ)^ 1-380 剛 1-381 1 Η Η 么 w、Nx> 1-371 Λ8ν^ ^χχ' 1-382 1-372 z^'Q-N^^^S ο'_、δ Η 、〇 1-383 如 1-373 0¾ 〜1Vi ο ν^ΝΛ_ 〇^Q,〇| 1-384 An. 0¾ 〜、K〇^j〇 1-374 y^-β N^s. 1-385 Ag-l· H 1-375 ✓^g-N Ν/ν H 、Ni〇 1-386 七卜K〇。一 1-376 〜Ntl 1-387 H 以OMe -78- 1376367 【化8 8] - 1-388 kNVS 1-399 〜H〇^r。 - 1-389 ^Ny^OMe ^OMe 1-400 V八 〜㈡"QrV 1-390 々B 1-401 H 0 H • 1-391 XX、 、no 1-402 1-392 Λ3ν^ H 以Ό 1'403 1-393 ^N〇〇 1-404 d'b Νγ%. ^NHz I-3S4 d'b 1-405 °'° H • 1-395 Ί On、 c^c, 1-406 (ft* 〜bon、 1-396 1-407 〜Νγ^ 2HCI 1-397 cTb 1-408 〇"° 〜Κχχ8 1-398 N^n H 1-409 0¾ -79- 1376367
Η 1-426 .Η Η ό.0 1-427
【化8 9】 1-410 H 〜 1-421 XX^COiH 1-411 〜h 0^ nh2 1-422 H 〜NsD , ^N〇-〇K 1-412 J'l 〜HtV n’ns 1-423 _^β 一 〜ho 1-413 H 1-424 Me 0 1-414 1-425 Me
Μ17 々'ί 一 I-41S 1-419 1-420 W—R〇l,h
OH 〆 ΝΝ 〇〇 LA^s^C02Me -80- 1376367 【化9 0] 1-432 M33 ,Η Ηit 1434 I H ΛΝ' 00
CO 1-435 I H ΛΝ' 00
H
1-436 1-437 1438 1-439 I H x^sN' 00 y—NoSMe
,H ^sN、 00 K〇C〇
H 1-440 ^Lsn CN Me Nn,
H OM _N I
1-441 <:S H N, 1442 〇〇 H 」N、 00 日r
0 0 M43 oso 〇0X3 1444 1-445 1-446 n^q,〇cf2chf2 1-447 1448 1449 1450 1-451 1-452 1-453 1454 1455
-81 - 1376367 【化9 1】
1-456 1-457 1-458 1-459 1-460 1-461 1-462 1-463 1-464 1-465 1-466
ΙΑ6Ί IA62 1469 1470 1471 1-472 1-473 1474 1475 1476 W77
-82 1376367 【化9 2】 1-478 M79 1-480 Μ ^0S0 Η •N/LO Ν Me
0^c〇2M Η 1-481
1-482 1-483 Μ84 4?·
H N0°"C〇2Me M95
1-485
XO2H H 1-486
Λ 0°' 1-487 -^0°
,CN 1-488 1489 1490 1-491 e M92 l〇pC02H 1-493 I-A94 1-496 NMe〇 1-497 1498 1-499
-83- 1376367 [化9 3] 1-500 1-501 1-502 it 1-503 1-504 1-505 ^.ί3. 〇0Me 1-510 〜Mc〇 1 0 H U〇Me 1-511 ^ν^Ν^^ΧΌΝΗ— BrS K^C02Me 1-512 〜βΌυ〇Ν 已 1-513 ^"€csm> HO Nx^ 1-514 1-515 so2imh2 1-516 -Ν 1-506 Ν w〇c° ο^ό
1-517 eft) 1-507 Ο 1-518 .n^.och3 OCH, )CH, H N.
CN I Η Η欠―N〇c f3 1-508 ^S-N, XX〕 1-519 1-509 .R^q^C0NH2 1-520
S 84 1376367
【化9 4】 1-521 1-522 1-523 1-524 1-525 1-526 1-527
1-528
1-529 1-530 1-531
〇L N〇〇 1-532 1-533 1-534 1-535 1-536 1-537 1-538 1-539 1-540 O〇 T〇七
r q ^ , -85-
1376367 【化9 5】 1-543 1-544 1-545 1-546 1-547 1-548 1-549 1-550 1-551 1-552 I-切欠〇^ 1-554 1-555 1-556 1-557 1-558 1-559 1-560 1-561 1-562 1-563 1-564
1376367 【化9 6]
1-565 1-566 1-567 1-568 1-569 1-570 1-571 1-572
1-576 1-577 1-578 1-579 1-580 1-581 1-582 1-583
co2h
Nu>〇K
Mi N
SOJ
I H γ^Ι Me
I H 1-573 1-574 1-575
OH
C02Me 1-584 H 〇〇 LXn 〇0' 1-585
0〇Me -87- 1376367 【化9 7】 1-587 1-589 1-590 ^SNr^i Η00 kA,N 』SN^i Η 00乂sV、Η 〇〇
x-592 1-593 1-594 1-595 Η 00 kXN ;SNr^ H 00 k^LN4M〇j
Η N^CI 1-599 如0¾ νά A^nNjQ H 1-600 1-601 H 1-602 °°C .n^ocf2chf2 〇 1-603 ^N〇L SMe 1-604 1-605 Jc〇o CN 1-606 ^OMe 1-607 N" 1-596
Me H Nn,
1-597 1-608 IT Br OMe〜
1-598 h C02Me 〇〇 kxLN 备C02Me u 0 0 U^njCn f C Λ ·* -88- 1376367 【化98】 1-611 1-610
N-NH
1-612 1-613
1-614 1-615 1-616 1-617 1-618 1-619 1-620
1-623 1-624 1-625 1-626 1-627 1-628 1-629 1-630 1-631
89- 1376367 【化9 9】 1-632 1-633 1-634 七ciOJ ^〇s〇tXii Η 1-635 1-636 1-644 〇S〇X^n^〇^CN VoO ⑽七cfcu^j Ns^ Me I-⑽ \>°X) Me H N〇2 I補々cfojji3 1-637 1-638 1-639 1-640 1-641 1-642 1-643 乂。S(?〇J々c?〇J^-c〇2Me Λ〇5〇ΧΧην〇〇 ^C02Me 1-653 1-654 J:sf ^Qf°^NMG2
1-649 1-650 ^oCLRji? 00 cu
N !-651 ^〇ν〇^Μ^Χ) 1-652
4R1CXR A
OMe A〇s〇〇LRXrNMe2
OJ
-90- 1376367
【化100】 1-656 OJ Η 0 Χτ〔 1-668 '〇^R_^rC0NH2 Ο v
丨OJf Λ〇5〇ΤΧΕ]νΟ〇Μ8 Η Η ^OMe 1-660 〇Ό XXnyS Ν 心C02Me ^SclR^ob ^ΟΒA0Si〇J 1-657 〇b〇 1-658 1-659 00 1-661 1-662 0 05 [Sj^vvOl-^664 ^TX^C0 1-663 1-665 1-666 1-667 (iJbN〇Jr、 ^'CN,Η VAOJ 戊〕 1-669 tx> 1-670 ^bO^Wv^/C〇NH^々i〇J3. 1-671 1-672 1-673 1-674 1-675 1-676
^XX 1-677 〇% 1-678 1-679 so2nh2 H n^-^och3
OJ1 0CH3CH: x>, cf3
g〇J cf、、〇
NH -91 - 1376367
【化101】 1-680 ^JA OO
1-690 ,OAc 00 1-681 00 L〇Pr 1-691 1-682 1-683
C〇〇H 1-692 1-693 1-684
1-694 乂J〇J』E Cl Σ-685 ^Ol! 1-695 1-686 1-696
>WNT^ H OMe 4 CX^N s^^0-CN 1-687 1-697 1-688 1-698 W〇J. 'N-N ^NHMe
OEt 1-689 C00B 1-699 0_0 ζΧΝ
^pD r c :】 > -w f -92- 1376367 【化102】 q Η ^〇s〇 A^h x-711 ^Srx^sSm2 l-102 Ab1·712
1-703 >1』
COOH 白 1-713
SMe 1-704
2 1-714 NH. ★icu X)rs' 1-705 1-706
1-707 1-708 1-716 1-717 1-718
^?OJW〇J
Et °X)
H
JyJ^CH20H osnh2 1-709
NHAc 1-719
-93- 1376367 【化103】 1-720 1-730 00 Ο0'
Et 1-721 α〇δ〇ΗΧΧ^ 1-731 ^〇NXXn 1-722 ,Η 1-723 Η 1-733 0 0 O^C0NMe2
a〇s〇xxs c O^C〇2Me
X-724 ^-CXB 1-734 i H Jsn
O Ό 0 0 Ov^N^jO^CONHMe 1-725 1-735 I H ^SN 00
tXHN
Na〇:
1-726 H 0 0 IA.N
1-736 〇〇 Ox^cnO 1-727
Usi 00
i〇J 1-737
0
^〇s〇XXK
1-728 1J XXKjOl, 1-738 I H λ〇Ν 0¾ 〇r 1-729 1-739 ^XXK, ,0Me 、0Me -94- 1376367 【化104】 1-740
H Me , 1-750 "COO Me 1-741
^XXW 1-751
H H OMe k>^V,N'0^C〇NMe2 1-742 1-743 參 Η 1-752 〇〇 00
1-753
NH
aP
1-744 u H
1-754 o
No 0 1-745 1-755
On〇 ,OJ. KCOOMe 1-746 eg. 1-756 〇L(
H .Rj\L〇〆 1-747 Ό^ΝΟΗ 1-757 1-748 1-758 H <Jui〇J· ^c,
TO OMe OMe 1-749 °^〇ji〇O〇' 1-759 -95-
1376367 【化106】 la-23 la-24 la-25 la-26
la-27 la.-2 8 la-29
la-30 la-31 la-32 la-33 〇 H *^F 0〇SbO-..N^L,F,H FVNcr 七〇.崎^o.
tX Ό: OMe OMe la-35 la-36 la-37 la-38 la-39 Ia40 Ia41 Ia42 Ia43 Ia44
-97- 1376367 【化10 7】 I“5 o^o
07、W獅〜¥
No
Ia^7 Ο Ν0) la-58
Ia^8 ,.n 'Μ
la-49 ^00 13-,. Ο la-60 la-50
51 增
Wxxt
la-61 Η
la-62 ★〇sfc,」W〇,,..
0 1¾.
Me -埝〇..、- 0^0
"Nt> NHS02Me la-53 W〇,_
Hn
la-64
H la-54 說〇·,
H Λ la-65 W〇.,JWtx
N
On la-55
la-66
NHS〇2Ph OH
-98- 1376367 【化108]
la-67 la-68 la-69 la-70 la-71
la-72 la-73 la-74 la-75
la-83 la-84 la-79 la-80 la-81 la-82
la-76 la-77
-99- 1376367 【化109] la-89 la-90 la-91
la-104 la-105 la-106 la-107 la-108 la-109 la-110 la-111
la-123 Ia-124 , H la-125 , H Ia-126 H H 〇〇 Uk^N la-127 la-130 la-131 la-122
〇、n R
H 丨丨W VCO 〇〇 o: c〇 o, O' cf3 CF,
Woj
Ia-132 O H °'〇 O^n^q^conh-C -100- 1376367 【化1 1 0】 la-133 la-134
Ia-135
;Op la-136 Ϋ la-137 cu
F la-138 !αρ
la-139 0¾ XXJ '0
Ia_14。為 J
Ia-141 \S〇N<Q la-142 〇〇 o CF,
Ι&—143 W 'xx> ^-〇cf3 la-144 la-145 la-146 la-147 la-148 la-149 la-150 la-151 la-152 la-153 la-154 1376367 【化1 1 1】 Ia-155 忍 Ia_166 CF,
H la-156 Η3〇^Ό h la_l67u.』€〇 H3C^ H Ia_157 〇〇 ia-168 ,b la-169
\ η少H 〇〇 U:,M fl la-158 oo
H 00 '〇J、 cf3 00
H 00
'〇J la-159 cu. ^〇sS° la-171 la-160 o
la-161
Op cp3 la-172 la-173 la-162 o la-163 la-164 la-165 ^os6"
NTYCOOoO la-174 la-175 la-176
00 a』 O〇
H 。〇 00
o〇o〇0O -102- ΒΊ636Ί 1^1121 ia-\n la-m 爲- M^CF3 la-\SO Η Ia493
Ia-\90 ^os〇S〇, Ο
Ia-\19 la-\Sl
5
Ia-\94 v ^00 Ό·<.^^ομη^Ό-J^o'
la-脱
Xa-lS3 %St),
Ia-\84
t7a
Ia-\95
Ia-\96 ^O, 、
N 'Oo
la-197
U5 广cf(3U
Ia-19S
〇s〇OJ t>0〇
滿 W〇.,J
Ia-187 la-188 la-189 o'b H op
la-199 h, Ό·Ά 八 Ia-2〇〇 Τ'δ-Ν,χ^. h ΤΙ Ψ 〇〇〇-w. ,H h OcP〇_〇,0,-"Nt>co^ Ia·201 v切OUD 1咖
-103- 0 1376367 【化1 口】 la-203 la-204
Ad la-216 la-219 la-220 xIo, la-205 s
Asn O'b^aiX)· cf3
o O〇x5
Xa-221 Ό〇-^ la-222_十v?…“I瑪少 X,20B i&.224 VhO η 06 ㈣智 〇J 々3 Ia_225 Ia-21〇 ^α«
Xa-2〇^ /cjt) ,
la-226
ia-2nw M〇Jv' b H la-228 Ή, la-213 〇 la-229 la-214 ia23〇 Ia-215 贫 O'少
〇〇H
la-227
H CH3
CONH
-104- 1376367 【化1 1 4】 la-231 la-232 la-233 la-234 la-235 la-236 la-237 la-238 la-239 la-240 la-241 la-242 la-243 la-244
-105- ;v 如9
Ib-14 lb-15 lb-16 lb-17 lb-18
^19 ^0-¾ 负-'0 一如』tv
Ib-^
Ib-20 lb-21 lb-22
-106- 1376367 【化1 1 6】 lb-23 秦4f
Ib-24 lb-25 lb-26 lb-27 lb-28 lb-29 lb-30 lb-31 lb-32 lb-33
lb-35 lb-36 lb-31 lb-38 lb-39 lb-40 Ib^l lbA2 lb-43 lb-44
-107- 1376367 【化1 1 7】 lb-45 lb-46 lb-47 lb-48 lb-49
So』 々〇 〇L』-
H
lb-57 ^〇Jj lb-56 'Q^h
Ib-58 lb-59
H XX^OH^NS)<
H lb-50 h
lb-60 h
0
H
H
lb-51 H lb-61 lb-62 lb-52
H σο η o H V H 〇 00
XXB x>
lb-63 H lb-53 〇〇 lb-64 lb-54
H
N^V 00 lb-65 o
JHS02Me Y1 hXX \ H >IHS02Ph μ 00 n
H lb-55
So』 lb-66
H
OH
00 < c -108- 1376367 【化1 1 8】 lb-68 ^
OJ ύα lb-78 Η
lb-79 lb-80 lb-81 lb-82 lb-83 lb-84 lb-85 Ib-76 Η 〇 滅Ο』 ίΧ^<Η
NyT!ΧΧγ XX
Ib-77
V lb-86 〇ν 〇ν
OH
Cl
Ό
OH Cl lb-87
H 00
F lb-88
"〇S〇0 R c^1 -109- 9】1376367 【化1 1 lb-89 'lb-90 lb-91 lb-92 lb-93 lb-94 lb-95 lb-96 lb-97 lb-98 lb-99 lb-100
CQ lb-101 tl 0 <n>..N^0CH3 Ib-102 lb-103 H ONH 2 lb-104 ^tio lb-105 N JM Ji^^CONH 乂 V lb-106 力 OoCN lb-107 说Ό·Ί XX,
Ib-108 lb-109
lb-110 0^1H2
^bO.^N f〇 110- 1376367 [化120] lb-111 lb-112 lb-113 lb-114 lb-115 lb-116 lb-117 lb-118 lb-119 I H H 〇v6 〇· ^N^V· 〇 b I H (Τό\Λ I H H 〇v0 xx> lb-123 lb-124 〜 lb-122 lb-125 lb-126
lb-127 』〇0
^6〇,.S Ό
Ib-120 lb-121
lb-128 〇· H N. 0¾1 H N. 0¾ 〕JOnT lb-129 说〇_ 1 H 1 κι )·』€〇 lb-130 H lb-131 H〜0 Mxx> lb-132 H 'V H .^N T ^1441376367 【化1 2 1】
lb-133 lb-134 lb-135 lb-136 Ib-137 lb-138 lb-139 lb-140 lb-141 lb-142 lb-143
lb-148 lb-149 lb-151 lb-152 lb-' lb-154 lb-146 Η^χ lb-147
〇b f3 lb-150
och3
,H ^ ^bO.HN
So
Q 112- 1376367 【化122】
lb-155 lb-156 lb-157 lb-158 lb-159 lb-160 lb-161 lb-162 lb-163 lb-164 lb-165
lb-166 lb-167 lb-168 lb-169 lb-171 lb-172 lb-173 lb-174 lb-175 lb-176
re、 -113 - 1376367 【化1 2 3】 lb-177 lb-178 lb-179 lb-180
N
o
SO^IH
lb-181 lb-182 τα so2nh lb-188 lb-189 lb-190 lb-191 lb-192
lb-183
•,N
TX a. lb-184 4ho.^
〇nJ
謂 H q 〇 6 kJ …Νγ^02Ν3 lb-187 Xnv-s hU ^CONH lb-185 化_194祝Ό』恥196感0』謂访〇_々 ^198没Ό』 114- 1376367
【化124] lb-199 lb-200 lb-201 lb-202 lb-203 lb-204 lb-205 lb-206 lb-207 lb-208 lb-209
lb-210 lb-211 lb-212 lb-213 lb-214 lb-215 lb-216 lb-219 lb-220 lb-221 lb-222 lb-223 lb-224 lb-225 lb-226
/ C 'i -115 - 1376367
【化1 2 5] Ic-1 Η (^x> Ic-13 Ic-2 Η ^N〇 Ic-14 ^ Ic-5 Η (Λ) Ic-16 >1^M Ic-7 I』^ Ic-8 ^XX Ic-18 Ic-9 Ic-19 ^ Ic-10 ^TX. Ic-20 Ic-11 Ic-21 Ic-12 >lsN^ Ic-22
0〇Me
N χχ cf3
H F
A
-116- 1376367 【化126]
Ic-23 Ic-24 Ic-25 Ic-26 Ic-27 Ic-28 Ic-29 Ic-30 Ic-31 Ic-32 Ic-33
I Η H F
Ic-35 Ic-36 Ic-37 Ic-38 Ic-39Ic, Ic41 Ic-42 Ic43 Ic44
-117- 1376367 【化127】
Ic-45 Ic-46 Ic-47
Ic-48 Ic-49 Ic-50 Ic-51 Ic-52 Ic-53
Ic-54 Ic-55
Ic-56 Ic-57 Ic-58 Ic-59 Ic-60 Ic-61 Ic-62 Ic-63 Ic-64 Ic-65 Ic-66
-118- 5¾1376367 r化1 2 8] Ic-67 Ic-68 Ic-69 Ic-70
N
Ic-78
Ic-79
Ic_8〇 滅 'ό|〇λ
Ic-71 Ic-73 Ic-74
Ic-75
Ic-76 0 6 ^*n〇w X> H Ic-77
Η n Ic-82 Ic-83 Ic-84 Ic-85 Ic-86 Ic-87
c -119 0 1376367 【化129] Ic-89 Ic-90 况
Ic_91 分 H 〇 〇 Ic-92 I h 〜sxX〕 Ic-93 0¾ H ON H2 Ic-94 Ic-95餐八 〜M^Q^ONH 乂 Ic-96 口 ^xxc Ic-97 Ic-98 3 八 Ic-99 H 〜Ν·ν^γ·^ ^so2nh2
Ic-100 Ic-101 Ic-102 Ic-103 Ic-104 Ic-105 Ic-106 Ic-107 Ic-108 Ic-109 Ic-110
-120- 1376367 【化130】 Ic-111 Ic-112 Ic-113 Ic-114 Ic-115 Ic-116 沒 Ic-122 H N.0% Λ
Ic-123
Ic-124
Ic-125 s
Ic-126
Ic-127
Ic-117
Ic-128
Ic-118
Ic-129
Ic-119
(fb
Ic-130
Ic-
H
Ic-121
Kx!x>
Ic-131
Ic-132 ¾¾¾¾¾¾¾¾¾¾¾ 1376367
【化1 3 1 Ic-133 Ic-134 Ic-135 Ic-136 Ic-137 Ic-138 Ic-139 Ic-140 0¾
H
H
xX
Ic-142 Ic-143 」H Ic-141 ^ 0¾
Ic-152 Ic-153 Ic-154
Ic-144 Ic-145 Ic-146 Ic-147 Ic-148 Ic-149 J H Ic-150 >^n crib u h Ic-151 >^N〇,6 -122- 1376367 [化132] Ic-155 ^6'
F3 F IC_156 3
Jl
Ic-157 Ic-158 Ic-159 Ic-160 Ic-161 Ic-162
Ic-163 Ic-164 Ic-165
Ic-166 Ic-167 Ic-168 Ic-169 Ic-171 Ic-172 Ic-173 Ic-174 Ic-175 Ic-176
* -123- 1376367 【化1 3 3]
Ic-177 Ic-178 Ic-179 Ic-180 Ic-181 Ic-182 Ic-183 Ic-184 Ic-185 Ic-186 Ic-187
H ^ 1f3 N H γ ^so2nh H 1» ^XXo nV U'SO〆] ^τχ ψ ^CONH
Ic-188 Ic-189 Ic-190 Ic-191 Ic-192 Ic-193 Ic-194 Ic-195 Ic-196 Ic-197 Ic-198
C -124- 1376367 【化134】 Ic-199Ic-2〇。#一βχχ〇
Ic-201 Ic-202 Ic-203 Ic-204 Ic-205
Ic-206 Ic-207 Ic-208 Ic-209
Ic-210 Ic-211
Ic-212 Ic-213 Ic-214 Ic-215 Ic-216 Ic-219 Ic-220 Ic-221 Ic-222 Ic-223 Ic-224 Ic-225 Ic-226
/ c ^ ·· <· -125 - 1376367
[化 1 3 5 ] Id-1 Id-13 Id-2 Id-14 ΙάΑ Id-16 Id-7 〜μό Id-17 Id-8 Η 〜Nxx Id-18 Id-9 Id-19 Id-10 Id-20 Id-11 0¾ Id-21 Id-12 ^Osp Id-22 -126- 1376367 [化 1 3 6] Id-23
Fl
Id-24 Id-25 Id-26
H F H
Id-27 Id-28 Id-29
I Η H F * 〇 b
Y I Η H F v->Ai Id-30 Id-31
Id-32
Id-33 4β—Ν€ξ4fl
Id-35 Id-36 Id-37 Id-38 Id-39 Id-40 Id-41 副2 Id-43 Id-44 H ,N_^OMe )Me
c -127 1376367
[化137] Id-45
Id-46
Id-47
Id-48
Id-49
Id-50
Id-51
Id-52
Id-53
Id-54
Id-55
Id-61 H 〇 l^TNMe 〇 Id-62 Id-63 H ^AvlHSO^Ie Id-64 H 〜ni〇l ^^NHSO^h Id-65 Id~66 H Q 〜ΝϊΚ>α
Id-56 八 Id-57 Id-58 ^Nr^〇〇 ^NS)< Id-59 八 Id-60 -128 1376367
【化1 3 8】 Id-67 0¾ Id-68 ^ώ;χ Id-69 Η Id-70 Id-71 Id-73 6 Η ι Υί ^N^V 、〇 Id-74 Id-75 ό〇^ Id-76 Id-77 Η ^γη〇^Ό
Id-78
Id-79
Id-80
Id-81
Id-82
Id-83
Id-84
Id-85
Id-86
Id-87
-129- 1376367 [化1 3 9] Id-89 Id-90
Id-91 Id-92 Id-93 Id-94 Id-95 Id-96 Id-97 Id-98 Id-99
Id-100 Id-101 Id-102 Id-103
Id-105 Id-106 Id-107 Id-108 Id-109 Id-110
H
-130- 1376367
【化140】 Id-111 Id-112 Id-113 Id-114 Id-115 Id-116 Id-117 Id-118 Id-119 Id-120
Id-121
Id-122 Id-123 Id-124 Id-125 Id-126 Id-127 Id-128 Id-129 Id-130 Id-131
Id-:
N ON H
-131 - 1376367 【化1 4 1】
Id-133 Id-134 Id-135 Id-136 Id-137 Id-138 Id-139 Id-140 Id-141 Id-142 Id-143
Id-144 Id-145 Id-146 Id-147
Id-148 0¾ H Id-149 八k Id-150 Id-151 H Id-152 ch3
Id-153 Id-154
-132- 1376367 【化142】 Id-155 PC;
Id-156
Id-167 介 hCF3 Id-168 ^v^^NTQ^>〇
Id-161 Id-162 Id-163 Id-164 Id-165
说一 N€^ χχ〇Χ>°Ν〇
Id-169 Id-171 Id-172 Id-173 Id-174 Id-175 Id-176
C -133- 1376367 【化1 43】 Id-177
Id-178 Id-179 Id-180 Id-181 Id-182 Id-183 Id-184 Id-185 Id-186 Id-187 ^6'0¾ Χλ:〇%
〇cf3ΧΧξΝ Xi'SOjJlH -N^QpSO^lH'X\5
N'qSoXD
Id-188 Id-189 Id-190 Id-191 Id-192 Id-193 Id-194 Id-195 Id-196 Id-197 Id-198
£ -134- 1376367 [化144] Id-199 Id-200
H
Id-201 υ Η
H CH
Id-202 ^6N
Id-204 Id-205 Id-206 Id-207 Id-208 Id-209 Id-210 Id-211
H
〇6
H
osJ
Id-212 Id-213 Id-214 Id-215 Id-216 Id-219 Id-220 Id-221
Id-222 Id-223 Id-224 Id-225
Id-226
1376367 【化145】 Ig-1
Ig-13 15-2 ^bXXM^ 12-4
Ig-14
Ig-16 ^Sxxw. 〇γ XX, -〇Me
Ig-17
Ig-7 H ,N <fb
〇J
Ig-18 Ό
Ig-8
Ig-9
Ig-l〇
Ig-11
Ig-12
^〇J ^bXXK 〇.XX Όγ
Ig-19
Ig-20 Ig-21 Ig-22
-136-
XV 1376367 【化146】^-23 ^ίχχβ
F
Ig-35 OMe
Ig-24
F
Ig-25
xX
Ig-36
0-6
Cl OJI. fe-26 丄、
Is-37 ^NXXK. lg-27
Ig-38
Ig-39
Ig-28
Ig-29
Ig-30
Ig-31
Ig-32
Ig-33 Ψ F^r'N'v^6:^bXXR.
Ig屬
Ig^l
Ig42
Ig^3
Ig44
^bXXR ^Sxxw^bXXK #〇J oo
NyTy.、 C, oc,
Na
OMe { c -137 X: 00 1376367 【化147] fe-45 ^!χχ}
Ig-56
H
Ig-46
Ig-57 00
OJ'tXR
Ig-47 o,
Ig-58
Na
^bXXK
Ig-48
H
Ig-49
H
Ig-59 X:
,N 00 XX^Ny^f
Ig-60
H
H
Oj Ig-61 00
Ig-51 〇〇 XXJ\
Ig-62 Ig-63 Ig-64 oo 00 00
XXR w丨OJ
H
Ig-65 ^〇\χπ
Jg-66 oo o o c -138- 1376367 【化148】 Ig-67 XX% lg-69^Oji o'b
Ig-70
Ig-71
Ig-74
Ig-75
Ig-76
Ig-77 lg-78 ^bXXR ^6XXl
'N
o, Y5
Ig-79 龜+ Ig 8。气分 ^XX\iJy㈣ SClJ.
Ig-82
Ig-83
Cl
Ό
Ig-85
Ig-86
Ig-87
Ig-88 ^!xxw xx
OH
Cl
OH o^> -139- 【化i 491 Η lg-S9 Ig肩#似令 ^93 ^tXtt^' Ό yoo
)CH^ :H3 COWHa lg-101 ㈣2 ^-104 ^tXS/j^-105 ^bO^fj,
Xf3 一 %似价 W〇6
Ig Λ〇1
lg-的 搶96 一#t>J^ 一 lg^09 ig-n〇 1376367
Ig-122 【化1 5 Ο】 Ig-ΠΙ ㈣伽0〆23匕113 心^
Ig-124
^ ^Ixx^ ¥125 ^QJJ
Ig-U5 Ig-116 h
Ig-127
¥n7々S〇j汉〕化挪。,。
Xg429 ^ΧΧΗ 每⑴9 gxx^^Vs ig-^°
(fb
Ig-12〇
Ig431
Ig-121
^^ί6〇
Ig-132 1376367 【化1 5 1】 ^-133
Ig-134
Ig-135 .I H 〇
H
Ig-136 >sN ';〇p cT6
〇J
Ig-137
?F
F
Ig-138 :0
Ig-144 Ig-145 is-146 仏147 ^XXS 太^txa^F
Ig-149 .ϋ
xX
Ig-139 Ig-140 Ig-141 Ig-142 Ig-143
Ig-152 〇-6 ^50 och3
XX ^6〇LHn Ig-154
-142- 1376367 【化1 5 2】
Ig-155 ^-156 如 ㈣
F3
Onfy 每-160編 lg-\6\
Ig-162
Ig-163
Ig-164 0¾ ^bXXK ^btxs
Of
Ig-165
〇4xx<?
Ig-166 Ig-167 Ig-168 Ig-169 Ig-171 Ig-172 Ig-173 Ig-174 ig-175 Ig-176
-143 1376367 [化1 5 3]㈣77偏汶 Ig-178 ^Uvi^
Ig-188 ^!xx
^btXR
^-189 ^ ^-190 ^bCLK ㈣孤C3 ,H ^-180 la-191Ig-192Saj
Ig-181
Ig-182
^bXXR 3〇J
^bXX
Ig-183
〇T
Ig-193 成(
Ig-194 _ ^0J I Η fe-18H"〇s〇2〇_#€〇! 丫 ^x< -s〇2〇
:0NH
Ig-195
Ig-196
Ig-197
Ig-198 ^ίχχκ^!xxw VtXX]\^ίχχ -144- 1376367 【化154】 #Οϋ
Jg-\99 ^-200 XXC fe-201
ONH
Ig-202 〇v6 Ig-215 Is-204 ^xx«X°12-205 h 〇6 丨 H ^-207
xf?° ^-208 ^bOJi Ig-209 N Ig-210
ig-211
Ig-212 Ig-213 Ig-214 Ig-216 Ig-217 Ig-220 Ig-221 Ig-222 fe-223 Ig-224 Ig-225 Ig-226
1376367
【化15 5】Ih-2 4Hxx« IhHaIh_7 ^btXR^1-8 ^δΧΧΒIh_n 滅XXR Ih-12 "^5 iQl^N
X^N
oaTXXX、
XV
Ih-13 ih-14 Ih-16 Ili-17 Ih-18 Ih-19 Hi-20 Ih-21 Hi-22
-146- 1376367 [化 1 5 6 ] Ih-23 Ih-24 Ih-25 Ih-26 0%
H • N Ih-27 Hi-28
i H F _
Ih-29 or
Ih-33
Ih-35 Ih-36 Ih-37 Di-38 Ih-39 Hi40 Ih-41 Hi-42 Ih43 Ih-44
含iXXB
cC
{ Q ^ > * -147- 1376367 【化1 5 7】 Ih45 'CLn lh-56 〇。〇
H
丨H μ iw',H Ih-47 ^?ΧΧην^λ
Ih^B IM9 ^tXfi ΰι-57 ^txs.
Ih-50
Ih-51
Ih-52
Ih-53
^〇iXJ\ WtXJ tSvr、。 % m_58 Stx”· Ώι-59h 、\5 Ih-60 m-61 >^1X13
Ih-62 ^〇XXJ\
H 〇
Na v~
Me
Wc
Xh-63
Ih-64 ^tXR. t>, NHSO^ie
Ih-54 ^tXH.
Ih-65 ^O^NHSO^h 3tx lh-55
^btX^〇sW
Ih-66
Cl ^VH.sX) -148 - 1376367 【化1 5 8】
Ih-67 Ih-68 Di-69 Ih-70 Ih-71
Ih-78
Ih-72
H
-149- o 0WH2
⑽5 91 11a IV9〇 ^,91 a〇cH3 t^OCH: IV'02 ^103 如你gtXtt办
•^-95 ^bO^O' ih-96
Oq 一办必 •^Λ〇^ 也-99
'^O'SO#^ ^ΛλΟ
Oi〇
1376367 【化1 6 1 Ih-133 111-134^XXR."
Ih-144
Ih-145 H N 0%
Ih-135
Hi-136
^bXX ;〇p
Ih-146
Ih-147 XXll-^-CF;滅xx收
Hi-137
Ih-148
H OO!
Olf ih-. Ih-139 Hi-i4〇 Ih-141 Ih-142 Hi-143
Ih-149 Ih-151 111452 Ih-153 Ih-154 CT6 ^!xxw Hi-150
Ό 4Kxx" 0
-152- 1376367 【化1 6 2]
Ih-155
Ih-156
Ih-157
Ih-158 鲁 Ih-159
Ih-160
Ih-161
Ih-162 • Ih-163
Ih-164
Ih-165
Ih-166 Ih-167 Ih-168 Ih-169 Ih-171
Ih-172 Ih-173 Ih-174 Ih-175 Ih-176
c -153 - 1376367 [化 1 6 3 ] Ώι-177
Ih-178 Ih-179 Ih-180 Hi-181
H 〇b
cf3 o
Ih-188 Ih-189 Ih-190 Ih-191 so2nh
Uxx^bXX iSbtX^soJH ^-192>.n ^-193 ^-183 . 0 ^-194 ^!oj\m495^tx ^so2tvQ> ""Us
Ih-182
Hi-184
Ih-185
^-196 ^bXX
Ih-187
^btXS
〇sw,3111-197 ^bXX
XX onh Ih-198 -154- 1376367 【化16 4】 Ih-199
Ih-200
Ih-201
Ih-202
Ih-203
Ih-204
Ih-205
Ih-206
Ih-207
Ih-208
Hi-209
Ih-210
Ih-211 祝OOI ^XXJ\^xxa iixxw
Ih-214
Ih-212
Ih-213
Ih-215
Ih-216
^bXXR
cf3
D
Ih-219
Ih-220
Ih-221 H N 0¾ H .N cfb H N 0%
〇J ώρ3 CF3
XX
Ih-222 η V 0¾ Ih-223 h F' ^224 滅 o〇^F XXy Ih-225 H ^ 〇6^XXn^kf3 -155 - 1376367 化合物1-72 [化 165]
*H-NMR (DMSO-d ) δ : 0.90-1.05 (m, 2 Η), 1.05-1.15 (m, 6Η), 1.25 (s, 9H,), 1.15 c
-1.32 (m, 3H), 1.41 (m, !H), 1.75-1.98 (m, 4H), 2.11 (m, 1H), 2.58-3.38 (m, 5H), 3 • 58-3.76 (m,2H), 5. Π (m, 1H), 6.25-6.92 (m, 5H)融點:147-149cC 化合物〖a-140 [化 166]
'H-NMR (CDC.1) δ : 1.02-1.20 (m, 2 H), 1.17-1.32 (m, 2 H), 1.37 (d, 6H, J = 6.9 Hz), 1.46-1.70 (in, 4H), 1.86-1.95 (m, 2H), 2.08-2.18 (m, 2H), 3.01 (d, 2H, J = 6. 9 Hz), 3.13 (m, 1H), 3.25 (m, 1H), 3.87 (d, 1H, J = 8.4 Hz) , 6.61(d, 2H, J = 8.7 Hz ),7.39 (d, 2H, J = 8.7 Hz)
化合物la-141 [化 167]
H-NMR (CDCI) δ : 1.00-1.30 (m, 4 H), 1.37 (d, 6H, J = 6.9 Hz), 1.59 (m, 1H), 1. 3 87-1.98 (m, 2H), 1.99-2.18 (m, 5H), 2.85 (q, 3H, J = 7.5 Hz), 2.97 (d, 2H, J = 6.9 Hz), 3.12 (m, 1H), 3.23 (m, 1H), 3.88 (d, 1H, J = 8.1 Hz), 6.53 (d, iH, J = 7.8 Hz) ,6.63 (brs, 1H), 7.04 (d, 1H, j = 7.8 Hz) Mass: 35l[M+H] 化合物la-178 -156- 1376367 [化 168]
'H-NMR (CDC1) δ : 1.08-1.36 (m, 4 Η), 1.39 (s, 9H), 1.59 (m, 1H), 1.90-1.99 (m, 3 2H), 2.16-2.26 (m, 2H), 3.17-3.34 (m,3H), 3.69 (d, 1H, J = 9.3 Hz), 6.68 (d, 1H, J =9.3 Hz), 7.77 (dd, 1H, J = 2.1 Hz and 9.3 Hz); 8.49 (brs, 1H) Mass: 394[M+H]+ 化合物lb-138 [化 169]
YOj δ : 1.02-1.34 (m, 4 Η), 1.37 (d, 6H, J = 6.6 Hz), 1.57 (m, 1H), 1. 丨H_NMR (CDC13) 87-1.97 (m, 2H), 2.07-2.18 (m, 2H), 2.93 (d, 2H, J = 6.6 Hz), 3.13 (m, 1H), 3.25 ( m,lH),3.99(cUH,J = 8.4Hz),6.38(m,lH),6.49(brs,lH),6.97(q,m,J=9· 3 Hz) Mass:347[M+H] 化合物Ii-2 [化 170]
'H-NMR (DMSO-d ) 5 : 0.91-1.06 (m, 2H), 1.12-1.28 (m, 11H), 1.31-1.47 (m, 1H) 6 ,1.75-1.94 (m, 4H), 2.19 (t, 2H, J = 11.3 Hz), 2.79 (t, 2H, J = 6.0 Hz), 2.93-3.08 ( m, 1H), 2.97 (q, 2H, J = 7.42 Hz), 3.46 (m, 2H), 3.57-3.69 (m, 2H), 5.71 (t, 1H, J = 5.2 Hz), 5.77 (d, 1H, J = 11.5 Hz), 5.88-5.96 (m, 2H), 7.01 (d, 1H, J = 7,4 Hz). 化合物Π-3 [化 171] -157- 1376367
lH-NMR (DMSO-d ) δ : 0.90-1.07 (m, 2 H), 1.15-1.21 (m, 1H), 1.27 (s, 9H), 1.40-6
1.49 (m, 2H), 1.82 (d, 2H, J = 11.6 Hz), 1.92 (d, 2H, J = 11.6 Hz), 2.79-2.84 (m, 2 H), 2.97-3.10 (m, 1H), 3.24 (s, 3H), 3.55-3.62 (m, 2H), 3.84-3.91 (m, 2H), 5.50-5. 59 (m, 1H), 6.40 (d, 1H, J = 8.0 Hz), 6.56 (s, 1H), 6.72 (d, 1H, J = 8.4 Hz), 6.97 (d, 1H, J = 8.4 Hz).融點:166-168°C 化合物[i-4 [化 17¾
'H-NMR (DMSO-d ) δ : 0.87 (t, 3H, J = 7.2 Hz), 0.93-1.06 (m, 2H), 1.13-1.21 (m, 6
1H), 1.26 (s, 9H), 1.37-1.49 (m, 2H), 1.61-1.72 (m, 2H), 1.82 (d, 2H, J = 12.0 Hz) ,1.91 (d, 2H, J = 12.0 Hz), 2.78-2.84 (m, 2H), 2.97-3.08 (m, 1H), 3.61-3.71 (m, 2 H), 5.52-5.60 (m, 1H), 6.40 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H), 6.73 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 8.8 Hz).融點:185-186°C 化合物Ii-5 [化 173]
'H-NMR (DMSO-d ) 5 : 0.90-1.05 (m, 2H), 1.26 (s, 9H), 1.28-1.31 (m, 1H), 1.35-6 1.47 (m, 8H), 1.81 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.77-2.84 (m, 2 -158- 1376367
Η), 2.96-3.07 (m, 1Η), 4.30-4.42 (m, 1H), 5.51-5.64 (m, 1H), 6.39 (d, 1H, J = 8.0 Hz), 6.55 (s, 1H), 6.72 (d, 1H, J = 8.8 Hz), 7.07 (d, 1H, J = 8.8 Hz).融點:156-15 7°C 化合物丨卜6 [化 174]
'H-NMR (DMSO-d ) δ : 0.91-1.07 (in, 2H), 1.19-1.25 (m, 4H), 1.26 (s, 9H), 1.38-6 1.49 (m, 2H), 1.82 (d, 2H, J = 8.8 Hz), 1.91 (d, 2H, J = 8.8 Hz), 2.79-2.84 (m, 2H). 2.97-3.07 (m, 1H)( 3.69-3.80 (m, 2H), 5.51-5.63 (ra, 1H), 6.41 (d, 1H, J = 8.0 Hz) ,6.56 (s, 1H), 6.72 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 8.8 Hz〉·融點:178-179°C 化合物Ii-7 [化 175]
'H-NMR (DMSO-d ) δ : 0.92-1.07 (m, 2H), 1.19-1.22 (m, 1H), 1.26 (s, 9H), 1.38-6 1.48 (m,2H), 1.8έ (d, 2H, J = 11.6 Hz), 1.91 (d, 2H, J = 11.6 Hz), 2.79-2.84 (m, 2 H), 2.95-3.09 (m, 1H), 3.25 (s, 3H), 5.52-5.60 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6. 56 (s, 1H). 6.72 (d, 1H, J = 8.4 Hz), 6_92 (d, 1H, J = 8.4 Hz).融點:206-2071 化合物li-8 [化 176]
-159- 1376367 5H-NMR (DMSO-d ) 5 : 0.91-1.05 (m, 2H), 1.16-1.24 (m, 1H), 1.26 (s, 9H), 1.37-6 1.47 (m, 2H), 1.81 (d, 2H, J = 12.8 Hz), 1.90 (d, 2H, J = 12.8 Hz), 2.75-2.81 (m. 2 H), 2.96-3.08 (m, 1H), 5.45-5.52 (m, 1H), 6.33 (d, 1H. J = 8.4 Hz), 6.50 (s, 1H), 6. 68-6.80 (m, 2H), 11.02 (brs, 1H).融點:213-214^: 化合物li-9 [化 177]
lH-NMR (DMSO-d ) δ : 0.91-1.08 (m, 2 H), 1.17-1.30 (m, 8H), 1.44 (brs, 1H), 1.8 6 2.(d, 2H, J = 12.4 Hz), 1.89 (d, 2H, J = 12.4 Hz), 2.78-2.82 (m, 2H), 2.97-3.15 (m, 2H), 3.23 (s, 3H), 3.55-3.62 (m, 2H), 3.83-3.90 (m, 2H), 5.52-5.59 (m, 1H), 6.40 ( d, 1H, J = 8.0 Hz), 6.55 (s, 1H), 6.92 (d, 1H, J = 8.0 Hz), 6.97 (d, 1H, J = 8.4 Hz). 融點::120-121°C 化合物丨i-10 [化 178]
lH-NMR (DMSO-d ) 8 : 0.88 (t, 3H, J = 7.2 Hz), 0.93-1.08 (m, 2H), 1.17-1.30 (m, 6 8H), 1.44 (brs, 1H), 1.52-1.61 (m, 2H), 1.83 (d, 2H, J = 12.0 Hz), 1.90 (d, 2H, J = 12.0 Hz), 2.78-2.84 (m, 2H), 2.98-3.15 (ra, 2H), 3.62-3.71 (m, 2H), 5.52-5.60 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.57 (s, 1H), 6.92 (d, 1H, J = 8.0 Hz), 6.97 (d, 1H, J = 8.4 Hz).融點:144-145。。 化合物li-11 [化 179] -160- 1376367
'H-NMR (DMSO-dJ δ : 0.90-1.08 (m, 2H), 1.15-1.30 (m, 8H), 1.33-1.50 (m, 7H), 6 l. 82 (d. 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.78-2.86 (m, 2H), 2.96-3.14 ( m, 2H), 4.30-4.45 (m, 1H), 5.50-5.61 (m, 1H), 6.40 (d, 1H, J = 7.6 Hz), 6.55 (s, 1 H), 6.92 (d,1H, J = 7.2 Hz), 7.07 (d, 1H,J = 7.6 Hz).融點:137-138T: 化合物H-12
[化 180]
'H-NMR (DMSO-d ) δ : 0.92-1.07 (m, 2H), 1.14-1.30 (m, 11H), 1.36-1.50 (m, 1H) 6
,1.82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.78-2.85 (m, 2H), 2.97-3.15 (m, 2H), 3.69-3.79 (m, 2H), 5.52-5.60 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.56 (s, 1 H), 6.92 (d, 1H, J = 7.2 Hz〉,6.98 (d, 1H. J = 8.4 Hz).融點:158-159°C 化合物Ii-13 [化 181]
'H-NMR (DMSO-d ) δ : 0.90-1.06 (m, 2H), 1.12-1.30 (m, 8H), 1.34-1.51 (m, 1H), 6 l. 82 (d, 2H, J = 12.0 Hz), 1.88 (d, 2H, J = 12.0 Hz), 2.77-2.83 (m, 2H), 2.95-3.12 ( m, 2H), 3.25 (s, 3H), 5.51-5.59 (m, 1H), 6.41 (d, 1H, J = 8.8 Hz), 6.56 (s, 1H), 6.8 6-6.97 (m, 2H).融點.:157-1581 化合物Ii-14 1376367 [化 182]
'H-NMR (DMSO-d ) 5 : 0.91-1.08 (m, 2 Η), 1.12-1.30 (m, 5H), 1.38-1.50 (m, 1H), 6 l. 82 (d, 2H, J = 12.0 Hz), 1.88 (d, 2H, J = 12.0 Hz), 2.77-2.85 (m, 2H), 2.90-3.09 (m, 3H), 3.23 (s, 3H), 3.55-3.61 (m, 2H), 3.84-3.91 (m, 2H), 5.52-5.60 (m, 1H), 6. 40 (d, 1H, J = 8.4 Hz), 6_55 (s, 1H), 6.89-7.00 (m, 2H).融點:150-151°C 化合物U-15
[化 L83] H
XXl^0 'H-NMR (DMSO-d ) δ : 0.88 (s, 3H), 0.90 (s, 3H), 0.92-1.08 (m, 2H), 1.12-1.30 ( 6
m, 5H), 1.35-1.51 (m, 1H), 1.83 (d, 2H, J = 12.4 Hz), 1.89 (d, 2H, J = 12.4 Hz), 2. 00-2.16 (m, 1H), 2.77-2.84 (m, 2H), 2.90-3.10 (m, 3H), 3.42-3.55 (m, 2H), 5.50-5. 65 (m, 1H), 6.40 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H),6.88-7.01 (m, 2H)融點:132-13 3°C
化合物Ii-16 [化 184]
lH-NMR (DMSO-d ) δ : 0.87 (t, 3H, J = 6.8 Hz), 0.90-1.08 (m,' 2H), 1.10-1.28 (m, 6 5H), 1.35-1.50 (m, 1H), 1.59-1.72 (m, 2H), 1.82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.77-2.85 (m, 2H), 2.90-3.09 (m, 3H), 3.61-3.71 (m, 2H), 5.52-5.61 (m, 1H), 6.40 (d, 1H, J = 8.0 Hz), 6.56 (s, 1H), 6.97 (d, 2H, j = 8.0 Hz).融點:136 ' V·» «· -162- 1376367 -137t: 化合物li-Π [化 185] Η
'H-NMR (DMSO-d) 5 : 0.92-1.06 (m. 2H), 1.12-1.28 (m, 5H), 1.33-1.50 (m, 7H), 6 l. 81 (d, 2H, J = 12.0 Hz), 1.88 (d, 2H, J = 12.0 Hz), 2.78-2.84 (m, 2H), 2.90-3.08 (
m, 3H), 4.28-4.44 (m, 1H), 5.49-5.79 (m, 1H), 6.39 (d, 1H, J - 8.0 Hz), 6.55 (s, 1 H), 6.97 (d, 1H, J = 7.6 Hz), 7.07 (d, 1H, J = 8.0 Hz). :124-125°C 化合物I卜18 [化 186]
'H-NMR (DMSO-d ) 5 : 0.90-1.07 (m, 2H), 1.12-1.29 (ra, 8H), 1.36-1.51 (m, 1H), l. 82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.78-2.86 (m, 2H), 2.90-3.09 (
m, 3H), 3.68-3.80 (m, 2H), 5.51-5.61 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.57 (s, 1 H), 6.97 (d, 2H, J = 8.4 Hz).融點:163-164T 化合物Ii-19 [化 187]
\ 'h-NMR (DMSO-d ) 6 : 0.89-1.08 (m, 2H), 1.11-1.30 (m, 5H), 1.35-1.51 (m, 1H), l. 82 (d, 2H, J = 10.8 Hz), 1.89 (d, 2H, J = 10.8 Hz), 2.75-2.88 (m, 2H), 2.89-3.10 ( m, 3H), 3.25 (s, 3H), 5.48-5.60 (m, 1H), 6.42 (d, 1H, J = 7.6 Hz), 6.56 (s, 1H), 6.9 -163- 1376367 2 (d, 1H, J = 7.6 Hz), 6.98 (d, 1H, J = 5.6 Hz).融點.:189-190°C 化合物Ii-20 [化 188]
'H-NMR (DMSO-d ) δ : 0.95-1.13 (m, 2H), 1.31-1.59 (m, 10H), 1.73-1.92 (m, 4H) 6
,2.12-2.26 (m, 2H), 2.84 (d, 2H, J = 6.0 Hz), 3.07-3.30 (m, 4H), 4.30-4.46 (m, 1H ),5.64 (brs, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.57 (s, 1H), 7..08 (d, 1H. J = 8.4 Hz). 融點:165-1661 化合物丨卜21 [化 189]
'H-NMR (DMSO-d ) δ : 0.86-1.25 (m, 10H), 1.40 (d, 3H, J = 6.9Hz), 1.52 (m, 1H), 6
1.82-1.93 (m, 4H), 2.95-3.00 (m, 5H), 3.63-3.91 (m, 2H), 4.61-4.68 (m, 1H), 6:73 (brs, 2H), 7.01 (d, 2H, J = 7.8Hz), 7.11 (d, 1H, J = 8.1Hz,). 化合物Π-22 [化 190]
'H-NMR (DMSO-d ) δ : 0.98-1.10 (m, 2 H), 1.15-1.34 (m, 5H), 1.36-1.43 (m, 9H), 6 1.53 (m, 1H), 1.82.1-93 (m, 4H), 2.94-3.01 (m, 6H), 4.52 (m, 1H), 4.63 (m, 1H), 6 -164- 1376367 .73 (brs, 2H), 7.02 (d, 1H, J = 7.5Hz), 7.21-7.25 (m, 1H). 化合物li-23 [化 191]
'κ-NMR (DMSO-d ) 6 : 0.86-1.04 (m, 4 H), 1,25 (s, 10H), 1.30 (s, 6H), 1.38 (s, 3 6
H), 1.40 (s, 3H), 178-1.92 (m 4H), 2.76-2.80 (m, 2H), 3.03 (m, 1H), 4.54-4.63 (m, 1H), 5.57 (m, 1H), 6.16 (s, 1H), 6.22 (d, 1H, J = 8.4Hz), 6.76 (d, 1H, J = 8.4Hz), 6. 98 (d, 1H, J = 8.4Hz). 化合物Ii-24 [化 192]
iH-NMR (DMS〇-d ) δ : 0.98-U1 (m, 5 H), 1.15-1.31 (m, 20H), 1.57 (m, 1H), 1.8 6
2.1-93 (m, 4H), 2.74-2.81 (m, 1H), 3.01-3.06 (m, 2H), 3.35 (m, 1H), 3.40 (m, 1H), 4.04-4.17 (m, 3H), 6.77 (d, 1H, J = 9.0Hz), 化合物Ii-25 [化 193]
'H-NMR (DMSO-d ) δ : 0.98-1.20 (m, 13 H), 1.30 (d, 3H, J = 3H), 1.59 (m, 1H), 1 6 .81-1.91 (m, 4H), 2.73-2.83 (m, 1H), 2.94-3.04 (m, 4H), 3.35-3.45 (m, 2H), 4.08-4
-165- 1376367 .19 (m, 3H), 6.88 (brs, 3H), 7.03 (d, 1H, J = 8.4Hz). 化合物U-26 [化 194]
2 HCI H 、,、 'H-NMR (DMSO-d ) δ : 1.02-1.10 (m, 2H), 1.19-1.32 (m, 2H), 1.26 (s, 9H), 1.55 ( 6
m, 1H), 1.86-1.93 (m, 4H), 3.01-3.04 (m, 3H), 6.76 (d, 1H, J = 8.7 Hz), 7.03 (m, 1 H), 7.37-7.43 (m, 3H), 7,76-7.80 (m, 1H), 8.20-8.23 (m, 1H). 8.34-8.40 (m, 1H), 8 .78-8.79 (m, 1H) 化合物li-27 [化 195]
'H-NMR (DMSO-d ) 5 : 1.03-1.10 (m, 2H), 1.20-1.30 (m. 2H), 1.21 (d. 6H, J = 6.9 6
Hz), 1.53 (m, 1H), 1.88 (m, 4H), 2.99-3.15 (m, 3H), 7.33-7.35 (m, 3H), 7.71-7.75 (m, 1H), 8.16-8.18 (m, 1H), 829-8.32 (m, IK), 8.76-8.78 (m, 1H)
化合物Ii-28 [化 196]
'H-NMR (DMSO-d ) 6 : 1.04-1.11 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H, J =7.2 6
Hz), 1.59 (m, 1H), 1.87-1.91 (m, 4H), 2.93-3.08 (m, 2H), 2.97 (q, 2H, J =7.2 Hz), 3.06-3.08 (m, 2H), 7.01 (m, 1H), 7.17 (d, 1H, J =7.5Hz), 7.43 (d, 1H, J =7.5Hz), 7. 50-7.57 (m, 2H). 7.80-7.84 (m, 1H), 8.25-8.27 (m, 1H), 8.39-8.44 (m. 1H), 8.80-8. -166- 1376367 82 (m, 1H) 化合物li-29 [化 197]
'H-NMR (DMSO-d) δ : 0.99-1.10 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H, J =7.5 6 .
Hz), 1.52 (m, 1H), 1.84-1.91 (m, 4H), 2.94-3.01 (m, 5H), 6.88 (m, 1H), 7.00 (d, 1H ,J =7.8 Hz), 7.26-7.28 (m, 2H), 7.38 (m, 1H), 7.76 (d, 1H, J = 3.3. Hz), 7.90 (d, 1 H, J =3.3 Hz) 化合物Ii-30 [化 198] 2Ησ ^ 'h-NMR (DMSO-d) 6 : 0.93-1.08 (m, 2 H), 1.18-1.33 (m, 2H), 1.26 (s, 9H), 1.45 6
(m, 1H), 1.78-1.97 (m, 4 H), 2.86-2.94 (m, 2H), 2.95-3.10 (m, 1H), 5.91 (m, 1H), 6.55 (d, 1H, J = 7.6 Hz), 6.63-6.71 (m, 2H), 6.73 (d, 1H, J = 8.0 Hz), 7.06 (s, 1H), 7.15 (t, 1H, J = 8.0 Hz), 7.60 (s, 1H), 8.11 (s, 1H), 8.31 (s, 1H) 化合物Ii-31 [化 199]
'H-NMR (DMSO-d) δ : 0.93-1.08 (m, 2 H), 1.13-1.28 (m, 2H), 1.26 (s, 9H), 1.43 6 (m, 1H), 1.76-1.97 (m, 4 H), 2.83-3.18 (m, 3H), 5.79 (m, 1H), 6.21 (s, 2H), 6.44 ( d, 1H, J = 6.8 Hz), 6.58-6.67 (m, 2H), 6.73 (d, 1H, J = 8.0 Hz), 7.10 (t, 1H. J = 8.0 -167- 1376367
Hz), 7_2i (s, 2H)融點.:205-206t: 化合物U-32 [化200] cr 'H-NMR (DMSO-d ) 6 : 0.90-1.05 (m, 2 H), 1.05-1.28 (m, 11H), 1.41 (m, 1H), 1. 6
75-1.92 (m, 4 H), 2.11 (t, 2H, J = 10.0 Hz), 2.73-2.82 (m, 2H), 2.91-3.08 (m, 3H), 3.24 (d, 2H, J = 11.2 Hz), 3.62-3.72 (m, 2H), 5.07 (m, 1H), 6.47 (d, 2H, J = 7.2 Hz ),6.72 (d, 2H, J = 7.2 Hz), 6.97 (d, 1H, J = 7.6 Hz)融點:165-166t: 化合物Ii-33 [化 201]
^-NMR (DMSO-d ) 6 : 0.91-1.06 (m, 2H), 1.15-1.26 (m, 8H), 1.33-1.48 (m, 1H), 6
1.71-1.93 (m, 4H), 2.88 (d, 2H, J = 6.5 Hz), 2.93-3.15 (m, 2H), 5.70 (brs, 2H), 6.6 3 (d, 2H, J = 9.1 Hz), 6.93-6.96 (m, 1H), 7.38-7.42 (m, 2H), 7.57 (d, 2H, J = 9.1 H z), 7.88-7.93 (m, 2H) 化合物[卜34 [化202] Ή » HC,
U^tV〇rF Q% 'H-NMR (DMSO-d ) δ : 0.98-1.02 (m, 2H), 1.16-1.18 (m, 5H), 1.42 (s, 1H), 1.75-1.91 (m, 4H), 2.88 (d, 2H, J = 6.6 Hz), 2.96 (q, 3H, J = 7.3 Hz), 6.63 (d, 2H, j = 8. c -168- 1376367 9 Hz), 6.99-7.02 (m, 1H), 7.38-7.41 (m, 2H), 7.57 (d, 2H, J = 8.9 Hz), 7.89-7.92 ( m, 2H). 化合物Ii-35 [化203]
'H-NMR (DMSO-d ) δ : 0.90-1.52 (m, 5H), 1.L9 (t, 3H, J = 7.2 Hz), 1.75-1.96 (m, 8
4H), 2.50-3.10 (m, 3H), 2.62 (q, 2H, J = 7.2 Hz), 5.55-5.70 (m, 1H ), 6.57 (d, 2H, J = 8.7 Hz), 6.80-7.04 (m, 4H), 7.01 (d, 1H, J = 7.8 Hz), 7.34 (d, 2H, J = 8.7 Hz) 化合物Ii-36 [化204]
lH-NMR (DMSO-d) δ : 0.90-1.50 (m, 5H),1.19 (t, 3H, J = 7.2 Hz), 1.75-1.95 (m, 6 4H), 2.70-3.10 (m, 3H), 2.97 (q, 2H, J = 7.2 Hz), 3.70 (s, 3H), 5.40-5.50 (m, 1H ), 6.53 (d, 2H, J = 8.7 Hz), 6.74 (d, 2H, J = 8.7 Hz), 6.78-6.90 (m, 4H), 6.99 (d, 1H, J = 7.8 Hz)
化合物li-37 [化205]
Ή-NMR (CDC1) 6 : 1.02-1.32 (m, 4 H), 139 (s, 9H,), 1.58 (m, 1H), 1.86-1.96 (m, 3 2H), 2.12-2.22 (m, 2H), 3.02 (d, 2H, J = 6.6 Hz), 3.25 (m, 1H), 3.67 (d, 1H, J = 9.3 Hz) , 6.67(d, 2H, J = 8.7 Hz), 7.41 (d, 2H, J = 8.7 Hz) Mass:393[M+H] 化合物Ii-38 -169- 1376367 tXc, 'H-NMR (DMSO-d ) 5 : 0.93-1.07 (m, 2H), 1.17-1.26 (m, 2H), 1.19 (t, 3H, J = 7.1 6
Hz), 1.43 (s, 1H), 1.77-1.85 (m, 2H), 1.85-1.94 (m, 2H), 2.82 (t, 1H, J = 5.8 Hz), 2.98 (m, 1H), 2.97 (q, 2H, J = 7.1 Hz), 5.87 (m, 1H), 6.56 (d, 2H, J = 8.6 Hz), 6.98 (d, 1H, J = 7.6 Hz), 7.02 (d, 2H, J = 8.6 Hz).
[化206]
化合物Ii-39 [化207]
JH-NMR (DMSO-d ) δ : 0.98-1.10 (m, 2H), 1.19-1.35 (m, 2H), 1.29 (s, 9H), 1.46 ( 6 s, 1H), 1.73-1.98 (m, 4H), 2.93 (m, 1H), 3.04 (m, 1H), 6.60-6.69 (m, 2H), 6.75 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 7.6 Hz), 7.49 (d, 1H, J = 8.8 Hz), 8.05 (s, 1H). 化合物Ii-40 [化208]
'H-NMR (DMSO-d ) 6 : 0.96-1.09 (in, 2H), 1.16-1.29 (m, 2H), 1.19 (t, 3H, J = 7.3
Hz), 1.45 (s, 1H), 1.76-1.94 (m, 4H), 1.76 (s, 2H), 2.93 (t, 2H, J = 5.8 Hz), 2.97 ( q, 2H, J = 7.3 Hz), 6.66 (s, 1H), 6.94-7.01 (m, 2H), 7..49 (d, 1H, J = 8.6 Hz), 8.04 ( s, 1H). 化合物Ii_41 [化209] -170- 1376367
JH-NMR (DMSO-d ) δ : 0.91-1.05 (m, 2H), 1.17-1.33 (m, 2H), 1.26 (s, 9H), 1.35-6 1.48 (m, 1H), 1.76-1.86 (m, 2H), 1.86-1.95 (m, 2H), 2.76-2.82 (m, 1H), 2.96-3.08 (m, 1H), 3.71 (s, 3H), 5.21-5.30 (m, 1H), 6.57 (d, 1H, J = 8.6 Hz), 6.73 (d, 1H, J = 8.6 Hz), 7.02 (dd, 1H, J = 8.6, 2.3 Hz), 7.44 (d, 1H, J = 2.3 Hz). 化合物Ii-42 [化 210]
'H-NMR (DMS〇-d〉δ : 0.98-1.01 (m, 2H), 1.18-1.28 (m, 2H), 1.19 (t, 3H, J = 7.1 6
Hz), 1.42 (s, 1H), 1.76-1.85 (m, 2H), 1.85-1.93 (m, 2H), 2.79 (t, 2H, J = 5.9 Hz), 2.97 (q, 2H, J = 7.1 Hz), 3.02 (m, 1H), 3.71 (s, 3H), 5.26 (m, 1H), 6.58 (d, 1H, J = 8.6 Hz), 6.98 (d, 2H, J = 7.8 Hz), 7.02 (d, 2H, J = 8.6 Hz), 7.44 (br s, 1H). 化合物丨i-4'3 [化 211]
'H-NMR (DMSO-d ) 5 : 0.98-1.06 (m, 2H), 1.16-1.25 (m, 2H), 1.18 (t, 3H, J =7.5 6
Hz), 1.51 (m, 1H), 1.83-1.91 (m, 4H), 2.85 (t, 2H, J = 6.3 Hz),. 2.97 (q, 2H, J = 7.5 Hz), 3.04(m, 1H), 3.56 (s, 3H), 5.46 (t, 1H, J = 6.3 Hz). 5.76 (s, 1H), 6.49 (d, 1H,J =7.8 Hz), 7.21 (t, 1H, J = 7.5Hz), 7.32 (t, 2H, J = 7.5 Hz), 7.68 (d, 2H, J = 7.5 Hz ) 化合物Ii-44 -171 - 1376367 [化 212]
'H-NMR (DMSO-d ) 6 : 0.96-1.05 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.24 (m, 2H), 1.48 (m, 1H), 1.76-1.91 (m, 4H), 2.91 (d, 2H, J = 6.6 Hz), 2.97 (q, 2H, J = 7.2 Hz), 6.35 (s, 1H), 6.99 (d, 1H, J = 7.8 Hz), 7.46-7.49 (m, 3H), 7.73-7.76 (m, 2H) 化合物Π-45 [化213]
lH-NMR (DMSO-d ) δ : 0.92-1.08 (m, 2H), 1.15-1.22 (m, 1H), 1.26 (s, 9H), 1.37-6 1.51 (m, 2H), 1.81 (d, 2H, J = 11.6 Hz), 1.91 (d, 2H, J = 11.6 Hz), 2.76-2.86 (m, 2 H), 2.97-3.08 (m, 1H), 3.35 (s, 3H), 5.82-5.91 (m, 1H), 6.26 (d, 1H, J = 13.6 Hz), 6.39 (s, 1H), 6.73 (brs, 1H).融點.:215-216¾ 化合物U-46 [化 214]
'H-NMR (CDC1) δ : 1.02-1.32 (m, 4H), 1.24 (d, 6H, J = 6.0 Hz), 1.39 (s, 9H), 1.5 3 4 (m, 1H), 1.84-1.94 (m, 2H), 2.12-2.22 (m, 2H), 2.39 (t, 2H, J = 10.5 Hz), 2.94 (d ,2H, J = 6.9 Hz), 3.24 (m, 1H), 3.38 (d, 1H, J = 9.6 Hz), 3.61 (d, lH, J = 9.6 Hz), 3.72-4.00 (m, 2H), 5.83-5.94 (m, 1H), 5.96-6.10 (m, 2H). 化合物Π-47 [化 215] -172- 1376367
'H-NMR (DMSO-d ) δ : 0.91-1.07 (m, 2H), 1.16-1.34 (m, 11H), 1.40 〇η, 1H), 1.79 (d, 2H, J = 12.5 Hz), 1.90 (d, 2H, J = 11.9 Hz), 2.82 (t, 2H, J = 5.5 Hz), 3.01 (m. 1 H), 6.12-6.18 (m, 3H), 6.30 (t, 1H, J = 5.5 Hz), 6.76 (d, 1H, J = 8.7 Hz). 化合物li-48 [化 216]
!H-NMR (CDC13) 6 : 1.00-1.28 (m, 4H), 1.39 (s, 9H), 1.56 (m, 1H), 1.91 (d, 2H, J =12.4 Hz), 2.08-2.21 (m, 4H), 2.58 (t, 2H, J = 8.1 Hz), 2.97 (d, 2H, J = 6.0 Hz), 3. 23 (m, 1H), 3.70 (d, 1H, J = 9.4 Hz), 3.80 (t, 2H, J = 7.1 Kz), 6.66 (d, 2H, J = 8.7 Hz), 7.36 (d, 2H, J = 8.7 Hz).
化合物ii-49 [化 217]
'H-NMR (DMS〇-dB) δ : 0.92-1.06 (m, 2H), 1.17-1.33 (m, 11H), 1.41 (m, 1H), 1.80 (d, 2H, J = 12.9 Hz), 1.90 (dj 2H, J = 11.4 Hz), 2.82 (t, 2H, J = 6.1 Hz), 3.01 (m, 1 H), 6.07 (t, 1H, J = 5.3 Hz), 6.34-6.43 (m, 2H), 6.51 (dd, 1H, J1 = 8.2 Hz, J2 = 1.8 Hz), 6.75 (d, 1H, J = 8.5 Hz), 7.11 (t, 1H, 8.2 Hz). 化合物li-50 -173 - 1376367 [化218] 'H-NMR (DMSO-d ) δ : 0.92-1.08 (m, 2H), 1.14-1.31 (m, 8H), 1.43 (m, 1H), 1.76-6 1.94 (m, 4H), 2,82 (t, 2H, J = 6.0 Hz), 2.95-3Λ6 (m, 2H), 5.90 (t, 1H, J = 5.5 Hz), 6.56 (d, 2H, J = 8.7 Hz), 6.95 (d, 1H, J = 7.9 Hz), 7.03 (d, 2H, J = 8.6 Hz).
化合物Ii-51 [化 219].
'H-NMR (DMSO-d ) δ : 0.90-1.08 (m, 2H), 1.13Ί.31 (m, 8H), 1.42 (m, 1H), 1.76- 6 1.94 (m, 4H), 2.83 (t, 2H, J = 6.0 Hz), 2.95-3.16 (m, 2H), 6.07 (t, 1H, J = 5.4 Hz), 6.36-6.46 (m, 2H), 6.53 (dd, 1H, J1 = 8.1 Hz, J2 = 1.9 Hz), 6.95 (d, 1H, J = 7.9 Hz ),7.12 (d, 1H,J=8.1 Hz).
化合物Ii-52 [化220]
'H-NMR (DMSO-d ) δ ·. 0.91-1.10 (m, 2H), 1.19-1.37 (m, llH), 1.45 (m, 1H), 1.78 6 -1.90 (m, 4H), 2.84 (t, 2H, J = 6.0 Hz), 3.04 (m, 1H), 4.64 (q, 2H, J = 9.0 Hz), 5.73 (t, 1H, J = 5.4 Hz), 6.13-6.21 (m, 2H), 6.26 (d, 1H, J = 7.2 Hz), 6.78 (d, 1H, J = 8. 4 Hz), 6.99 (t, 1H, 8.0 Hz). -174- 1376367 化合物Π-53 [化 221]
'H-NMR (DMSO-d ) δ : 0.90-1.06 (m, 2H), 1.13-1.30 (m, 8H), 1.42 (m, 1H), 1.75- 6 1.93 (m, 4H), 2.80 (t, 2H, J = 6.2 Hz), 2.93-3.16 (m, 2H), 5.66 (t, 1H, J = 5.5 Hz). 6.53 (d, 2H, J = 9.1 Hz), 6.89 (d, 2H, J = 8.8 Hz), 6.92 (t, 1H, J = 75 Hz), 6.94 (
H~F
d, 1H, J = 8.0 Hz). 化合物Ii-54 [化222]
]H-NMR (DMSO-d ) δ : 0.88-1.05 (m, 2H), 1.14-1.32 (m, 11H), 1.41 (m, 1H), 1.75 6
-1.94 (m, 4H), 2.77 (t, 2H, J = 6.0 Hz), 3.01 (m, 1H), 4.54 (q, 2H, J = 9.0 Hz), 5.33 (t, 1H, J = 5.8 Hz), 6.49 (d, 2H, J = 8.8 Hz), 6.75 (d, 1H, J = 8.8 Hz), 6.80 (d, 2H, J = 8.8 Hz). 化合物Ii-55 [化 223]
'H-NMR (DMSO-d ) δ : 0.90-1.06 (m, 2H), 1.14-1.31 (m, 8H), 1.40 (m, 1H), 1.74- β 1.93 (m, 4H), 2.79 (t, 2H, J = 5.9 Hz), 2.94-3.15 (m, 6H), 3.69 (t, 4H, J = 4.8 Hz), -175 - 1376367 5.70-5.94 (m, 4H), 6.94 (d, 1H, J = 8.0 Hz). 化合物1ί-56 [化224] €〇 'H-NMR (DMSO-d ) δ : 0.98-1.14 (m. 2H), 1.15Ί.32 (m, 5H), 1.54 (m, 1H), 1.83-6
1.96 (m, 4H), 2.89-3.10 (m, 5H), 6.17 (t, 1H, J = 5.2 Hz), 6.63 (d, 1H, J = 2.2 Hz), 7.02 (d, 1H, J = 7.7 Hz), 7.21 (dd, 1H, J1 = 9.1 Hz, J2 = 2.5 Hz), 7.27 (dd, 1H, J1 =8.2 Hz, J2 = 4.4 Hz), 7.67 (d, 1H, J = 9.1 Hz), 7.97 (d, 1H, J = 8.2 Hz), 8.45 (dd, 1H, J1 =4.3 Hz,J2 = 1.5 Hz). 化合物Ii-57 [化225]
'H-NMR (DMSO-d ) 8 : 0.97-1.14 (m, 2H), 1.17-1.34 (m, 8H), 1.54 (m, 1H), 1.83-6 1.96 (m, 4H), 2.94 (t, 2H, J = 6.0 Hz), 2.99-3.18 (m, 2H), 6.17 (t, 1H, J = 5.4 Hz), 6.63 (d, 1H, J = 2.5 Hz), 6.96 (d, 1H, J = 7.7 Hz), 7.21 (dd. 1H, J1 = 9.1 Hz, J2 = 2 .5 Hz), 7.27 (dd, 1H, J1 = 8.2 Hz, J2 = 4.1 Hz), 7.67 (d, 1H, J = 9.1 Hz), 7.97 (d, 1 H, J = 8.0 Hz), 8.45 (dd, 1H, J1 = 4.3 Hz, J2 = 1.5 Hz). 化合物H-58 [化226] -176- 1376367
Ο 'H-NMR (DMSO-d ) δ : 0.90-1.07 (m, 2H), 1.12-1.29 (m, 5H), 1.40 (m, 1H), 1.74-1.93 (m, 4H), 2.80 (t, 2H, J = 5.9 Hz), 2.92-3.07 (m, 7H), 3.69 (t, 4H, J = 4.8 Hz), 5.69-5.95 Cm, 4H), 6.99 (d, 1H, J = 7.7 Hz). 化合物Π-59 [化227]
lH-NMR (DMSO-d ) δ : 0.94-1.11 (tn, 2H), 1.14-1.30 (m, 5H), 1.47 (m, 1H), 1.78-6 l. 95 (m, 4H), 2.88-3.09 (m, 5H), 3.80 (s, 3H), 6.09 (t, 1H, J = 5.6 Hz), 6.81-6.86 ( m, 1H), 6.96 (dd, 1H, J1 = 8.8 Hz, J2 = 2.8 Hz), 7.01 (d, 1H, J = 7.4 Hz), 7.29 (t, 1 H, J = 8.0 Hz), 7.45-7.51 (m, 2H), 7.66 (d, 1H, J = 8.5 Hz), 8.04 (d, 1H, J = 2.8 Hz )_ 化合物Ii-60 [化228]
'H-NMR (DMSO-d ) 6 : 1.03 (m, 2H), 1.19 (t, 2H, J = 7.8 Hz), 1.21 (m, 2H), 1.46 6 (m, 1H), 1.76-1.95 (m, 4H), 2.90 (t, 2H, J = 5.8 Hz), 2.97 (q, 2H, J = 7.3 Hz), 3.03 (m, 1H), 3.80 (s, 3H), 5.95 (m, 1H), 6.90 (m. 1H), 6.98 (d, 1H, J = 7.8 Hz), 6.98 (d d, 1H, J = 7.8, 7.8 Hz), 7.06 (d, 1H, J = 8.6 Hz), 7.26 (dd, 1H, J = 7.8, 7.8 Hz), 7.6 -177- 1376367 1 (d, 1H, J = 8.6 Hz), 7.69 (d, 1H, J = 7.8 Hz), 8.03 (s, 1H). 化合物Ii-61 [化229] 為.J、 'h-NMR (DMSO-d ) δ : 0.96-1.09 (m, 2H), 1.18-1.29 (ra,2H), 1.19 (t, 3H, J = 7.6 6
Hz), 1.47 (m, 1H), 1.87 (m, 5H), 2.90 (t, 2H, J = 6.3 Hz), 2.97 (q, 2H, J = 7.6 Hz), 3.02 (m, 1H), 5.98 (m, 1H), 6.63 (d, 2H, J = 8.3 Hz), 6.98 (d,. 1H, J = 7.3 Hz), 7.14 (m, 1H), 7.73 (s, 2H), 7.83 (d, 2H, J = 8.3 Hz), 8.52 (d, 1H, J = 4.0 Hz). 化合物Ii-62 [化 230]
'H-NMR (DMSO-d) δ : 0.98-1.01 (m, 2H), 1.20 (s, 9H), 1.20-1.37 (m, 2H), 1.42 ( 6
m, 1H), 1.76-1.96 (m, 4H), 2.28-2.37 (m, 2H), 2.75-2.85 (m, 2H), 3.02 (m, 1H), 3. 36 (t, 2H, J = 7.8 Hz), 3.57 (t, 2H( J = 6.3 Hz), 5.66 (m, 1H), 6.54 (d, 2H, J = 8.0 Hz), 6.73 (d, 1H, J = 8.6 Hz), 7.00 (d, 1H, J = 8.0 Hz). 化合物Ii-63 [化 231]
'H-NMR (DMSO-d; δ : 0.96-1.14 (m, 2H), 1.14-1.32 (m, 2H), 1.19 (t, 3H, J = 7.2 -178 1376367
Hz), 1.50 (m, 1H), 1.76-1.96 (m, 4H), 2.91-3.10 (m, 3H), 2.97 (q, 2H, J = 7.2 Hz), 6.28 (m, 1H), 7.02 (d, 1H, J = 7.8 Hz), 7.32-7.46 (m, 3H), 8.20 (d, 1H, J = 6.9 Hz ),8.22 (s, 2H). 化合物丨i-64 [化232]
'H-NMR (DMSO-d ) δ : 1.03-1.15 (m, 2H), 1.18-1.29 (m, 2H), 1.24 (d, 6H, J = 6.3
Hz), 1.52 (m, 1H), 1.86-1.94 (m, 2H), 2.10-2.19 (m, 2H), 2.40 (t, 2H, J = 6.0 Hz), 2.95 (d, 2H, J = 6.0 Hz), 3.23 (m, 1H), 3.40 (d, 2H, J = 11.4 Hz), 3.75-3.85 (m, 2H ),3.86 (d, 1H, J = 9.3 Hz), 6.14 (d, 1H, J = 8.5 Hz), 6.15 (s, 1H), 6.29 (d, 1H, J = 8 .5 Hz), 7.06 (d. 1H, J = 8.5 Hz). 化合物Π-65 [化233]
'H-NMR (CDC1) δ :1.08-1.16 (m, 2H), 1.14 (d, 6H, J = 6.8 Hz), 1.21-1.30 (m, 2H ),1.29 (s, 9H), 1.78 (t, 2H, J = 10.6 Hz), 1.83-1.92 (m, 2H), 2.11-2.19 (m, 2H), 2. 78 (d, 2H, J = 10.6 Hz), 3.06 (s, 2H), 3.23 (m, 1H), 3.38 (s, 2H), 3.70-3.80 (m, 2H) ,4,02 (d, 1H, J = 9.9 Hz), 5.37 (s, 1H), 6.30 (s, 1H). 化合物Ii-66 [化234]
179- 1376367 'H-NMR (DMSO-d ) δ : 1.01-1.12 (m, 2H), 1.20-1.34 (m, 2H), 1.27 (s, 9H), i.54 ( 6 m, 1H), 1.82-1.99 (m, 4H), 2.91-2.98 (m, 2H), 3.06 (m ,1H), 6.17 (s, 1H), 6.63 (s, 1H), 6.78 (d, 1H, J = 9.0 Hz), 7.20 (m, IH), 7.27 (m, 1H), 7.77 (d, 1H, J = 9.0 Hz), 7.98 (d, 1H, J = 9.0 Hz), 8.54 (s, 1H). 化合物Ii-67 [化2 35]
H-NMR (DMSO-d) 5 : 0.92-1.06 (m, 2H). 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.42 ( e m, 1H), 1.78-1.88 (m, 2H), 1.88-1.96 (m, 2H), 2.78-2.86 (m, 2H), 3.02 (m ,1H), 5. 89 (s, 1H), 6.56 (d, 1H, J = 8.4 Hz), 6.76 (d, 1H, J = 8.4 Hz), 7.02 (d, 1H, J = 8.4 Hz). 化合物Ii-68 [化236]
H-NMR (DMSO-d) δ : 0.92-1.05 (m, 2H), 1.19 (s, 9H), 1.20-1.32 (m, 2H), 1.26 ( 6 s, 9H), 1.42 (m, 1H), 1.80-1.96 (m, 4H), 2.77 (s, 2H), 3.04 (m, 1H), 5.29 (s, 1H), 6.44 (d, 1H, J = 7.2 Hz), 6.68 (d, 1H, J = 7.2 Hz), 6.75 (d, 1H, J = 8.4 Hz). 化合物Π-69 [化 237]
lH-NMR (DMSO-d ) δ : 0.95-1.10 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.47 ( 6 -180- 1376367 m, lJ-ί), 1.80-1.88 (m, 2H), 1.88-1.95 (m, 2H), 2.88-2.95 (m, 2H), 3.02 (s, 1H), 6. 07 (m, 1H), 6.77 (d, 1H, J = 8.4 Hz), 6.97 (d, 1H, J = 7.6 Hz), 7.26 (t, 1H, J = 7.6 Hz), 7.35-7.42 (m, 2H), 7.46 (d, 1H, J = 8.4 Hz), 7.91 (d, 1H, J = 7.6 Hz), 8.04 (s, 1H). 化合物Ii-70 [化238]
'H-NMR (DMSO-d) δ : 0.93-1.05 (m, 2H), 1.10-1.32 (m, 2H), 1.26 (s, 9H), 1.42 ( m, 1HX 1.78-1.86 (m, 2H), 1.86-1.95 (m, 2H), 2.78-2.83 (m, 2H), 3.03 (m, 1H), 4. 80 (q, 2H, J = 9.2 Hz), 5.48 (t, 1H, J = 5.6 Hz), 6.69:6.76 (m, 2H), 7.08 (dd, 1H, J =8.8, 2.4 Hz), 7.45 (d, 1H, J = 2.4 Hz). 化合物Ii-71 [化239]
'H-NMR (DMSO-d ) δ : 0.96-1.10 (m, 2H), 1.20-1.32 (m, 2H), 1.27 (s, 9H), 1.82-6 1.88 (m, 2H), 1.88-1.97 (m, 2H), 2.83-2.88 (m, 2H), 3.04 (m, 1H), 5.82 (s, 1H), 6.6 9 (m, 1H), 6.76 (d, 1H, J = 8.8 Hz), 7.12 (dd, 1H, J = 9.2, 8.8 Hz), 7.37 (m, 1H). 7. 87 (d, 1H, J = 2.8 Hz), 7.99 (s, 1H). 化合物Ii-72 [化240]
181 - 1376367
[化244]
化合物li-73 [化 241] 化合物[i-74 [化242] 化合物Ii-75 [化243] 化合物Π-77 [化245] 化合物〗卜78 [化246] -182- 1376367
化合物Ii-79 [化247]
7¾ 化合物1卜80 [化248]
化合物Ii-81 [化249]
化合物Ii-82 [化250]
化合物li-83 ,c、 183 - 1376367
[化 251] 1XD..,j 化合物Ii-84 [化252]
'H-NMR (DMSO-d ) 6 : 0.91-1.08 (m, 2H), 1.14-1.30 (t, 3H, J = 7.5 Hz ), 1.41 (m 6 ,1H), 1.73-1.94 (m, 4H), 2.34-2.46 (m, 2H), 2.85 (t, 2H, J = 6.6 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.00 (m, 1H), 3.25 (t, 2H, J = 7.5 Hz), 3.53 (t, 2K, J = 6.6 Hz), 6.27 (d ,2H, J = 11.7 Hz), 6.52 (t, 1H, J = 5.1 Hz), 7.00 (d, 1H, J = 7.2 Hz). 化合物丨i-85 [化 253]
化合物Ii-86 [化 254]
化合物Π-87 [化255] -184- 1376367
化合物Π-88 [化256]
化合物Π-89 [化 257]
化合物U-90 [化 258]
0¾ U,J
HCI 化合物Ii-91 [化259]
'H-NMR (DMS〇-d ) δ : 0.92-1.05 (m, 2H), 1.13 (d, 6H, J = 6.0 Hz), 1.18-1.30 (m, 1376367 2H), 1.21 (d, 6H, I = 6.4 Hz), 1.40 (m, 1H), 1.76-1.83 (m, 2H), 1.83-1.93 (m, 2H), 2.19 (dd, 1H, J = 11.2, 11.2 Hz), 2.76-2.82 (m, 2H), 3.01.(m, 1H), 3.09 (m, 1H), 3. 45 (d, 2H, J = 11.2 Hz), 3.58-3.69 (m, 2H), 5.67 (m, 1H), 5.77 (d, 1H, J = 12.0 Hz) ,5.90 (s, 1H), 5.91 (m, 1H), 6.91 (d. 1H, J = 7.6 Hz). 化合物li-92 [化260]
'H-NMR (DMSO-d ) δ : 0.90-1.07 (m, 2H), 1.14-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.32-1.46 (tn, 1H), 1.75-1.92 (m, 4H), 2.78-2.83 (m, 2H), 2.95-3.18 (m, 6H), 3.66-3.72 (m, 4H), 5.75 (brs, 1H), 6.00 (s, 1H), 6.04 (s, 1H), 6.11 (s, 1H), 6.95 (d, 1H, J = 9.0 Hz). 化合物Ii-93 [化 261]
'H-NMR (DMSO-d ) δ : 0.90-1.08 (m, 2H), 1.13-1.27 (m, 5H), 1.42 (m, 1H), 1.74- 1.93 (m, 4H), 2.30-2.40 (m, 2H), 2.81 (d, 2H, J = 6.6 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.00 (m, 1H), 3.49 (t, 2H, J = 7.5 Hz), 3.66 (t, 2H, J = 6.6 Hz), 5.00-5.50 (brs, 2H ),6.07-6.15 (m, 2H), 6.25(s, 1H), 7.00 (d, 1H, J = 6.6Hz). 化合物Ii-94 [化262]
i c -186 - 1376367 'H-NMR (DMSO-d) δ : 0.92-1.07 (m, 2H), 1.15-1.32 (m, 5H), 1.21 (d, 6H, J = 6.9 6
Hz), 1.42 (m, 1H), 1.74-1.93 (m, 4H), 2.30-2.42 (m, 2H), 2.81 (d, 2H, J = 6.6 Hz), 2.92-3.18 (m, 2H), 3.49 (t, 2H, J = 7.5 Hz), 3.66 (t, 2H, J = 6.6 Hz), 4.70-5.30 (br s, 2H), 6.05-6.16 (m, 2H), 6.25 (s, 1H), 6.95 (d, 1H, J = 8.1Hz). 化合物丨i-95 [化263]
'H-NMR (DMSO-d) δ : 0.90-1.06 (m, 2H), 1.16-1.31 (d, 6H, J = 6.9 Hz), 1.40 (m, 6 1H), 1.73-1.94 (m, 4H), 2.34-2.46 (m, 2H), 2.84 (t, 2H, J = 6.0 Hz), 2.94-3.16 (m, 2H), 3.28 (t, 2H, J = 7.5 Hz), 3.53 (t, 2H, J = 6.6 Hz), 6.27 (d, 2H, J = 11.7 Hz), 6 .52 (t, 1H, J = 5.4 Hz), 6.94 (d, 1H, J = 7.8 Hz). 化合物Ii-96 [化264]
'H-NMR (DMSO-d) δ : 0.91-1.04 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.40 ( 6 tn, 1H), 1.76-1.95 (m, 4H), 2.77-2.83 (m, 2H), 2.99-3.04 (m, 5H), 3.67-3.72 (m, 4 H), 5.71 (m, 1H), 5.79 (d, 1H, J = 11.7 Hz), 5.89 (s, 1H), 5.90 (m, 1H), 6.72 (d, 1H ,J = 8.4 Hz). 化合物Ii-97 [化265]
187- 1376367 'H-NMR (DMSO-d ) S : 0.92-1.03 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.41 ( 6 m, 1H), 1.77-1,93 (m, 4H), 2.78-2.83 (m, 2H), 2.97-3.05 (m, 5H), 3.68-3.72 (m, 4 H), 5.36 (m, 1H), 6.04 (d, 1H, J = 8.0 Hz), 6.10 (s, 1H). 6.11 (d, 1H, J = 8.0 Hz), 6. 72 (d, 1H, J = 8.0 Hz), 6.89 (dd, 1H, J = 8.0, 8.0 Hz). 化合物Ii-98 [化266]
lH-NMR (DMSO-d ) δ : 0.92-1.04 (m, 2H), 1.17-1.29 (m, 2H), 1.21 (d, 6H, J = 6.4
Hz), 1.41 (m, 1H), 1.75-1.92 (m, 4H), 2.77-2.83 (m, 2H), 2.95-3.05 (m, 5H), 3.09 (m, 1H), 3.67-3.72 (m, 4H), 5.36 (m, 1H), 6.04 (d, 1H, J = 8.0 Hz), 6.10 (s, 1H), 6. 11 (d, 1H, J = 8.0 Hz), 6.89 (dd, 1H, J = 8.0, 8.0 Hz), 6.92 (d, 1H, J = 8.0 Hz). 化合物Ii-99 [化267]
'H-NMR (DMSO-d ) δ : 0.90-1.06 (m, 2H), 1.15-1.31 (m, 2H), 1.21 (d, 6H, J = 6.9 6
Hz), 1.39 (m, 1H), 1.47-1.62 (m, 6H), 1.74-1.94 (m, 4H), 2.78 (t, 2H, J = 6.0 Hz), 2.93-3.16 (m, 6H), 5.64-5.76 (m, 2H), 5.83-5.92 (m, 2H), 6.94 (d, 1H, J = 7.8 Hz). 化合物Π-100 [化268]
'H-NMR (DMSO-d ) δ : 0.90-1.06 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H, J = 6.9 6 -188- 1376367
Hz), 1.40 (m, 1H), i.74-1.96 (m, 8H), 2.79 (t, 2H, J = 6.0 Hz), 2.93-3.18 (m, 6H), 5.48-5.67 (m, 4H), 6.94 (d, 1H, J = 8.1 Hz). 化合物[i-101 [化269]
'H-NMR (DMSO-d) δ : 0.90-1.06 (m, 2H), 1.13-1.29 (m, 2H), 1.18 (t, 3H, J = 7.5 6
Hz), 1.39 (m, 1H), 1.47-1.62 (m, 6H), 1.75-1.94 (m, 4H), 2.79 (t, 2H, J = 6.0 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.03-3.10 (m, 4H), 5.64-5.75 (m, 2H), 5.83-5.91 (m, 2H), 7.00 (d, 1H, J = 7.8 Hz). 化合物li-102 [化270]
Ό
o
'H-NMR (DMSO-d ) δ : 0.90-1.07 (m, 2H), 1.13-1.29 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.41 (m, 1H), 1.74-1.96 (m, 8H), 2.79 (t, 2H, J = 6.0 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.00 (m, 1H), 3.09-3.19 (m, 4H), 5.46-5.66 (m, 4H), 6.99 (d, 1H, J = 7.2 Hz). 化合物Ii-103 [化 271]
'H-NMR (DMSO-d ) δ : 0.91-1.03 (m, 2H), 1.16-1.29 (m, 2H), 1.21 (d, 6H, J = 6.8 6
Hz), 1.40 (m, 1H), 1.75-1.92 (m, 4H), 2.20 (s, 3H), 2.35-2.43 (m, 4H), 2.75-2.82 ( -189- 1376367 m, 2H), 2.88-3.13 (m, 6H), 5.67 (m, 1H), 5.76 (d, 1H, J = 11.2 Hz), 5.82-5.92 (m, 2H), 6.91 (d, 1H, J = 8.0Hz). 化合物li-104 [化272]
'H-NMR (DMSO-d) δ : 0.92-1.02 (m, 2H), 1.19-1.32 (m, 2H), 1.26 (s, 9H), 1.39( 6
m, 1H), 1.75-1.95 (m, 4H), 2.19 (s, 3H), 2.38-2.42 (m, 4H), 2.77-2.83 (m, 5H), 2.9 8-3.09 (m, 5H), 5.67 (m, 1H), 5.76 (d, 1H, J = 11.2 Hz), 5.88 (m, 1H), 5.88 (s, 1H), 6.72 (d, 1H, J = 8.8Hz). 化合物li-105 [化273]
lH-NMR (DMSO-d ) 8 : 0.95-1.09 (m, 2H), U8-1.31 (m, 2H), 1.22 (d, 6H, J = 6.8 6
Hz), 1.44 (m, 1H), 1.78-1.93 (m, 4H), 2.87-2.92 (m, 2H), 3.03 (m, 1H), 3.10 (m, 1 H), 6.13 (m, 1H), 6.21 (m, 1H), 6.22 (s, 2H)( 6.51 (s, 1H), 6.52 (d, 1H, J = 8.0 Hz), 6.92 (d, 1H, J = 8.0 Hz), 7.26 (s, 2H). 化合物Ii-106 [化274]
'H-NMR (DMSO-d) δ : 0.97-1.08 (m, 2H), 1.17-1.29 (m, 5H), 1.40-1.68 (m, 3H), 6 190- 1376367 1.80-1.92 (m, 2H), 2.90 (t, 2H, J = 6.0 Hz), 2.94-3.06 (m, 3H), 6.12-6.22 (m, 4H), 6.50-6.54 (m, 2H), 6.94-7.00 (m, 1H), 7.26-7.27 (m, 2H). 化合物[卜107 [化275] 'H-NMR (DMSO-d ) δ : 0.91-1.03 (m, 2H), 1.16-1.29 (m, 2H), 1.21 (d, 6H, J = 6.4 6
Hz), 1.40 (m, 1H), 1.74-1.92 (m, 4H), 2.75-2.81 (m, 2H), 2.84 (s, 3H), 3.00 (m, 1 H), 3.09 (m, 1H), 3.25 (s, 3H), 3.35-3.47 (m, 4H), 5.59-5.67 (m, 4H), 6.91 (d, 1H, J = 8.0 Hz). 化合物li-108 [化276]
^-NMR (DMSO-d ) δ : 0.92-1.03 (m, 2H), 1.18-1.32 (m, 2H), 1.26 (s, 9H), 1.40 ( 6
m, 1H), 1.75-1.94 (m, 4H), 2.75-2.81 (m, 2H), 2.83 (s, 3H), 3.01 (m, 1H), 3.25 (s, 3H), 3.34-3.47 (m, 4H), 5.58-5.70 (m, 4H), 6.72 (d, 1H, J = 8.4 Hz). 化合物丨i-109 [化277]
'H-NMR (DMSO-d.) δ : 0.90-1.51 (m, 10H), 1.21 (d, 6H, J = 6.9 Hz), 1.56-1.67 ( m, 3H), 1.71-1.93 (m, 6H), 2.64 (s, 3H), 2.78 (t, 2H, J = 6.0 Hz), 2.93-3.17 (m, 2H -191 - 1376367 ),3.44 (m, 1H), 5.56-5.77 (tn, 4H), 6.94 (d, IH, J = 7.8 Hz). 化合物Π-110 [化278]
'H-NMR (DMSO-d) 6 : 0.83-1.01 (m, 2H), 1.00-1.40 (m, 3H), 1.21 (d, 6H, J = 6.9 6
Hz), 1.68-1.91 (m, 4H), 2.73 (t, 2H, J = 6.0 Hz), 2.90-3.15 (m, 2H), 2.95 (s, 3H), 4,48 (s, 2H), 5.60-5.72 (m, 4H), 6.94 (d, 1H, J = 7.8 Hz), 7.15-7.35 (m, 5H). 化合物Ii-111 [化279]
*H-NMR (DMSO-d) 6 : 0.97-1.14 (m, 2H), 1.14-1.33 (m, 5H), 1.45-1.61 (m, 1H), 6
1.81-1.96 (m, 4H), 2.90-3.10 (m, 5H), 6.34 (t, 1H, J = 5.2 Hz), 6.51 (d, 1H, J = 2.2 Hz), 6.99-7.07 (m, 2H), 7.36 (dd, 1H, J = 8.2, 4.1 Hz), 8.02 (d, 1H, J = 8.5 Hz), 8. 48 (dd, 1H, J = 4.1,1.4Hz). 化合物U-L12 [化280]
βχΧκ lH-_R (DMSO-d > δ _· 0.97-1.13 (m, 2H), 1.17-1.34 (m, 8H), 1.45-1.59 (m, 1H), 6 1.81-1.99 (m, 4H), 2.94 (t, 2H, J = 5.9 Hz), 2.99-3.21 (m, 2H), 6.33 (t, 1H, J = 5.4 Hz), 6.51 (d, 1H, J = 2.2 Hz), 6.96 (d, 1H, J = 7.7 Hz), 7.02 (dd, 1H, J = 13.5, 2.2 -192- 1376367
Hz), 7.36 (dd, 1H, J = 8.2, 4.1 Hz), 8.02 (d, 1H, J = 8.5 Hz), 8.48 (dd, 1H, J = 4.1, 1.4 Hz). 化合物I卜113 [化 281] 'H-NMR (DMSO-d ) δ : 0.93-1.13 (m, 2H), 1.15-1.34 (m, 8H), 1.39-1.57 (m, 1H),
1.79- 1.95 (m, 4H), 2.87 (t, 2H, J = 6.2 Hz), 2.94-3.16 (m, 2H), 3.54 (s, 3H), 5.66 ( t, 1H, J = 5.5 Hz), 6.49 (d, 1H, J = 9.6 Hz), 6.73 (d, 1H, J = 2.8 Hz), 6.91-7.02 (m, 2H), 7.29 (d, 1H, J = 9.3 Hz), 7.72 (d, 1H, J = 9.3 Hz). 化合物丨卜114 [化282]
'H-NMR (DMSO-d ) δ : 0.93-1.10 (m, 2H), 1.14-1.33 (m, 8H), 1.41-1.56 (m, 1H), 6
1.79- 1.94 (m, 4H), 2.89 (t, 2H, J = 6.0 Hz), 2.95-3.16 (m, 2H), 6.00 (t, 1H, J = 5.4 Hz), 6.84 (dd, 1H, J = 8.8, 2.2 Hz), 6.95 (d, 1H, J = 8.0 Hz), 7.07 (d, 1H, J = 2.2 Hz), 7.72 (d, 1H, J = 8.8 Hz), 8.86 (s, 1H). 化合物Ii-115 [化283]
lH-NMR (DMSO-d ) δ : 0.94-1.06 (m, 4H), 1.26 (s, 9H), 1.40-1.51 (m, 1H), 1.84 ( 6 d, 2H, J = 12.4 Hz). 1.91 (d, 2H, J = 12.4 Hz), 2.85-2.90 (m, 2H), 2.97-3.06 (m, 1 H), 5.93-5.99 (m, 1H), 6.63-6.79 (m, 3H), 7.40 (d, 1H, J = 8.8 Hz), 8.32 (s, 1H). -193 1376367 化合物Π-116 [化284] XQ- Ο *H-NMR (DMSG'd ) δ : 0.95-1.07 (m, 4H), 1.26 (s, 9H), 1.39-1.47 (m, 1H), 1.80 ( 6
d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.87-2.93 (m, 2H), 2.98-3.06 (m, 1 H), 3.37 (s, 3H), 6.27 (s, 1H), 6.55 (d, 1H, J = 8.8 Hz), 6.73 (d, 1H, J = 8.8 Hz), 6. 80 (t, 1H, J = 5.2 Hz), 7.32 (d, 1H, J = 8.8 Hz). 化合物丨i-117 [化285]
*H-NMR (DMSO-d ) § : 0.94-1.08 (m, 4H), 1.20 (s, 3H), 1.22 (s, 3H), 1.39-1.51 ( 6
m, 1H), 1.80 (d, 2H, J = 12.4 Hz), 1.88 (d, 2H, J = 12.4 Hz), 2.87-2.94 (m, 2H), 2. 97-3.07 (m, 1H), 3.08-3.14 (m, 1H), 3.37 (s, 3H), 6.27 (s, 1H), 6.55 (d, 1H, J = 8.4 Hz), 6.82 (t, 1H, J = 5.6 Hz), 6.94 (d, 1H, J = 8.0 Hz), 7.32 (d, 1H, J = 8.4 Hz). 化合物U-U8 [化286]
>〇 *H-NMR (DMSO-d ) δ : 0.92-1.06 (m, 4H), 1.26 (s, 9H), 1.38-1.50 (m, 1H), 1.83 ( 6 d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.80-2.86 (m. 2H), 2.96-3.06 (m, 1 H), 3.26 (s, 3H), 5.58-5.65 (m, 1H), 6.27 (d, 1H, J = 8.4 Hz), 6.38 ($, 1H). 6.75 (d ,1H, J = 8.4 Hz), 6.99 (d, 1H, J = 8.4 Hz). -194- 1376367 化合物Ii-119 [化287]
'H-NMR (DMSO-d ) δ : 0.94-1.06 (m, 4H), 1.26 (s, 9H), 1.39-1.50 (m, 1H), 1.84 ( 6 d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.81-2.89 (m, 2H), 2.96-3.07 (m, 1 H). 3.51 (s, 3H), 5.79-5.84 (m, 1H), 6.60 (s, 1H), 6.75 (d, 1H, J = 8.8 Hz), 7.03 (d ,1H, J = 8.8 Hz), 7.19 (d, 1H, J = 8.8 Hz).
化合物Π-120 [化288]
'H-NMR (DMSO-d ) δ : 0.93-1.10 (m, 4H), 1.26 (s, 9H), 1.37-1.40 (m, 1H), 1.42 ( 6 s, 3H), 1.44 (s, 3H), 1.83 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.79-2.96 (m, 2H), 2.97-3.07 (m, 1H), 4.33-4.46 (m, 1H), 5.50-5.59 (m, 1H), 6.25 (d, 1H, J =8.8 Hz), 6.57 (s, 1H), 6.75 (d, 1H, J = 8.4 Hz), 7.00 (d, 1H, J = 8.4 Hz).
化合物Ii-121 [化289]
'H-NMR (DMSO-d ) 6 : 0.90-1.06 (m, 4H), 1.26 (s, 9H), 1.36-1.49 (m, 1H), 1.82 ( c d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.80-2.87 (m, 2H), 2.95-3.97 (m, 1 H), 3.27 (s, 3H), 5.85-5.92 (m, 1H), 6.33 (s, 1H), 6.36 (s, 1H), 6.75 (d, 1H, J = 8.8 Hz). 化合物U-122 -195- 1376367 [化290]
'H-NMR (DMSO-d ) δ : 0.92-1.08 (m, 4H), 1.26 (s, 9H), 1.38-1.41 (m, 1H), 1.42 ( 6 s, 3H), 1.43 (s, 3H), 1.82 (d, 2H, J = 11.8 Hz), 1.90 (d, 2H, J = 11.8 Hz), 2.83-2.88 (m, 2H), 2.98-3.06 (m, 1H), 4.33-4.47 (m, 1H), 6.35 (s, 1H), 6.54 (s, 1H), 6.76 (d, 1H, J = 8.4 Hz), 8.32 (s, 1H).
化合物U-123 [化 291]
'H-NMR (DMSO-d ) δ : 0.93-1.06 (m, 4H), 1.22 (s, 3H), 1.24 (s, 3H), 1.26 (s, 9H) 6
,1.39-1.50 (m. 1H), 1.81 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.87-2.93 (m, 2H), 2.96-3.07 (m, 1H), 4.39-4.47 (m, 1H), 6.30 (s, 1H), 6.54 (d, 1H, J = 8.8 Hz), 6.77 (d, 1H, J = 8.8 Hz), 6.86 (t, iH, J = 5.2 Hz), 7.32 (d, 1H, J = 8.4 Hz). 化合物Ii-124 [化292]
^-NMR (DMSO-d ) δ : 0.90-1.05 (m, 4H), 1.26 (s, 9H), 1.36-1.51 (m, 1H), 1.79 ( 6
d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.80-2.86 (m, 2H), 3.01 (s, 3H), 3.0 2-3.05 (m, 1H), 3.49 (t, 2H, J = 4.8 Hz), 4.26 (t, 2H, J = 4.8 Hz), 6.02 (s, 1H), 6.2 0 (t, 1H, J = 5.6 Hz), 6.31 (d, 1H, J = 8.8 Hz), 6.74 (d, 1H, J = 8.8 Hz), 7.43 (d, 1H -196- 1376367 ,J = 8.4 Hz). 化合物Π-125 [化293]
'H-NMR (DMSO-d ) δ : 0.92-1.02 (m, 4H), 1.08 (t, 3H, J = 7.2 Hz), 1.25 (s, 9H), 6 l. 35-1.42 (m, 1H), 1.79 (d, 2H, J = 12.0 Hz), 1.90 (d,2H, J = 12.0 Hz), 2.80-2.86 (
m, 2H), 2.96-3.05 (m, 1H), 3.42-3.51 (m, 4H), 4.20-4.26 (m, 2H), 6.03 (s, 1H), 6.2 0 (s, 1H), 6.31 (d, 1H, J = 8.8 Hz), 6.75 (d, 1H, J = 8.8 Hz), 7.42 (d, 1H, J = 8.8 H z). 化合物Ii-126 [化294]
'H-NMR (DMSO-d ) δ : 0.92-1.02 (m, 4H), 1.09 (s, 3H), 1.11 (s, 3H), 1.25 (s, 9H) 6
,1.43-1.55 (m, 1H), 1.80 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.0 Hz), 2.84 (m, 2H), 2.97-3.08 (m, 1H), 3.37 (t, 2H, J = 5.2 Hz), 4.18 (t, 2H, J = 5.2 Hz), 4.71-4. 80 (m, 1H), 6.05 (s, 1H), 6.19 (t, 1H, J = 5.2 Hz), 6.32 (d, 1H, J = 8.8 Hz), 6.74 (d, 1H, J = 8.4 Hz), 7.18 (d, 1H, J = 8.4 Hz). 化合物Ii-127 [化295]
-197- 1376367 *H-NMR (DMSO-d ) δ : 0.94-1.12 (m, 2H), 1.14-1.39 (m, 5H), 1.34-1.56 (m, 1H), 6 1.70-1.97 (m, 4H), 2.87-3.10 (ra, 5H), 6.17 (t, 1H, J = 5.2 Hz), 6.94-7.06 (m, 2H), 7.35-7.47 (m, 4H), 7.75-7.80 (m, 1H), 8.07 (d, 1H, J = 3.0 Hz). 化合物Ii-128 [化296]
*H-NMR (DMSO-d ) δ : 0.96-1.12 (m, 2H), 1.14-1.31 (m, 5H), 1.31-1.55 (m, 1H), 6 1.70-1.96 (m, 4H), 2.89-3.09 (m, 5H), 6.24 (t, 1H, J = 5.4 Hz), 6.94-7.05 (m, 2H), 7.24 (d, 1H, J = 6.9 Hz), 7.52 (t, 1H, J = 8.0 Hz), 7.75 (d, 1H, J = 8.8 Hz), 7.88-7. 97 (m, 2H), 8.07 (d, 1H, J = 2.5 Hz). 化合物Π-129 [化297]
'H-NMR (DMSO-d,) 5 : 0.98-1.12 (m, 2H), 1.18-1.30 (m, 2H), 1.19 (t, 3H, J = 6.8 b
Hz), 1.48 (m, 1H), 1.79-1.95 (m, 4H), 2.92-3.09 (m, 3H), 2.97 (q, 2H, J = 6.8 Hz), 6.27 (m, ΙΗλ 7.01 (d, 1H, J = 8.0 Hz), 7.39-7.47 (m, 2H), 7.56 (m, 1H), 8.18-8.25 (m, 2H), 8.23 (s, 2H). 化合物Ii-130 [化298]
-198- 1376367 'H-NMR (DMSO-d) 6 : 0.96-1.12 (m, 2H), 1.15-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 6
Hz), 1.45-1.64 (m, 1H); 1.78-1.96 (m, 4H), 2.97 (q, 2H, J = 7.2 Hz), 2.95-3.15 (m ,1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 6.94-7.02 (m, 2H), 7.38 (t, 1H, J = 6.0 Hz), 7.46 (t, 2H, J = 7.5 Hz), 7.78 (d, 1H, J = 9.0 Hz), 7.96 (d, 2H, j = 9.0 Hz). 化合物[i-131 [化 299]
*H-NMR (DMSO-d ) δ : 0.96-1.12 (ra, 2H), 1.15-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 6
Hz), 1.48-1.62 (m, 1H), 1.78-1.96 (m, 4H), 2.98 (q, 2H, J = 7.2 Hz), 2.94-3.10 (m ,1H), 3.22-3,28 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 7.02 (d, 1H, J = 9.0 Hz), 7.10 (t ,1H, J = 5.4 Hz), 7.22 (td, 1H, J = 9.0, 3.0 Hz), 7.47-7.56 (m, 1H), 7.77-7.88 (m, 3H). 化合物Ii-132 [化300]
^-NMR (DMSO-d) δ : 0.96-1.13 (m, 2H), 1.15-1.32 (m, 2H), 1.19 (t, 3H, J = 7.5 6
Hz), 1.48-1.65 (m, 1H), 1.78-1.96 (m, 4H), 2.98 (q, 2H, J = 7.2 Hz), 2.94-3.12 (m ,1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 7.01 (d, 1H, J = 6.0 Hz), 7.09 (t ,1H, J = 5.4 Hz), 7.27-7.35 (m, 2H), 7.42-7.50 (m, 1H), 7.57 (dd, 1H, J = 9.0, 3.0 Hz), 7.86 (td, 1H, J = 7.5, 3.0 Hz). 化合物Π-133 -199- 1376367 [化 301]
'H-NMR (DMSO-d ) δ : 0.92-1.08 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d. 6H, J = 6.6 6
Hz), 1.42-1.58 (m, 1H), 1.72-1.94 (m, 4H), 2.95-3.20 (m, 4H), 4.89-4.98 (m, 2H), 6.65 (brs, 1H), 6.92 (d, 1H, J = 9.0 Hz), 6.91-6.98 (m, 1H), 7.03 (d, 1H, J = 9.0 H z).
化合物li-134 [化302] 七l w 'H-NMR (DMSO-d ) δ : 0.90-1.08 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.42-1.58 (m, 1H), 1.72-1.94 (m, 4H), 2.92-3.20 (m, 4H), 6.74 (t, 1H, J = 6.0 Hz), 6.94 (t, 1H, J = 6.0 Hz), 6.97 (s, 1H), 7.08-7.24 (m, 5H). 化合物Ii-135 [化303]
lH-NMR (DMSO-d ) δ : 0.95-1.10 (m, 2H), 1.12-1.30 (m, 2H), 1.19 (t, 3H, J = 7.2 6
Hz), 1.48-1.60 (m, 1H), 1.76-1.94 (m, 4H), 2.92-3.10 (m, 1H), 2.97 (q, 2H, J = 7. 2 Hz), 3.18-3.30 (m, 2H), 6.89 (d, 1H, J = 9.6 Hz), 7.02 (brs, 1H), 7.11 (t, 1H, J = 5.4 Hz), 7.42-7.56 (m, 2H), 7.85 (d, 1H, J = 9.6 Hz), 7.93 (d, 1H, J = 7.5 Hz), 8.03 (s, 1H). 化合物Ii-136
-200- 1376367 [化 304]
7¾ 'H-NMR (DMSO-d ) δ : 0.98-1.12 (m, 2H). 1.13-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 6
Hz), 1.48-1.62 (m, 1H), 1.78-1.96 (m, 4H), 2.92-3.12 (m, 1H), 2.97 (q, 2H, J = 7. 2 Hz), 3.22-3.32 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 7.01 (d, 1H, J = 7.5 Hz), 7.20 (t ,1H, J = 6.0 Hz), 7.62 (s, 1H), 7.91 (d, 1H, J = 9.0 Hz), 8.02 (s, 2H). 化合物Ii-137 [化305]
Ή-NMR (DMSO-d) δ : 0.95Ί.12 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 6
Hz), 1.65-1.95 (m, 5H), 2.93-3.12 (m, 1H), 2.97 (q, 2H, J = 7.2 Hz), 3.25-3.40 (m ,2H), 5.07-5.16 (m, 2H), 7.01 (d, 1H. J = 7.5 Hz), 7.25 (t, 1H, J = 6.0 Hz), 7.92-8. 03 (m, 3H), 8.33 (d, 1H, J = 6.0 Hz). 化合物li-138 [化306]
^-NMR (DMSO-d ) δ : 0.91Ί.26 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.36-1.43 (m, 6 1H), 1.78-1.90 (m, 4H), 2.90-3.07 (m, 3H), 2.96 (q, 2H, J = 7.5 Hz), 5.69 (t, 1H, J =5.7 Hz), 5.81 (d, 1H, J = 2.4 Hz), 7.00 (d, 1H, J = 7.8 Hz), 7.16-7.39 (m, 3H), 7. 73-7.79 (m, 1H), 7.86-7.88 (m, 1H). -201 - 1376367 化合物Π-139 [化307]
'H-NMR (DMSO-d) δ : 0.90-1.06 (m, 4H), 1.20 (s, 3H), 1.22 (s, 3H), 1.40-1.52 (m, 1H), 1.81 (d, 2H, J = 12.4 Hz), 1.88 (d, 2H, J = 12.4 Hz), 2.90-2.98 (m, 2H), 2. 99-3.13 (m, 2H), 5.68 (t, 1H, J = 5.6 Hz), 5.81 (s, 1H), 6.93 (d, 1H, J = 8.8 Hz). 7. 16-7.40 (m, 3H), 7.76 (t, 1H, J = 8.0 Hz), 7.87 (s, 1H).
化合物丨i-140 [化308]
lH-NMR (DMSO-d ) δ : 0.90-1.06 (m, 4H), 1.26 (s, 9H), 1.40-1.49 (m, 1H), 1.82 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.90-2.99 (m, 2H), 3.01-3.06 (m, 1 H), 5.67 (t, 1H, J = 6.0 Hz), 5.81 (s, 1H), 6.74 (d, 1H, J = 8.4 Hz), 7.14-7.40 (m, 3 H), 7.76 (t, 1H, J = 8.4 Hz), 7.87 (s, 1H).
化合物Π-141 [化 309]
H-NMR (DMSO-d ) δ : 0.97-1.06 (m, 2H), 1.18-1.27 (m, 2H), 1.21 (d, 6H, J = 6.9
Hz), 1.45-1.59 (m, 1H), 1.76-1.81 (m, 2H), 1.87-1.91 (m, 2H), 2.97-3.09 (m, 1H), 3.10-3.13 (m, 1H), 3.17-3.22 (m, 2H), 6.94-7.02 (m, 2H), 6.98 (td, 1H, J = 7.8, 1. 2 Hz), 7.36 (dd, 1H, J = 7.8, 0.6 Hz), 7.65 (dd, 1H, J = 7.8, 0.6 Hz), 8.00-8.05 (m, 1H). -202- 1376367 化合物Ii-142 [化 310]
'H-NMR (DMSO-d ) δ : 0.96-1.04 (m, 2H), 1.18-1.28 (m, 2H), 1.20 (d, 6H, J = 6.9 6
Hz), 1.43-1.59 (m, 1H), 1.74-1.79 (m, 2H), 1.85-1.90 (m, 2H), 2.92-3.07 (m, 1H), 3.09-3.18 (m, 3K), 6.92-6.99 (m, 2H), 7.10 (td, 1H, J = 7.8, 1.2 Hz), 7.21 (dd, 1H ,J = 7.8, 0.6 Hz), 7:31 (dd, 1H, J = 7.8, 0.6 Hz), 7.89-7.97 (m, 1H).
化合物[ί-143 [化 311]
'H-NMR (DMSO-d ) δ : 0.97-1.07 (m, 2H), 1.17-1.23 (m, 2H), 1.18 (t, 3H, J = 7.2 6
Hz), 1.42-1.57 (m, 1H), 1.73-1.78 (m, 2H), 1.86-1.90 (m, 2H), 2.93-3.02 (m, 1H), 2.97 (q, 2H, J = 7.2 Hz), 3.11 (t, 2H, J = 6.3 Hz), 6.91-7.02 (m, 2H), 7.19 (dd, 1H, J = 8.4, 4.8 Hz), 7.34 (dd, 1H, J = 9.3, 2.4 Hz), 8.00 (t, 1H, J = 6.0 Hz).
化合物li-144 [化 312]
Vl-NMR (DMSO-d ) δ : 0.97-1.08 (m, 2H), 1.16-1.24 (m, 2H), 1.18 (t. 3H, J = 7.2 6
Hz), 1.42-1.59 (m, 1H), 1.74-1.80 (m, 2H), 1.85-1.90 (m, 2H), 2.92-3.03 (m, 1H), 2.97 (q, 2H, J = 7.5 Hz), 3.18 (t, 2H, J = 6.3 Hz), 6.99-7.07 (m, 2H), 7.33 (dd, 1H, J = 9.0, 4.8 Hz), 7.58 (dd, 1H, J = 8.7, 2.7 Hz). 8.00 (t, 1H, J = 5.4 Hz). 1376367 化合物Ii-145 [化 313]
'H-NMR (DMSO-d ) δ : 0.97-1.09 (m, 2H), 1.17-1.23 (m, 2H), 1.18 (t, 3H, J = 7.2 6
Hz), 1.43-1.59 (m, 1H), 1.72-1.81 (m, 2H), 1.85-1.92 (m, 2H), 2.95-3.06 (m, 1H), 2.97 (q, 2H, J = 7.5 Hz), 3.19 (t, 2H, J = 6.0 Hz), 7.01 (d, 1H, J = 8.1 Hz), 7.20-7. 23 (m, 1H), 7.33 (dd, 1H, J = 8.7, 0.6 Hz), 7.58 (dd, 1H, J = 2.1, 0.9 Hz), 8.11-8.1 8 (m, 1H). 化合物Π-146 [化 314]
*H-NMR (DMSO-d ) 5 : 0.98-1.06 (m, 2H), 1.15-1.21 (m, 2H), 1.18 (t, 3H, J = 7.2 ti
Hz), 1.42-1.58 (m, 1H), 1.70-1.81 (m, 2H), 1.82-1.96 (m, 2H), 2.93-3.00 (m, 3H), 3.13-3.19 (m, 2H), 6.98-7.02 (m, 2H), 7.26-7.27 (m, 1H), 7.32-7.35 (m, 1H), 8.18 -8.21 (m, 1H). 化合物Ii-147 [化 315]
lH-NMR (DMSO-d ) δ : 0.98-1.04 (m, 2H), 1.16-1.23 (m, 2H), 1.18 (t, 3H, J = 7.2 6
Hz), 1.43-1.59 (m, 1H), 1.73-1.78 (m, 2H), 1.86-1.89 (m, 2H), 2.93-3.00 (m, 3H), -204- 1376367 3.11-3.15 (m, 2H), 6.72-6.79 (m, 1H), 7.00-7.08 (m, 2H), 7.29-7.34 (m, 1H), 8.13 -8.16 (m, 1H). 化合物H-148 [化 316]
'H-NMR (DMSO-d ) δ : 0.94-1.06 (m, 2H), U5-1.26 (m, 2H), 1.18 (t, 3H, J = 7.2 6
Hz), 1.45-1.58 (m, 1H), 1.72-1.80 (m, 2H), 1.84-1.92 (m, 2H), 2.96 (q, 2H, J = 7. 2 Hz), 2.96-3.05 (m, 1H), 3.09-3.16 (m, 2H), 6.99 (d, 1H, J = 8.0 Hz), 7.13 (dd, 1 H, J = 8.0, 2.0 Hz), 7.20 (d, 1H, J = 8.4 Hz), 7.49 (d, 1H, J = 2.0 Hz), 8.11 (t, 1H, J = 6.0 Hz). 化合物Ii-149 [化 317]
]H-NMR (DMSO-d ) δ : 0.96-1.08 (m, 2H), 1.12-1.24 (m, 2H), 1.18 (t, 3H, J = 7.2 6
Hz), 1.43-1.59 (m, 1H), 1.74-1.80 (m,2H), 1.86-1.91 (m, 2H), 2.93-3.01 (m, 3H), 3.17-3.22 (m,2H), 7.00-7.05 (m, 2H), 7.37-7,39 (m, 1H), 7,65-7.68 (m,1H), 8.22 -8.26 (m, 1H). 化合物li-150 [化 318]
F 'H-NMR (DMSO-d ) 5 : 0.98-1.08 (m, 2H), 1.15-1.29 (m, 2H), 1.21 (d, 6H, J = 6.9 6 -205 - 1376367
Hz), 1.44-1.60 (m, 1H), 1.74-1.80 (m, 2H), 1.86-1.91 (m, 2H), 2.95-3.17 (m, 2H), 3.21-3.27 (m, 2H), 6.95-6.98 (m, 1H), 8.10 (dd, 1H, J = 8.4, 2.7 Hz), 8.19 (dd, 1H ,J = 3.0, 1.5 Hz), 8.44-8.47 (m, 1H). 化合物Ii-151 [化 319]
Cl *H-NMR (DMSO-d ) δ : 0.99-1.04 (m, 2H), 1.15-1.23 (m, 2H), 1.21 (d, 6H, J = 6.3
5
Hz), 1.43-1.59 (m, 1H), 1.73-1.81 (m, 2H), 1.85-1.91 (m, 2H), 2.97-3.18 (m, 2H), 3.21-3.29 (m, 2H), 6.95-6.98 (m, 1H), 8.20-8.23 (m, 2H), 8.58-8.61 (m, 1H). 化合物Ii-152 [化320]
^-NMR (DMSO-d) δ·: 0.96-1.04 (m, 2H), 1.15-1.26 (m, 2H), 1.25 (s, 9H), 1.56-6
1.62 (m, 1H), 1.78-1.83 (m, 2H)( 1.87-1.93 (m, 2H), 2.98-3.08 (m, 1H), 3.17 (t, 2H ,J = 6.3 Hz), 3.48 (s, 3H), 6.47 (d, 2H, J = 8.7 Hz), 6.89-6.96 (m, 2H), 7.11-7.19 ( m, 2H). 化合物Ii-153 [化 321]
'H-NMR (DMSO-d) δ : 0.95-1.04 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H, J = 7.5 6 -206- 1376367
Hz), 1.41 (m, 1H), 1.7L-1.94 (m, 4H), 2.80-2.89 (m, 2H), 2.92-3.10 (m, 2H), 2.97 (q, 2H, J = 7.5 Hz), 3.21-3.30 (m, 2H), 6.25-6.35 (m, 2H), 6.39 (dd, 1H, J = 8.4, 2. 1 Hz), 7.01 (d, 1H, J = 7.5 Hz), 7.01 (dd, 1H, J = 8.4, 8.4 Hz). 化合物Ii-154 [化322]
'H-NMR (DMSO-d ) δ : 0.91-1.09 (m, 2H), 1.16-1.28 <m, 2H), 1.18 (t, 3H, J = 7.5 6
Hz), 1.42 (m, 1H), 1.74-1.95 (m, 4H), 2.80-3.16 (m, 9H), 2.97 (q, 2H, J = 7.5 Hz), 6.24-6.36 (m, 2H), 6.30 (dd, 1H, J = 8.4, 2.1 Hz), 7.10 (dd, 1H, J = 8.4, 2.1 Hz), 7 .05 (d, 1H, J = 8.4 Hz). 化合物Π-155 [化323]
化合物Π-156 [化 324]
F D 化合物Ii-157 [化325] -207- 1376367
化合物li-158 [化326]
'H-NMR (DMSO-d ) 6 : 0.91-1.07 (m, 2H), 1.10-1.30 (m, 5H), 1.41 (m, 1H), 1.76-6 1.94 (m, 4H), 2.74-2.83 (m, 2H), 2.83 (s, 3H), 2.90-3.08 (m, 3H), 2.96 (s, 3H), 5.6 8 (m, 1H), 6.39 (m, 1H), 6.58 (m, 1H), 6.95 (dd, 1H, J = 8.4, 8.4 Hz), 7.00 (d, 1H, J =7.8 Hz). 化合物U-159 [化 327]
化合物li-160 [化 328]
化合物Ιί-161 [化329] -208- 1376367
化合物Ii-162 [化 330]
化合物[i-163 [化 331]
化合物Ii-164 [化332]
□ 化合物Π-165 [化333]
-209- 1376367 化合物I卜166 [化334]
F 0 化合物丨卜167 [化335]
化合物Π-168 [化336]
化合伽卜169
[化337]
化合物Ii-170 [化338] -210- 1376367
化合物Ii-171 [化339]
化合物Π-172 [化340]
化合物Ii-173 [化 341]
'H-NMR (DMSO-d ) δ : 0.95-1.08 (rn, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H, J = 7.2 6
Hz),1.43 (m, 1H), 1.76-1.85 (m, 2H), 1.85-1.93 (m, 2H), 2.76-2.82 (m, 2H), 2.88 ( t, 2H, J = 6.0 Hz), 2.97 (t, 2H, J = 7.2 Hz), 3.00 (m, 1H), 3.64-3.70 (m, 4H), 6.33 ( m, 1H)( 6.37 (d, 1H, J = 8.4 Hz), 6.56 ($, 1H), 7.00 (d, 1H, J = 7.8 Hz), 7.28 (d, 1H ,J = 8.4 Hz). 化合物Ii-174 -211 - 1376367 [化342]
ο cf3 化合物[i-175 [化343]
化合物丨i-176 [化344]
化合物Ii-177 [化345]
化合物Ii-178 [化 346]
-212- 1376367 化合物Π-179 [化347]
化合物1卜180 [化348]
化合物Η-181 [化 349]
化合物Ii-182 [化350]
化合物Ii-183 [化 351]
-213 - 1376367 化合物li-184 [化352]
化合物li-185 [化 353]
化合物丨i-186 [化354] Η NV-WCp3 1¾
化合物[i-187 [化 355]
化合物丨i-188 [化 356] -214- 1376367
化合物li-189 [化357]
化合物Ii-190 [化 358]
化合物Ii-191 [化359]
化合物Π-192 [化360]
-215 1376367 化合物Ii-193 [化 361]
化合物[i-194 [化362]
化合物Ii-195 [化 363]
化合物Ii-196 [化364]
化合物Ii-197 [化365] r £ -216- 1376367
化合物I卜198 [化366]
化合物Ii-199 [化367]
化合物Π-200 [化368]
化合物Ii-20i [化 369]
化合物Π-202
-217- 1376367 [化 370] Vo、 JUCF3 化合物丨i-203 [化 371] 化合物Ii-204 ' [化372] 化合物Ii-206 [化374]
化合物Π-205 [化373]
-218 - 1376367
化合物Ij-2 [化375] 〜馬 'H-NMR (DMSO-d ) 5 : 0.98-1.24 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.40 (m, 1H), 6 1.78-1.88 (m, 2H), 2.02-2.14 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 2.86 (q, 2H, J = 7.2 Hz), 3.64-3.82 (m. 1H), 6.40 (d, 2H, J = 8.1 Hz), 7.01 (d, 2H, J = 7.2 Hz), 7.32-7. 50 (m, 4H), 7.99 (d, 2H, J = 6.9 Hz) 化合物Ij-3 [化376]
1.78-1.88 (ra, 2H), 2.02-2.14 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (rn, 1H), 6.40-6.50 (m,2H), 6.85-6.92 (m, IH), 6.97-7.03 (m, 1H), 7.22-7.35 (m, 2H), 7.36-7.46 (m, 2H). 7.88-7.96 (m, 1H) 化合物lh4 [化377]
-219- 1376367 'h-NMR (DMSO-d ) δ : 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.38 (m, 1H), 6 1.78- 1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.50 (t, 1H, J = 3.9 Hz), 6.53 (s, 1H), 7.00 (t, 1H, J = 5.7 Hz), 7.25 (t, 1H, J = 7.2 Hz), 7.34-7.45 (m, 2H), 7.55 (d, 2H, j = 7.2 Hz), 7.67 (dd, 1H, J = 8.7, 2.7 Hz), 8.29 (d, 1H, J = 2.7 Hz) 化合物Ij-5 [化378] Q. 0
'H-NMR (DMSO-d ) δ : 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.38 (m, 1H), 6 1.78- 1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.52 (d, 1H, J = 8.4 Hz), 6.60 (d, 1H, J = 7.8 Hz), 7.01 (t, 1H, J = 5.7 Hz), 7.20-7.36 (m, 3H), 7.46 (t, 1H, J = 8.1 Hz), 7.55 (d, 1H, J = 8.7 Hz), 8.15 (s, 1H) 化合物Ij-6 Wk379]
H !H-NMR (DMSO-d ) 6 : 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), i.40 (m, 1H), 6 1.78- 1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.51 (d, 1H, J = 8.7 Hz), 6.60 (d, 1H, J = 7.5 Hz), 7.01 (t, 1H, J = 5.7 Hz), 7.02-7.12 (m, 1H), 7.36-7.48 (m, 3H), 7.71 (dd, 1H, J = 8.7, 2.1 Hz), 8.33 (d, 1H, J = 2.1 Hz) 化合物Ij-7 [化380] -220 1376367
'h-NMR (DMSO-d ) δ : 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.40 (m, 1H), 6 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (ΐ, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.50 (d, 2H, J = 8.7 Hz), 6.99 (t, 1H, J = 6.0 Hz), 7.16-7. 26 (m, 2H), 7.52-7.68 (m, 3H), 8.25 (s, 1H) 化合物丨j-8 [化 381]
^-NMR (CDC1) 5 : 1.15-1.26 (m, 4H), 1.40 (t, 3H, J = 7.5 Hz), 1.55-1.58 (m, 1H 3 ),1.93 (d, 2H, J = 9.7 Hz), 2.23 (d, 2H, J = 9.7 Hz), 3.01-3.11 (m, 4H), 3.56-3.61 ( m, 1H), 3.84 (s, 3H), 4.34 (t, 1H, J = 6.1 Hz), 4.83-4.86 (m, 1H), 6.46 (d, 1H, J = 8 .6 Hz), 6.99 (d, 1H, J = 8.5 Hz), 7.05 (d, 1H, J = 8.5 Hz), 7.29 (s, 1H), 7.30-7.34 ( m, 1H), 7.69 (dd, 1H, J = 8.7, 2.4 Hz), 8.25 (s, 1H). 化合物Ij-9 [化382]
JH-NMR (CDC1) δ : 1.16-1.24 (m, 4H), 1.40 (t, 3H, J = 6.2 Hz), 1.55-1.59 (m, 1H ),1.94 (d, 2F-I, J = Π.8 Hz), 2.23 (d, 2H, J = 11.8 Hz), 3.03-3.09 (in, 4H), 3.58-3.6 2 (m, 1H), 3.88 (s, 3H), 4.29 (t, 1H, J = 6.4 Hz), 4.85-4.89 (m, 1H), 6.49 (d, 1H, J =8.7 Hz), 6.88 (dd, 1H, J = 8.7, 2.2 Hz), 7.04-7.06 (m, 1H), 7.10 (d, 1H, J = 8.7 H z), 7.36 (t, 1H, J = 7.9 Hz), 7.70 (dd, 1H, J = 8.7, 2.2 Hz), 8.32 (s, 1H). 化合物Ij-l〇 -221 - 1376367 [化383]
'H-NMR (CDC1) 6 : 1.19-1.30 (m, 4H), 1.41 (t, 3H, J = 6.3 Hz), 1.56-1.59 (m, 1H 3 ),1.94 (d. 2H, J = 11.1 Hz), 2.23 (d, 2H, J = 11.1 Hz), 3.01-3.11 (m, 4H), 3.57-3.6 1 (m, 1H), 3.87 (s, 3H), 4.27 (t, 1H, J = 6.4 Hz), 4.98 (s, 1H), 6.50 (dd, 1H, J = 8.7 ,2.2 Hz), 6.99 (d, 2H, J = 8.9 Hz), 7.43 (d, 2H, J = 8.7 Hz), 7.68 (dd, 1H, J = 8.7, 2.2 Hz), 8.25 (s, 1H).
化合物lj-11 [化384]
'H-NMR (DMSO-d) δ : 0.93-1.08 (m, 2H), 1.09-1.25 (m, 5H), 1.39 (m, 1H), 1.75- 6
1.86 (m, 2H), 1.95-2.07 (m, 2H), 2.34 (s, 3H), 2.78 (t, 2H, J = 6.2 Hz), 2.98 (q, 2H ,J = 7.3 Hz), 3.65 (tn, 1H), 6.45-6.53 (m, 2H), 7.01 (t, 1H, J = 5.6 Hz), 7.07 (d, 1H ,J = 7.1 Hz), 7.23-7.38 (m, 3H), 7.64 (dd, 1H, J1 = 8.8 Hz, J2 = 2.5 Hz), 8.26 (d, 1 H, J = 2.5 Hz). 化合物Ij-12 [化385]
'H-NMR (DMSO-d) δ : 0.93-1.08 (ra, 2H), 1.09-1.27 (m, 11H), 1.39 (m, 1H), 1.76 Θ -1.87 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.2 Hz), 2.84-3.03 (m, 3H), 3.66 (m, 1H), 6.45-6.54 (m, 2H), 7.01 (t, 1H, J = 5.8 Hz), 7.13 (d, 1H, J = 6.9 Hz), 7.27 -7.41 (m, 3H), 7.66 (dd, 1H, J1 = 8.8 Hz, J2 = 2.5 Hz), 8.27 (d, 1H, J = 2.2 Hz).
-222- 1376367 化合物lj-13 [化386] 'H-NMR (DMSO-d ) 6 : 0.92-1.09 (m, 2H), 1.09-1.25 (ra, 5H), 1.39 (m, 1H), 1.76- fi
1.85 (m, 2H), 1.95-2.06 (m, 2H), 2.78 (t, 2H, J = 6.2 Hz), 2.98 (q, 2H, J = 7.3 Hz), 3.68 (m, 1H), 6.52 (d, 1H, J = 8.8 Hz), 6.66 (d, 1H, J = 8.0 Hz), 7.02 (t, 1H, J = 5.5 Hz), 7.23 (d, 1H, J = 8.1 Hz), 7.49-7.55 (m, 2H), 7.62 (d, 1H, J1 = 8.5 Hz), 7.72 ( dd, 1H, J1 = 8.8 Hz, J2 = 2.5 Hz), 8.35 (d, 1H, J = 2.5 Hz). 化合物Ihl4 [化387]
'H-NMR (DMSO-d) δ :· 0.92-1.22 (m, 4H), 1.22 (d, 6H, J = 6.4 Hz), 1.39 (m, 1H), 6
1.76-1.86 (m, 2H), 1.95-2.03 (m, 2H), 2.81 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.60-3.75 (m, 1H), 6.65 (d, 1H, J = 4.8 Hz), 6.70 (s, 1H), 6.88-6.98 (m, 2H)( 8.16 (d, 1H, J = 5.2 Hz). 化合物Ij-15 [化388]
'H-NMR (CDC1) 5 : 1.02-1.28 (m, 4H), 1.38 (d, 6H, J = 6.9 Hz), 1.52 (m, 1H), 1.8 3 5-1.94 (m, 2H), 2.11-2.21 (m, 2H), 3.01 (t, 2H, J = 6.6 Hz), 3.10-3.25 (m, 1H), 3.3 8-3.54 (m, 1H), 4.22 (ΐ, 1H, J = 6.3 Hz). 4.58 (d, 1H, J = 7.8 Hz), 6.34 (d, 1H, J = -223 1.8 Hz), 6.53 (dd, 1H, J = 5.4, 1.8 Hz), 7.93 (d, 1H, J = 5.4 Hz). 化合物丨hl6 [化389] 'H-NMR (CDCI) δ : 1.03-1.28 (m, 4H), 1.37 (d, 6H, J = 6.9 Hz), 1.52 (m, 1H), 1.8 3 4-1.93 (m, 2H), 2.11-2.21 (ra, 2H), 3.01 (t, 2H, J = 6.6 Hz), 3.09-3.24 (m, 1H), 3.4 0-3.54 (m, IH), 4.26 (t, 1H, J = 6.6 Hz), 4.44 (d, 1H, J = 8.1 Hz), 6.29 (d, 1H, J = 8.7 Hz), 7.33 (dd, 1H, J = 8.7, 2_7 Hz>, 7.99 (d, 1H, J = 2.7 Hz). 化合物Ihl7 [化390]
'H-NMR (DMSO-d) δ : 0.92-1.22 (m, 4H), 1.21 (d, 6H, J = 6.8 Hz), 1.36 (m, 1H), 6 1.76-1.84 (m, 2H), 1.92-2.00 (m, 2H), 2.80 (t, 2H, J = 6.4 Hz), 3.08-3.18 (m, 1H), 3.45-3.56 (m, 1H), 6.36 (d, 1H, J = 8.4 Hz), 6.43 (d, 1H, J = 7.2 Hz), 6.75 (d, 1H, J = 7.6 Hz), 6.94 (t, 1H, J = 6.0 Hz), 7.33 (t, 1H, J = 7.6 Hz). 化合物!j-18 [化 391]
'H-NMR (DMSO-d ) 5 : 0.98-1.24 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.40 (m, 1H), 6 1.78-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.64-3.82 (m, 1H), 6.40 (d, 2H, J = 8.4 Hz), 6.95-7.05 (m, 2H), 7.35-7.50 (m, 4H) ,7.99 (d, 2H, J = 7.2 Hz) -224- 1376367 化合物丨j-19 [化392]
'H-NMR (CDC1) δ : 1.22-1.38 (m, 4Η), 1.38 (d, 6H, J = 8.0 Hz), 1.54 (m, 1H), 1.8 3
6-1.95 (ra, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J = 6.0 Hz), 3.12-3.22 (m, 1H), 3.5 2-3.64 (m, 1H), 4.16 (t, 1H, J = 6.4 Hz), 4.82-4.92 (m, 1H), 6.46 (d, 1H, J = 8.0 H z), 7.10-7.20 (m, 2H), 7.23-7.33 (m, 1H), 7.37 (t, 1H, J = 8.0 Hz), 7.65 (d, 1H, J = 8.7 Hz), 8.24 (s, 1H). 化合物lj-20 [化393]
'H-NMR (CDC1) δ : 1.22-1.38 (m. 4H), 1.39 (d, 6H, J = 8.0 Hz), 1.54 (m, 1H), 1.8 3
6-1.95 (m, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J = 6.0 Hz), 3.12-3.22 (m, 1H), 3.5 2-3.64 (m, 1H), 4.16 (t, 1H, J = 6.4 Hz), 4.78-4.88 (m, 1H), 6.46 (d, 1H, J = 8.0 H z), 6.98(t, 1H, J = 5.7 Hz), 7.18 (d, 1H, J = 8.0 Hz), 7.23-7.29 (m, 1H). 7.33-7.40 ( m, 1H), 7.65 (d, 1H, J = 8.7 Hz), 8.29 (s, 1H). 化合物Ij-21 [化394]
CrF 'H-NMR (CDC1) 6 : 1.10-1.30 (m, 4H), 1.38 (d, 6H, J = 8.0 Hz), 1.54 (m, 1H), 1.8 3
6-1.95 (m, 2H). 2.18-2.26 (m, 2H), 3.03 (t/2H, J = 6.0 Hz), 3.13-3.22 (m, 1H), 3.5 2-3.64 (m, 1H), 4.15 (t, 1H, J = 6.4 Hz), 4.78-4.88 (m, 1H), 6.46 (d, 1H, J = 8.0 H -225- 1376367 z), 7.07-7.14 (m, 2H), 7.40-7.46 (m, 2H), 7.62 (d, 1H, J = 8.7 Hz), 8.23 (s, IH). 化合物Ij-22 [化395]
QMe 'H-NMR (DMSO-d ) δ : 0.95-1.25 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.25-1.50 (br 6
,1H), 1.81 (d, 2H, J = 11.4 Hz), 2.00 (d, 2H, J = 10.5 Hz), 2.81 (t, 2H, J = 6.6 Hz), 3.05-3.22 (m, IK), 3.58-3.80 (m, 1H), 3.76 (s, 3H), 6.49 (d, 2H, J = 8.7 Hz), 6.50 -6.70 (br, 1H), 6.95-7.10 (m, 3H), 7.20-7.32 (m, 2H), 7.51 (d, 1H, J = 7.2Hz), 8.05 (br, 1H). ESI(positive) 418.3 [M+H]+ 化合物丨j-23 [化396]
'H-NMR (DMSO-d ) δ : 0.95-1.32 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.25-1.55 (br 6
,1H), 1.82 (d, 2H, J = 11.4 Hz), 2.01 (d, 2H, J = 10.2 Hz), 2.81 (t, 2H, J = 6.6 Hz), 3.05-3.22 (m, 1H), 3.58-3.78 (m, 1H), 3.80 (s, 3H), 6.59 (d, 2H, J = 9.6 Hz), 6.85 (dd, 1H, J = 8.4 Hz, 2.4 Hz), 6.99 (t, 3H, J = 5.7Hz), 7.05-7.18 (m, 2H), 7.32 (d, 1 H, J = 7.8Hz), 7.76 (d, 1H, J = 8.4Hz), 8.27 (d, 1H, J = 2.1 Hz). ESI(positive) 418. 3 CM+H3+ 化合物Ij-24 [化397]
'H-NMR (DMSO-d ) δ : 0.92-1.25 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.28-1.48 (m, 6
-226- 1376367 1H), 1.81 (d, 2H, J = 10.8 Hz), 2.00 (d, 2H, J = 9.6 Hz). 2.81 (t, 2H, J = 6.6 Hz), 3 .08-3.22 (m, 1H), 3.58-3.74 (m, 1H), 3.77 (s, 3H), 6.51 (d, 2H, J = 8.7 Hz), 6.97 (d ,2H, J = 8.7 Hz), 6.98 (brs. 1H), 7.48 (d, 2H, J = 8.7 Hz), 7.63 (dd, 1H, J = 11.4Hz ,2.4Hz), 8.21 (d, 1H, J = 2.4 Hz). ESI(positive) 418.3[M+H]+ 化合物l〗-25 [化398]
lH-NMR (DMSO-d ) 6 : 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H), 1.78-1.88 ( 6 m, 2H), 1.95-2.05 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.60-3.80 (m, 1H), 6.65 (d, 1H ,J = 5.4 Hz), 6.70 (s, 1H), 6.87 (t, 1H, J = 6.0 Hz), 6.94 (d, 1H, J = 7.8 Hz), 8.16 ( d, 1H, J = 5.4 Hz) 化合物Ij-26 [化 399]
'H-NMR (DMSO-d ) δ : 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H), 1.78-1.88 (
m, 2H), 1.94-2.04 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz). 3.60-3.80 (m, 1H), 6.53 (d, 1H ,J = 8.7 Hz), 6.87 (t, 1H, J = 5.7 Hz), 7.19 (d, 1H, J = 7.5 Hz), 7.59 (dd, 1H, J = 9. 0, 2.4 Hz), 8.26 (d, 1H, J = 2.4 Hz) 化合物Ij-27 [化400]
'H-NMR (DMSO-d) δ : 0.92-1.22 (m, 4H); 1.26 (s, 9H), 1.38 (m, 1H), 1.76-1.86 ( -227- 1376367 m, 2H), 1.92-2.02 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.40-3.60 (m, 1H), 6.36. (d, 1H ,J = 8.1 Hz), 6.43 (d, 1H, J = 6.9 Hz), 6.80 (d, 1H, J = 7.5 Hz), 6.86 (t, 1H, J = 5.4 Hz), 7.34 (t, 1H, J = 8.4 Hz) 化合物Ij-28 [化 401] 0 0
'H-NMR ((DMSO-d ) δ : 0.93-1.18 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H) 6
,1.75-1.86 (m, 2H), 1.94-2.05 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 3.09-3.27 (m, 2H ),6.19 (d, 1H, J = 8.1 Hz), 6.64 (d, 2H, J = 8.7 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.33 ( d, 2H, J = 8.7 Hz) Mass:379[M+Hr 化合物ij-29 [化402]
lH-NMR (DMSO-d ) δ : 0.93-1.18 (m, 4H), 1.22 (s, 3H), 1.24 (s, 3H), 1.32-1.49 ( 6
m, 2H), 1.82 (d, 2H, J = 11.2 Hz), 2.04 (d, 2H, J = 11.2 Hz), 2.75-2.87 (m, 2H), 3. 07-3.28 (m, 2H), 6.64 (s, 1H), 6.96 (s, 1H), 7.10-7.22 (m, 2H), 7.25-7.39 (m, 2H), 7.77-7.90 (m,2H), 8.63 (s, 1H).融點:161-162°C 化合物Ih30 [化403] Η 'H-NMR (DMSO-d ) δ : 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.37 (m, 1H), 1.76-1.86 ( 6 m, 2H), 1.94-2.05 (m, 2H)( 2.88 (t, 2H, J = 6.3 Hz), 3.19 (m, 1H), 6.19 (d, 1H, J = -228- 1376367 7.5 Hz), 6.64 (d, 2H, J = 8.7 Hz), 6.88 (d, 1H, J = 6.0Hz), 7.33 (d, 2H, J = 8.7 Hz )Mass:392M+ 化合物[j-31 [化404]
F 'H-NMR (DMSO-d) δ : 0.92-1.16 (m, 4H), 1.26 (s, 9H), 1,36 (m, 1H), 1.72-1.83 ( 6
m, 2H), 1.92-2.02 (m, 2H), 2.87 (t, 2H, J = 6.3 Hz), 3.12 (m, 1H), 6.09-6.23 (m, 4 H), 6.87 (t, 1H, J = 6.0 Hz) Mass:361[M+H]+ 化合物Ij-32 [化405]
F F H 'H-NMR (CDCI) δ : 1.00-1.20 (tn, 4H), 1.40 (s, 9H), 1.42-1.64 (m, 2H), 1.84-1.9 3 5 (m, 2H), 2.09-2.20 (m, 2H), 3.07 (m, 1H), 3.07 (t, 2H, J = 6.3 Hz), 3.90 (m, 1H), 6.10 (dd, 2H, J = 9.6, 5.4 Hz).
化合物丨j-33 [化406]
'H-NMR (DMSO-d) δ : 0.93-1.21 (m, 5H), 1.28 (s, 9H), 1.33-1.46 (m, 1H), 1.82 ( 6 d, 2H, J = 11.6 Hz), 2.04 (d, 2H, J = 11.6 Hz), 2.86-2.95 (m, 2H), 3.03-3.29 (m, 1 H), 6.59-6.71 (m, 1H), 6.80-6.92 (m, 1H), 7.09-7.21 (m, 2H), 7.27-7.37 (m, 2H), 7 .77-7.88 (m, 2H), 8.58-8.67 (s, 1H).融点:172-173°C 化合物丨j-34 -229- 1376367 N八Cl 'H-NMR (DMSO-d ) δ : 0.96-1.08 (m, 2H), 1.12-1.24(m, 2H), 1.21 (d, 6H, J = 6.4 6
Hz), 1.38 (m, 1H), 1.76-1.86 (m, 2H), 1.92-2.00 (m, 2H), 2.80 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.48-3.60 (m, 1H), 6.95 (t, 1H, J = 5.6 Hz), 7.41 (d, 1H, J = 7.6 Hz), 7.63 (s, 1H), 7.82 (s, 1H).
[化407]
化合物Ij-35 [化408]
'H-NMR (DMSO-d ) 6 : 0.96-1.26 (m, 4H), 1.27 (s, 9H),. 1.38 (m, 1H). 1.78-1.88 ( m, 2H). 1.92-2.02 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.48-3.62 (m. 1H), 6.87 (t, 1H ,J = 6.0 Hz), 7.45 (d, 1H, J = 7.5 Hz), 7.63 (s, 1H), 7.82 (s, 1H) 化合物U-36 [化409]
lH-NMR (DMSO-d ) 8 : 0.96-1.06 (m, 2H), 1.12-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.39 (m, 1H), 1.78-1.84 (m, 2H), 1.95-1.99 (m, 2H), 2.81 (t, 2H, J = 6.0 Hz), 3.10-3.20 (m, 1H), 3.74-3.88 (m, 1H), 6.80 (s, 1H), 6.98 (t, 1H, J = 6.0 Hz), 7.93 ( d, 2H, J = 7.2 Hz), 8.53 (s, 1H). 化合物U-37 [化 410] -230- 1376367
'H-NMR (DMSO-d ) δ : 0.96-1.30 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.72-3.90 (m, 1H), 6.85 (d, 1H, J = 9.6 Hz), 6.93 (d, 1H, J = 7.5 Hz), 7.04 (t, 1H, J = 5.7 Hz), 7.26-7.38 (m, 2H), 7.40-7.52 (m, 1H), 7.57 (d, 1H, J = 9.0 Hz), 7 .85 (t, 1H, J =7.8 Hz)
化合物丨j-38 [化411]
'H-NMR (DMSO-d ) 6 : 0.96-1.30 (m, 4H), 1.19 (t. 3H, J = 7.2 Hz), 1.42 (m, 1H), 6 1.78-1.88 (rn, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.72-3.90 (m, 1H), 3.80 (s, 3H), 6.72 (d, 1H, J = 7.8 Hz), 6.77 (d, 1H, J = 9.0 Hz), 6.98-7.10 (m, 2H), 7.12 (d, 1H, J = 8.4 Hz), 7.38 (t, 1H, J = 8.1 Hz), 7.56 (d, 1H, J = 9.3 Hz), 7.61 (d, 1H, J = 7.8 Hz) 化合物lj-39'
[化 412]
'H-NMR (DMSO-d ) 5 : 0.96-1.30 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.42 (m, 1H), 6 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.72-3.90 (m, 1H), 6.85 (d, 1H, J = 9.6 Hz), 6.92 (d, 1H, J = 7.5 Hz), 7.04 (t, 1H, J = 5.7 Hz), 7.21 (t, 1H, J = 8.7 Hz), 7.46-7.56 (m, 1H), 7.75-7.88 (m, 3H) 化合物U-40 -231 - 1376367 [化 413]
'H-NMR (DMSO-d ) δ : 0.96-1.10 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.15-1.26 (m, 6 2H), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.76-3.87 (m, IK), 6.85 (d, 1H, J = 9.6 Hz), 6.91 (d, 1H, J = 7.5 Hz), 7.01 (t, 1H, J = 5.7 Hz), 7.42-7.52 (m, 2H), 7.83 (d, 1H, J = 8.0 Hz), 7 .93 (d, 1H, J = 8.0 Hz), 8.02 (s, 1H).
化合物Ij-41 [化 414]
]H-NMR (DMSO-d ) δ : 0.96-1.30 (m, 4H), 1.20 (t, 3H, J = 7.5 Hz), 1.42 (m, 1H), 6 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.76-3.90 (m, 1H), 6.88 (d, 1H, J = 9.3 Hz), 6.97 (d, 1H, J = 7.5 Hz), 7.03 (t, 1H, J = 5.7 Hz), 7.67-7.77 (m, 2H), 7.92 (d, 1H, J = 9.6 Hz), 8.26 (d, 1H, J = 6.9 Hz), 8.33(s, 1H)
化合物Ij-42 [化 415]
'H-NMR (DMSO-d ) 6 : 0.93-1.10 (m, 2H), 1.20 (t, 3H, J= 7.2 Hz), 1.22-1.28 (m, 6 1H), 1.35-1.50 (m, 2H), 1.84 (d, 2H, J = 12.0 Hz), 2.08 (d, 2H, J = 12.0 Hz), 2.63-2.76 (m, 2H), 2.91-3.03 (m, 2H), 3.75-3.90 (m, 1H), 6.86 (d, 1H, J = 9.2 Hz), 6.93 (d, 1H, J = 7.2 Hz), 6.98-7.07 (in, 1H), 7.36 (d, 1H, J = 7.2 Hz), 7.59 (t, 1H, J = 8. -232- 1376367
0 Hz), 7.85 (d, 1H, J = 9.2 Hz), 7·9卜8.02 (m, 2H).融点:i44-l45〇C 化合物Ij-43 [化 416]
'H-NMR (DMSO-d ) δ : 0.94-1.06 (m, 2H), 1.10-1.24 (m, 2H), 1.21 (d, 6H, J = 6.8 6
Hz), 1.39 (m, 1H), 1.76-1.86 (m, 2H), 1.98-2.06 (m, 2H), 2.81 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.62-3.74 (m, 1H), 6.84 (d. 1H, J =9.2 Hz), 6.88-6.98 (m, 2H), 7.31 (d, 1H, J = 9.6 Hz). 化合物丨j-44 [化 417]
'H-NMR (DMSO-d ) 5 : 0.94-1.26 (m, 4H), 1.20 (d, 6H, J = 6.6 Hz), 1.40 (m, 1H), 6 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.06-3.20 (m, 1H), 3.72-3.90 (m, 1H), 6.75-6.88 (m, 2H), 6.97 (t, 1H, J = 6.0 Hz), 7.30-7.48 (m, 3H), 7.76 (d, 1H, J = 9.3 Hz), 7.94 (d, 2H, J =8.4 Hz)
化合物U-45 [化 418]
lH-NMR (DMSO-d ) δ : 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 6 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.85 (d, 1H, J = 9.0 Hz), 6.91 (d, 1H, J = 7.5 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.25-7.36 (m, 2H), 7.40-7.50 (m, 1H), 7.57 (d, 1H, J = 6.9 Hz), 7.85 (t -233 - 1376367 ,1H, J=8.1 Hz) 化合物Ij-46 [化 419]
'H-NMR (DMSO-d ) 6 : 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.42 (m, 1H), 6 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.85 (d, 1H, J = 9.3 Hz), 6.90 (d, 1H, J = 7.5 Hz), 6.98 (t,1H,
J = 6.0 Hz), 7.21 (t, IH, J = 7.8 Hz), 7.46-7.56 (m, 1H), 7.75-7.86 (m, 3H) 化合物[卜47 [化420]
丫 Ά 'H-NMR (DMSO-d ) δ : 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 6 L78-L88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m( 1H), 3.74-3.92 (m, 1H), 6.81 (d, 1H, J = 7.5 Hz), 6.84 (d, 1H, J = 9.3 Hz), 6.98 (t, 1H, J = 6.3 Hz), 7.25-7.35 (m, 2H), 7.77 (d, 1H, J = 9.3 Hz), 7.96-8.06 (m, 2H)
化合物Ij-48 [化 421]
'H-NMR (DMSO-d ) δ : 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 6 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, IH), 3.74-3.92 (m, 1H), 3.80 (s, 3H), 6.71 (d, 1H, J = 7.8 Hz), 6.76 (d, 1H, J = 9.3 Hz), 6.98 (t, 1H, J = 5.7 Hz), 7.05 (d, 1H, J = 7.2 Hz), 7.12 (d, 1H, J = 7.8 Hz), 7.38 (t,
-234- 1376367 1H, J = 8.4 Hz), 7.56 (d, 1H, J = 9.3 Hz), 7.62 (d, 1H, J = 6.9 Hz) 化合物丨h49 [化 42¾ OMe 'H-NMR (DMSO-d) δ : 0.96-1.28 (ra, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.42 (m, 1H), 6
1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.82 (s, 3H), 6.78-6.88 (m, 2H), 6.92-7.04 (m, 2H), 7.37 (t, 1H ,J = 7.5 Hz), 7.46-7.58 (m, 2H), 7.79 (d, 1H. J = 9.3 Hz) 化合物丨j-50 [化423]
'H-NMR (DMSO-d ) 5 : 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 6 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.80 (s, 3H), 6.70 (d, 1H, J = 7.8 Hz), 6.82 (d, 1H, J = 9.3 Hz), 6.95-7.05 (m, 3H), 7.72 (d, 1H, J = 9.3 Hz), 7.90 (d, 2H, J = 9.0 Hz).
化合物[j-51 [化424]
〇vCF3 'H-NMR (DMSO-d ) δ : 0.92-1.05 (m, 2H), 1.07-1.20 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.76-1.85 (m, 2H), 2.02-2.10 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.57-3.68 (m, 1H), 4.89-4.98 (m, 2H), 6.47 (d, 1H, J = 8.0 Hz), 6.88 (d, 1H, J = 7.5 Hz), 6.96 (t, 1H, J = 6.0 Hz), 7.02 (d, 1H, J = 7.5 Hz). 1376367 化合物[j-52 [化425]
AxijjjXo 'H-NMR (DMSO-d) δ :.0.92-1.05 (m, 2H), 1.07-1.20 (m, 2H), 1.22 (d, 6H, J = 6.9 6
Hz), 1.39 (m, 1H), 1.52-1.74 (m, 6H), 1.77-1.85 (m, 2H), 1.87-1.97 (m, 2H), 2.02 -2.09 Cm, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.55-3.65 (m, 1H), 5.25 -5.32 (m, 1H), 6.19 (d, 1H, J = 8.0 Hz), 6.77 (s, 2H), 6.95 (t, 1H, J = 6.0 Hz). 化合物〖j-53 [化426]
*H-NMR (DMSO-d) 6 : 0.92-1.15 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 1.88-1.95 (m, 4H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.25-3.35 (m, 4H), 3.55-3.65 (m, 1H), 5.80-5.85 (m, 1H), 6.72 (d, 1H, J = 8.0 Hz), 6.80 (d, 1H, J = 8.0 Hz), 6.96 (t, 1H, J = 6.0 Hz).
化合物丨j-54 [化427]
Η lH-NMR (DMSO-d) δ : 0.92-1.20 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), e 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H). 3.58-3.65 (m, 1H), 6.56 (d, 1H, J = 8.0 Hz), 6.90-6.98 (m, 2H), 7.03-7.10 (m, 3H) ,7.15 (t, 1H, J = 8.0 Hz), 6.38 (t, 2H, J = 8.0 Hz). 化合物[j-55
-236- 1376367 [化428]
'H-NMR (DMSO-d ) 8 : 0.92-1.20 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 6.55 (d, 1H, J = 8.0 Hz), 6.90-6.98 (m, 2H), 7.05-7.15 (m, 3H) ,7.21 (t, 2H, J = 8.0 Hz).
化合物Ih56 [化429]
i-NMR (DMS〇-d ) δ : 0.92—1.20 (m, 4H), 1.21 (d, 6H, J = 6·9 Hz), 1‘38 (m, 1H). 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 3.75 (s, 3H), 6.49 (d, 1H, J = 8.0 Hz), 6.87-6.98 (m, 4H), 7.00 -7.07 (m, 3H). 化合物Ij-57 [化430]
'H-NMR (DMSO-d ) 6 : 0.96-1.28 (m, 4H), 1.27 (s, 9H), 1.40 (m, 1H), 1.78-1.88 ( m, 2H), 2.00-2.10 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.60-3.76 (m, 1H), 6.82-6.92 ( m, 2H), 6.96 (d, 1H, J = 7.8 Hz), 7.32 (d, 1H, J = 9.6 Hz). 化合物U-58 [化 431] -237- 1376367
'h-NMR (DMSO-d ) δ : 0.99-1.28 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz). 1.39 (m, 1H), 6 1.78-1.86 (m, 2H), 2.04-2.10 (m, 2H), 2.82 (t, 2H, J = 6.1 Hz), 3.06-3.20 (m, 1H), 3.80-3.96 (m, 1H), 6.71 (d, 1H, J = 9.0 Hz), 6.76-6.86 (m, 1H), 6.90-6.98 (m, 1H) ,7.10 (t, 1H, J =8.1 Hz), 7.39-7.50 (ra, 2H), 7.56 (d, 1H, J = 7.5 Hz), 7.78 (d, 1H, J = 7.5 Hz). 化合物Ij-59 .
[化432]
lH-NMR (DMSO-d ) δ : 0.99-1.28 (m, 4H). 1.27 (s, 9H), 1.40 (m, 1H), 1.80-1.85 ( 6 m, 2H), 2.04-2.09 (m, 2H), 2.91 (t, 2H, J = 6.1 Hz), 3.80-3.96 (m, 1H), 6.70 (d, 1H ,J = 9.0 Hz), 6.81-6.87 (m, 2H), 7.10 (t, 1H, J = 8.1 Hz), 7.39-7.44 (m, 2H), 7.56 ( d, 1H, J = 7.5 Hz), 7.79 (d, 1H, J = 7.5 Hz). 化合物Ij-60 [化433]
'H-NMR (DMSO-d ) δ : 0.97-1.09 (m, 2H), 1.23 (d, 6H, J = 6.9 Hz), 1.31-1.50 (m, 6 2H), 1.82-1.87 (m, 2H), 2.01-2.05 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.11-3.20 (m, 1H), 4.00-4.18 (m, 1H), 6.83 (d, 1H, J = 5.7 Hz), 6.90-7.06 (m, 2H), 7.45 (t, 1H, J =6.9 Hz), 7.59 (t, 1H, J = 8.1 Hz), 7.67 (d, 1H, J = 8.4 Hz), 7.83 (d, 1H, J = 5.7 H z), 8.27 (d, 1H, J= 7.5 Hz). 化合物Ij-61 -238 - 1376367 [化434]
'H-NMR (DMSO-d ) δ : 0.96-1.09 (m, 2H). 1.28 (s, 9H), 1.29-1.50 (m, 2H), 1.82-1.87 (m, 2H), 2.01-2.05 (m, 2H), 2.91 (t, 2H, J = 7.8 Hz), 4.00-4.18 (m, 1H), 6.82-6.89 (m, 2H), 6.97 (d, 1H, J = 7.5 Hz ), 7.45 (t, 1H, J = 7.2 Hz), 7.59 (t, 1H, J = 8. 1 Hz), 7.67 (d, 1H, J = 7.8 Hz), 7.84 (d, 1H, J = 6.0 Hz), 8.27 (d, 1H, J = 8.4 Hz). 化合物Ij-62
[化435]
'H-NMR (DMSO-d ) δ : 0.96-1.14 (m, 2H), 1.18-1.30 (m, 2H), 1.22 (d, 6H, J = 6.6 6
Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.14 (m, 2H)( 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.20 (m, 1H), 3.58-3.70 (m, 1H), 6.95-7.03 (m, 2H), 7.20 (t, 1H, J = 7.5 Hz ), 7.37 (d, 1H, J = 8.1 Hz), 7.64 (d, 1H, J = 7.5 Hz), 7.92 (d, 1H, J = 7.8 Hz).
化合物Ij-63 [化436]
lH-NMR (DMSO-d ) δ : 1.00 (dd, 2H, J = 24.8, 10.6 Hz), 1.15-1.22 (m, 2H), 1.18 6 (t, 3H, J = 7.6 Hz), 1.27 (s, 9H), 1.34-1.40 (m, 1H), 1.81 (d, 2H, J = 11.6 Hz), 2.07 (d, 2H, J = 11.6 Hz), 2.60 (q, 2H, J = 7.6 Hz), 2.89 (t, 2H, J = 6.3 Hz), 3.52-3.63 ( m, 1H), 6.87 (t, 1H, J = 5.8 Hz), 7.04 (d, 1H, J = 7.9 Hz), 7.27 (d, 1H, J = 8.2 Hz), 7.47 ($, 1H), 7.80 (d, 1H, j = 7.6 Hz). 化合物丨j-64 -239- 1376367 [化437] 〇〇 >r^X) 'H-NMR (DMS〇-d) δ : 0.92:i.l0 (m, 2H), 1.12-1.25 (m, 2H), 1.27 (s, 9H), 1.37 ( 6 m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.89 (t, 2H, J = 6.0 Hz), 3.50-3.66 ( m, 1H), 6.87 (t, 1H, J = 5.7 Hz), 7.03 (dd, 1H, J = 8.7, 2.7 Hz), 7.32-7.37 (m, 1H), 7.58 (dd, 1H, J = 8.7, 2.7 Hz), 7.92 (d, 1H, J = 7.2 Hz).
化合物lj-65 [化438]
'H-NMR (DMSO-d ) δ : 1.01 (dd, 2H, J = 24.6, 10.2 Hz), 1.21 (dd, 2H, J = 24.6, 1 6 0.2 Hz), 1.27 (s, 9H), 1.34-1.40 (m, 1H), 1.82 (d, 2H, J = 11.2 Hz), 2.08 (d, 2H, J = 11.2 Hz), 2.89 (t, 2H, J = 6.2 Hz), 3.59-3.65 (m, 1H), 6.87 (t, 1H, J = 5.8 Hz), 7. 21 (dd, 1H, J = 8.6, 2.4 Hz), 7.34 (d, 1H, J = 8.6 Hz), 7.77 (d, 1H, J = 1.8 Hz), 8.0 6 (d, 1H, J = 7.6 Hz).
化合物Ij-66 [化439]
*H-NMR (CDCl) δ : 1.09-1.46 (m, 4H), 1.41 (s, 9H), 1.54 (m, 1H), 1.90-2.00 (m, 3 2H), 2.24-2.34 (m, 2H), 3.09 (t, 2H, J = 6.6 Hz),'3.46-3.60 (m, 1H), 3.99 (t, 1H, J =6.6 Hz), 6.58 (brs, 1H), 7.58(s, 2H), 7.85 (s, 1H). 化合物Ih67 -240- 1376367 [化440]
'H-NMR (DMSO-d ) δ : 0.90-1.30 (m, 4H), 1.27 (s, 9H), 1.30-1.48 (m, 1H), 1.82 ( 6 d, 2H, J = 11.1 Hz), 2.08 (d, 2H, J = 9.6 Hz), 2.89 (t, 2H, J = 6.3 Hz), 3.55-3.70 ( m, 1H), 6.87 (t, 1H, J = 5.7 Hz), 7.17 (m, 1H), 7.41 (d, 1H, J = 8.7 Hz), 7.77 (d, 1 H, J = 1.5 Hz), 8.10 (d, 1H, j = 7.5 Hz). ESI(positive)m/z 466.2 [M+H]+
化合物Ij-68 [化 441]
'H-NMR (DMSO-d ) 5 : 0.90-1.28 (m, 4H), 1.25 (s, 9H), 1.32 (m, 1H), 1.76-1.82 ( 6 m, 2H), 2.00-2.10 (m, 2H), 2.87 (t, 2H, J = 6.6 Hz), 3.50-3.62 (m, 1H), 3.71 (s, 3H ),6.77 (dd, 1H, J = 8.7, 2.7 Hz), 6.84 (t, 1H, J = 5.7 Hz), 7.22-7.28 (m, 2H), 7.66 ( d, 1H, J = 7.2 Hz). 化合物丨j-69 [化442]
'H-NMR (DMSO-d ) δ : 0.94-1.10 (m, 2H), 1.12-1.25 (m, 2H), 1.27 (s, 9H), 1.37 ( m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.90 (t, 2K, J = 6.0 Hz), 3.52-3.68 ( m, 1H), 3.84 (s, 3H), 6.82 (d, 1H, J = 8.1 Hz), 6.88 (t, 1H, J = 5.4 Hz), 6.95 (t, 1H, J = 7.8 Hz), 7.23 (d, 1H, J = 7.8 Hz), 7.83 (d, 1H, J = 7.8 Hz). 化合物丨j-70 [化443] -241 - 1376367
!H-NMR _S〇-d ) δ : 0.98-1.10 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), U7-1.32 (m, 6 2H). 1.40 (m, 1H), 1.76-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.79 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.60-3.78 (m, 1H), 7.03 (t, LH, J = 6.3 Hz), 7.45-7.54 (m ,2H), 8.10 (s, 1H), 8.34 (d, 1H, J = 7.2 Hz). 化合物Ij-71 [化444]
'H-NMR (DMSO-d ) δ : 1.01 (dd, 2H, J = 26.1, 12.3 Hz), 1.16-1.22 (m, 2H), 1.22 6 (d, 6H, J = 6.6 Hz), 1.35-1.41 (m, 1H), 1.70-1.77 (rn, 1H), 1.82 (d, 2H, J = 11.6 Hz ),2.08 (d, 2H, J = 11.6 Hz), 2.81 (t, 2H, J = 6.3 Hz), 3.66-3.72 (m, 1H), 6.99 (t, 1 H, J = 6.3 Hz), 7.23 (dd, 1H, J = 8.1, 4.7 Hz), 7.66 (d, 1H, J = 8.1 Hz), 8.07 (d, 1H ,J = 4.7 Hz), 8.26 (d, 1H, J = 6.3 Hz). 化合物U-72 [化445]
JH-NMR (DMSO-d ) δ : 1.01 (dd, 2H, J = 24.8, 11.3 Hz), 1.18-1.23 (m, 2H), 1.27 6 (s, 9H), 1.36-1.39 (m, 1H), 1.82 (d, 2H, J = 11.5 Hz), 2.08 (d, 2H, J = 11.5 Hz), 2. 89 (t, 2H, J = 6.1 Hz), 3.65-3.73 (m, 1H), 6.87 (t, 1H, J = 5.7 Hz), 7.23 (dd, 1H, J =8.1, 4.8 Hz), 7.66 (d, 1H, J = 7.9 Hz), 8.07 (d, 1H, J = 4.7 Hz), 8.26 (d, 1H, J = 7 .6 Hz). -242- 1376367 化合物Ij-73 [化446]
'H-NMR (CDC1) δ : 1.09-1.46 (m, 4H), 1.41 (s, 9H), 1.55 (m, 1H), 1.92-2.02 (m, 2 3 H), 2.24-2.34 (m, 2H), 3.09 (t, 2H, J = 6.3 Hz), 3.58-3.72 (m, 1H), 3.98 (t, 1H, J = 6.0 Hz), 6.30 (brs,1H), 7.62(d, 1H, J = 8.1 Hz), 7.77 (d, 1H, J = 8.4 Hz).
化合物lj-74 [化447]
H ^-NMR (DMSO-d ) δ : 0.90-1.08 (m, 2H), 1.12-1.40 (m, 3H), 1.25 (s, 9H), 1.76-6 1.86 (m, 2H), 1.98-2.10 (m, 2H), 2.87 (d, 2H, J = 6.3 Hz), 3.40-3.56 (m, 1H), 6.85 (brs, 1H), 6.93 (t, 1H, J = 7.5 Hz), 7.07 (t, 1H, J = 7.5 Hz), 7.20 (d, 1H, J = 7.5 Hz ),7.29 (d, 1H, J = 7.8 Hz), 7.79 (brs, 1H). 化合物Ij-75 [化448]
Cl 'H-NMR (CDCU δ : 1.08-1.26 (m, 2H), 1.36-1.60 (m, 3H), 1.40 (s, 9H), 1.92-2.0 2 (m, 2H), 2.22-2.32 (m, 2H). 3.08 (t, 2H, J = 6.6 Hz), 3.68-3.80 (m, 1H), 4.03 (t, 1H, J = 6.0 Hz). 7.06 (brs, 1H), 7.20-7.36(m, 3H). 化合物lh76 i 化 449] -243 - 1376367
'H-NMR (DMSO-d ) 6 : 1.02 (dd, 2H, J = 25.2, 12.4 Hz), 1.17 (t, 3H, J = 7.1 Hz), 6 1.20 (t, 3H, J = 7.3 Hz), 1.26-1.35 (m, 2H), 1.37-1.42 (m, 1H), 1.83 (d, 2H, J = 11. 6 Hz), 2.05 (d, 2H, J = 11.6 Hz), 2.80 (t, 2H, J = 6.4 Hz), 2.99 (q, 2H, j = 7.3 Hz), 3.65-3.72 (m, 1H), 4.01 (q, 2H, J = 7.1 Hz), 6.32 (d, 1H, J = 7.9 Hz), 6.86-6.94 (m ,2H), 7.01 (t, 1H, J = 6.0 Hz), 7.12 (d, 1H, J = 6.9 Hz), 7.17 (d, 1H, J = 6.8 Hz). 化合物[j-77
[化450]
'H-NMR (DMSO-d ) δ : 1.02 (dd, 2H, J = 24.8, 10.8 Hz), 1.19-1.21 (m, 2H), 1.30 6 (s, 9H), 1.37-1.41 (m, 1H), 1.84 (d, 2H, J = 10.6 Hz), 2.06 (d, 2H, J = 10.6 Hz), 2. 92 (t, 2H, J = 6.3 Hz), 3.50-3.52 (m, 1H), 6.42 (d, 1H, J = 8.1 Hz), 6.83 (d, 1H, J = 7.9 Hz), 6.88-6.92 (m, 2H), 7.11-7.14 (m, 2H), 10.58 (s, 1H). 化合物Ij-78 [化 451]
'H-NMR (DMSO-d ) 5 : 0.97-1.05 (m, 2H), 1.20-1.26 (m, 2H), 1.28 (s, 9H), 1.34- 6 1.38 (m, 1H), 1.84 (d, 2H, J = 11.5 Hz), 2.07 (d, 2H, J = 11.5 Hz), 2.90 (t, 2H, J = 6.1 Hz), 3.47 (s, 3H), 3.63-3.69 (m, 1H), 6.34 (d, 1H, J = 7.6. Hz), 6.87-6.93 (m, 3 H), 7.11 (d, 1H, J = 8.4 Hz), 7.17 (d, 1H, J = 8.4 Hz). 化合物Ij-79 [化452] -244- 1376367
'H-NMR (DMSO-d ) δ : 1.03 (dd, 2H, J = 23.6, 10.8 Hz), 1.18 (t, 3H, J = 7.5 Hz), 1.25-1.34 (m, 2H), 1.29 (s, 9H), 1.37-1.40 (m, 1H), 1.86 (d, 2H, J = 11.7 Hz), 2.07 (d, 2H, J = 11.7 Hz), 2.92 (t, 2H, J = 6.2 Hz), 3.67-3.73 (m, 1H), 4.03 (q, 2H, J = 7.1 Hz), 6.34 (d, 1H, J = 7.9 Hz), 6.87-6.96 (m, 3H), 7.14 (dd, 1H, J = 8.1, 1.2 Hz) ,7.l9(dd, 1H, ] = 8.1, 1.2 Hz).
化合物Ij-80 [化453]
'H-NMR (DMSO-d ) δ : 1.00 (dd, 2H, J = 23.2, 11.9 Hz), 1.19-1.25 (m, 2H), 1.28 6 (s, 9H), 1.33-1.38 (m, 1H), 1.45 (s, 3H), 1.47 (s, 3H). 1.83 (d, 2H, J = 11.1 Hz), 2. 07 (d, 2H, J = 11.1 Hz), 2.90 (t, 2H, J = 6.1 Hz), 3.62-3.70 (m, 1H), 4.57-4.66 (m, 1H), 6.21 (d, 1H, J = 7.9 Hz), 6.82-6.94 (m, 3H), 7.18 (d, 1H, J = 7.6 Hz), 7.31 (d, 1H, J = 7.6 Hz).
化合物U-81 [化454]
化合物丨j-82 [化455]
-245 - 1376367 'H-NMR (DMSO-d ) 8 : 0.90-1.19 (m, 4H), 1.28 (s, 9H), 1.32-1.45 (m, 1H), 1.80 ( 6 d, 2H, J = 11.2 Hz), 1.98 (d, 2H, J = 11.2 Hz), 2.84-2.93 (m, 2H), 3.26 (s, 3H), 3.4 0-3.53 (m, 1H), 6.29 (d, 1H, J = 8.0 Hz), 6.38 (d, 1H. J = 7.2 Hz), 6.86 (s, 1H), 7.3 3 (d, 1H, J = 8.4 Hz). 化合物丨h83 [化456]
化合物丨j-84 [化457]
'H-NMR (DMSO-d ) δ : 0.92-1.20 (m, 4H), 1.18 (t, 3H, J = 7.2 Hz), 1.40 (m, 1H), 6
1.75-1.85 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.60-3.78 (m, 1H), 6.38 (d, 1H, J = 8.1 Hz), 6.67 (s, 1H), 6.72 (d, 1H, J = 5.4 Hz). 7.00 (t, 1H, J = 6.0 Hz), 7.36-7.54 (m, 3H), 7.62 (d, 2H, J = 6.9 Hz), 8.00 (d, 1H, J = 5.4 Hz) 化合物Ij-85 [化458]
'H-NMR (DMSO-d ) δ : 1.00-1.20 (m, 4H), 1.20 (t, 3H, J = 7.2 Hz), 1.43 (m, 1H), 6 1.80-1.88 (m, 2H), 2.03-2.13 (m, 2H), 2.81 (t, 3H, J = 6.0 Hz), 3.00 (q, 2H, J = 7.2 Hz), 3.26 (m, 1H), 6.17 (d, 1H, J = 7.6 Hz), 6.57 (s, 1H), 6.96-7.07 (m, 2H), 7.35 ( dd, 1H, J = 8.4, 4.0 Hz), 8.02 (d, 1H, J = 8.4 Hz), 8.47 (d, 1H, J = 4.0 Hz). -246- 1376367 化合物Ij-86 [化459] 'h-NMR (DMSO-d ) δ : 1.00-1.24 (m, 4H), 1.23 (d, 6H, J = 6.4 Hz), 1.42 (m, 1H), 6
1.80-1.88 (m, 2H), 2.03-2.12 (m, 2H), 2.79-2.87 (m, 2H), 3.16 (m, 1H), 3.27 (m, 1 H), 6.17 (d, 1H, J = 8.0 Hz), 6.57 (s, 1H), 6.99 (d, 1H, J = 8.0 Hz), 7.01 (s, 1H), 7. 35 (dd, 1H, J = 8.0, 4.0 Hz), 8.02 (d, 1H, J = 8.0 Hz), 8.47 (d, 1H, J = 2.8 Hz). 化合物Ij-87 [化460] 0 0 Η
'h-NMR (DMSO-d) δ : 0.95-1.08 (m, 2H)» Γ.11-1.25 (m, 2H), 1.20 (t, 3H, J = 7.2 6
Hz), 1.40 (m, 1H), 1.76-1.86 (m, 2H), 1.97-2.04 (rn, 2H), 2.73-2.82 (m, 2H), 2.99 (q, 2H, J = 7.2 Hz), 3.70 (m, 1H), 6.53 (d, 1H, J = 8.8 Hz), 6.53 (d, 1H, J = 8.8 Hz) ,7.01 (t, 1H, J = 6.0 Hz), 7.58 (d, 1H, J = 3.2 Hz), 7.79 (d, 1H, J = 3.2 Hz), 7.86 ( d, 1H, J = 8.8 Hz), 8.55 (s, 1H).
化合物Ij-88 [化 461]
^-NMR (DMSO-d) δ : 0.92-1.07 (m, 2H), 1.09-1.20 (m, 2H), 1.19 (t, 6H, J = 7.2 6
Hz), 1.39 (m, 1H), 1.75-1.83 (m, 2H), 1.95-2.03 (m, 2H), 2.74-2.81 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.66 (m, 1H), 6.48 (d, 1H, J = 8.4 Hz), 6.60 (d, 1H, J = 7.6 Hz) ,7.00 (t, 1H, J = 5.6 Hz), 7.06 (dd, 1H, J = 4.8, 2.4 Hz), 7.25 (d, 1H, J = 2.4 Hz), 7.37 (d, 1H, J = 4.8 Hz), 7.60 (dd, 1H, J = 8.4, 2.0 Hz), 8.26 (s, 1H). -247- 1376367 化合物Ij-89 [化462]
Hz), 1.39 (m, 1H), 1.76-1.84 (m, 2H), 1.96-2.04 (m, 2H), 2.73-2.81 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.65 (m, 1H), 6.41-6.50 (m, 2H), 7.01 (t, 1H, J = 6.0 Hz). 7.44 (d, 1H, J = 4.0 Hz), 7.58 (m, 1H), 7.59 (s, 1H), 7.68 (d, 1H, J = 8.0 Hz), 8.34 (s, 1 H). 化合物Ij-90 [化 463]
'H-NMRiDMSO-d) δ :0.95-1.08 (m,2H), 1.12-1.25 (m,2H), 1.19 (t>3H,J = 7.2 6
Hz), 1.39 (m, 1H), 1.76-1.86 (m, 2H), 1.94-2.03 (m, 2H), 2.75-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.71 (m, 1H), 6.54 (d, 1H, J = 8.8 Hz), 6.98-7.07 (m, 2H), 7.25 (s, 1H), 7.85 (dd, 1H, J = 8.8, 2.0 Hz), 8.07 (s, 1H), 8.56 (d, 1H, J = 2.0 Hz). 化合物Ij-91 [化464]
'H-NMR (DMSO-d) δ : 0.93-1.07 (m, 2H), 1.11-1.22 (m, 2H), 1.21 (d, 6H, J = 6.8 6
Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 1.95-2.03 (m, 2H), 2.77-2.83 (m, 2H), 3.14 (m. 1H), 3.72 (m, 1H), 6.53 (d, 1H, J = 8.8 Hz), 6.97 (t, 1H, J = 6.0 Hz), 7.02 (d, 1 H, J = 7.6 Hz), 7.25 (s, 1H), 7.84 (dd, 1H, J = 8.8, 2,0 Hz), 8.06 (s, 1H), 8.56 (d, 1 H, J = 2.0 Hz). S ) -248- 1376367 化合物lj-92 [化465]
!H-NMR (DMSO-d ) 8 : 0.92-1.03 (m, 2H), 1.11-1.23 (m, 2H), 1.21 (d, 6H, j = 6.8 6
Hz), 1.37 (m, 1H), 1.75-1.83 (m, 2H), 1.91-1.99 (m, 2H), 2.36-2.42 (m, 2H), 3.12 (m, 1H), 3.70 (m, 1H), 6.49 (d, 1H, J = 9.2 Hz), 6.97 (t, 1H, J = 6.0 Hz), 7.47 (d, 1 H, J = 8.0 Hz), 7.62 (d, 1H, J = 8.0 Hz), 8.36 (s, 1H).
化合物Ij-93 [化466]
'H-NMR (DMSO-d ) 6 : 0.95-1.13 (m, 4H), 1.23 (d, 6H, J = 6.9 Hz), 1.31-1.44 (m, 6 1H), 1.78-1.82 (m, 2H), 2.03-2.06 (m, 2H), 2.76-2.82 (m, 2H), 3.10-3.19 (m, 1H), 3.20-3.25 (m, 4H), 3.58-3.65 (m, 1H), 3.69-3.74 (m, 4H), 6.04 (d, 1H, J = 7.5 Hz) ,6.72 (d, 1H, J = 9.6 Hz), 6.95-6.99 (m, 1H), 7.10 (d, 1H, J = 9.6 Hz).
化合物Ij-94 [化467]
lH-NMR (DMSO-d ) 8 : 0.96-1.42 (m, 5H), 1.22 (d, 6H, J = 6.9 Hz), 1.79-1.83 (m, 2H), 2.03-2.07 (m, 2H), 2.80 (d, 2H, J = 6.3 Hz), 3.10-3.19 (m, 1H), 3.54-3.70 (m ,1H), 3.74 (s, 3H), 6.57-6.64 (m, 3H), 6.72-6.75 (m, 1H), 6.90-7.09 (m, 3H). 7.24 -7.30 (m, 1H). 化合物Ij-95 [化 468] -249- 1376367
'H-NMR (DMSO-d ) δ : 0.93-1.04 (m, 2H), 1.10-1.18 (m, 2H), 1.21 (d, 6H, J = 6.6
Hz), 1.34-1.44 (m, 1H), 1.78-1.87 (m, 2H), 2.02-2.12 (m, 2H), 2.77-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.52-3.70 (mf 1H), 6.64 (d, 1H, J = 8.0 Hz), 6.88-7.06 (m, 5H) ,7.12 (d, 1H, J = 8.0 Hz), 7.37-7.46 (m, 1H). 化合物lj-96 [化469]
'H-NMR (DMSO-d) δ : 0.90-1.04 (m, 2H), 1.05-1.18 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.33-1.43 (m, 1H), 1.75-1.84 (tn, 2H), 1.98-2.08 (m, 2H), 2.76-2.84 (m, 2H), 3.08-3.18 (m, 1H), 3.52-3.64 (m, 1H), 6.55 (d, 1H, J = 8.0 Hz), 6.91-7.00 (m, 2H) ,7.15-7.38 (m, 5H). 化合物IJ-97 [化 470]
'H-NMR (DMSO-d ) 6 : 0.96-1.08 (m, 2H), 1.12-1.25 (m, 2H), 1.19 (t, 3H, J = 7.2 6
Hz), 1.35-1.47 (m, 1H), 1.78-1.87 (m, 2H), 2.02-2.10 (m, 2H), 2.78-2.83 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.70-3.82 (m, 1H), 6.82 (d, 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 8.0 Hz), 7.01 (t, 1H, J = 4.5 Hz), 7.13 (d, 1H, J = 4.0 Hz), 7.43 (d, 1H, J = 4.0 Hz), 7.76 (d, 1H, J = 8.0 Hz). 化合物Ij-98 [化 471] -250- 1376367
'H-NMR (DMSO-d ) 5 : 0.97-1.10 (m, 2H), 1.17-1.28 (m, 2H), 1.19 (t, 3H, J = 7.2 6
Hz), 1.37-1.49 (m, 1H), 1.80-1.88 (m, 2H), 2.04-2.12 (in, 2H), 2.77-2.83 (m, 2H), 2.99 (q, 2H, J = 7.2 Hz), 3.76-3.88 (m, 1H), 6.85 (d, 1H, J = 8.0 Hz), 6.99-7.05 ( m, 2H), 7.61 (s, 1H), 7.90 (d, 1H, J = 8.0 Hz), 8.02 (s, 2H).
化合物Ij-99 [化472]
'H-NMR (DMSO-d ) 5 : 0.98-1.10 (m, 2H), 1.14-1.26 (m, 2H), 1.19 (t, 3H, J = 7.2 6
Hz), 1.37-1.48 (m, 1H), 1.80-1.88 (m, 2H), 2.04-2.13 (m, 2H), 2.77-2.83 (m, 2H), 2.96 (s, 6H), 2.99 (q, 2H, J = 7.2 Hz), 3.76-3.86 (m, 1H), 6.72-6.78 (m, 2H), 6.82 (d, 1H, J = 8.0 Hz), 7.02 (t, 1H, J = 4.5 Hz), 7.18 (d, 1H, J = 8.0 Hz), 7.26 (t, 1H, J =8.0 Hz), 7.34 (s, 1H), 7.74 (d, 1H, J = 8.0 Hz).
化合物I j-100 [化473]
^-NMR (DMSO-d ) δ : 0.98-1.10 (m, 2H), 1.16-1.27 (m, 2H), 1.19 (t, 3H, J = 7.2 6
Hz), 1.37-1.48 (m, 1H), 1.80-1.88 (m, 2H), 2.04-2.13 (m, 2H), 2.77-2.83 (m, 2H), 2.99 (q, 2H, J = 7.2 Hz), 3.76-3.86 (m, 1H), 6.83 (d, 1H, J = 8.0 Hz), 6.89 (d, 1H, J = 8.0 Hz), 7.02 (t„ 1H, J = 4.5 Hz), 7.42-7.50 (m, 3H), 7.53-7.59 (m, 2H). 化合物Ij-l〇l [化474] 1376367
'H-NMR (DMSO-d ) δ : 0.92-1.05 (m, 2H), 1.08-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.36-1.43 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.09 (m, 2H), 2.77-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.56-3.68 (m, 1H), 6.62 (d, 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 8. 0 Hz), 6.98 (t, 1H, J = 4.5 Hz), 7.10-7.15 (m, 3H). 7.43 (d, 2H, J = 8.0 Hz). 化合物Ihl〇2 [化475]
'H-NMR (DMSO-d ) δ : 0.92-1.05 (m, 2H), 1.08-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz〉,1.36-1.43 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.09 (m, 2H), 2.77-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.57-3.68 (m, 1H), 6.65 (d, 1H, J = 8.0 Hz), 6.94 (d, 1H, J = 8. 0 Hz), 6.97 (t, 1H, J = 4.5 Hz), 7.06 (d, 1H, J = 8.0 Hz), 7.13 (d, 1H, J = 8.0 Hz), 7 .18-7.26 (m, 2H), 7.41 (t, 1H, J = 8.0 Hz). 化合物Ij-103 [化476]
'H-NMR (DMSO-d ) 6 : 0.88-1.04 (m, 2H), 1.05-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.33-1.43 (m, 1H), 1.77-1.82 (m, 2H), 2.00-2.07 (m, 2H), 2.76-2.82 (m, 2H), 3.08-3.20 (m, 1H), 3.52-3.64 (m, 1H), 6.57 (d, 1H, J = 8.0 Hz), 6.92-7.00 (m, 2H) ,7.17 (d, 1H, J = 8.0 Hz), 7.23-7.28 (m, 2H), 7.38 (t, 1H, J = 8.0 Hz). 7.56 (d, 1H, J = 8.0 Hz). 化合物lj-104 、[化477] -252- 1376367 'H-NMR (DMSO-d ) δ : 0.96-1.08 (m, 2H), 1.12-1.24 (m, 2H), 1.19 (t, 3H, J = 7.6 6
Hz), 1.35-1.46 (m, 1H), 1.78-1.86 (m, 2H), 2.04-2.12 (m, 2H), 2.76-2.82 (m, 2H), 2.98 (q, 2H, J = 7.6 Hz), 3.67-3.78 (m, 1H), 6.27 (s, 2H), 6.71 (d, 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 8.0 Hz), 7.02 (brs, 1H), 7.52 (s, 2H), 7.67 (d, 1H, J = 8.0 Hz). 化合物Ij-105 [化478]
'H-NMR (DMSO-d ) 3 : 0.96-1.08 {m, 2H), 1.13-1.25 (m, 2H), 1.19 (t, 3H, J = 7.6 6
Hz), 1.35-1.46 (m, 1H), 1.78-1.87 (m, 2H), 2.04-2.12 (m, 2H), 2,76-2.83 (m, 2H), 2.99 (q, 2H, J = 7.6 Hz), 3.72-3.82 (m, 1H), 6.82 (d, 1H, J = 8.0 Hz), 6.85 (d, 1H, J = 8.0 Hz), 7.03 (t, 1H, J = 4.5 Hz), 7.12 (t, 1H, J = 4.0 Hz), 7.51 (d, 1H, J = 4.0 Hz), 7.56 (d, 1H, J = 4.0 Hz), 7.76 (d, 1H, J = 8.0 Hz). 化合物lj-106 [化479]
'H-NMR (DMSO-d ) δ : 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.33-1.45 (m, 1H), 1.76-1.85 (m, 2H), 2.02-2.08 (m, 2H), 2.76-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.57-3.67 (m, 1H), 6.63 (d, IH, J = 8.0 Hz), 6.92-7.00 (m, 3H) ,7.13 (d, 1H, J = 8.0 Hz), 7.29-7.36 (m, 1H), 7.42-7.50 (m, 1H). 化合物Ij-107 [化480]
-253 - 1376367
'H-NMR (DMSO-d ) δ : 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.33-1.43 (m, 1H), 1.75-1.83 (m, 2H), 1.98-2.06 (τη, 2H), 2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.52-3.63 (m, 1H), 6.57 (d, 1H. J = 8.0 Hz), 6.93 (d, 1H, J = 8. 0 Hz), 6.97 (t, 1H, J = 4.5 Hz), 7.12 (t, LH, J = 4.0 Hz), 7.19 (d, 1H, J = 8.0 Hz), 7 .33-7.47 (m, 2H).
化合物 [化 481]
'H-NMR (DMSO-d ) δ : 0.88-1.02 (m, 2H), 1.07-1,20 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.33-1.43 (m, 1H), 1.75-1.83 (m, 2H), 1.98-2.07 (m, 2H), 2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.54-3.63 (m, 1H), 6.63 (d, 1H, J = 8.0 Hz), 6.93-7.00 (m, 2H) ,7.14 (t, 1H, J = 8.0 Hz), 7.20-7.37 (m, 3H). 化合物丨j-109 [化482]
'H-NMR (DMSO-d ) 8 : 0.82-1.05 (m, 2H), 1.05-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.32-1.43 (m, 1H), 1.76-1.83 (m, 2H), 2.00-2.08 (m, 2H), 2.29 (s, 3H), 2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.56-3.66 (m, 1H), 6.55 (d, 1H, J = 8.0 Hz), 6.90 (d, 1H, J = 8.0 Hz), 6.93-7.00 (m, 3H), 7.05 (d, 1H, J = 8.0 Hz), 7.17 (d, 2H, J = 8. 0 Hz). 化合物[j-110 [化483] -254- 1376367
'H-NMR (DMSO-d) δ : 0.91-1.19 (m, 4H), 1.28 (s, 9H), 1.32-1.43 (m, 1H), 1.80 ( 6 d, 2H, J = 12.0 Hz), 2.07 (d, 2H, J = 12.0 Hz), 2.88 (t, 2H, J = 6.4 Hz), 3.16-3.27 ( m. 1H), 5.47 (d, 1H, J = 7.6 Hz), 5.80 (s, 1H), 6.S3 (d, 1H, J = 6.0 Hz), 7.15-7.40 ( m, 3H)f 7.75 (t, 1H, J = 8.4 Hz), 7.86 (s, 1H). 化合物丨j-111 [化 484]
!H-NMR (DMSO-d ) δ : 0.91-1.19 (m, 4H), 1.21 (d, 6H. J = 6.9 Hz), 1.32-1.43 (m, 1H), 1.76-1.82 (m, 2H), 2.02-2.12 (m, 2H), 2.77-2.83 (m, 2H), 3.08-3.27 (m, 2H), 5.48 (d, 1H, J = 8.1 Hz), 5.80 (d, 1H, J = 2.7 Hz), 6.95 (t, 1H, J = 6.0 Hz), 7.15-7. 39 (m, 3H), 7.75 (td, 1H, J = 8.4, 1.8 Hz), 7.86 (t, 1H, J = 2.7 Hz). 化合物Ij-112 [化 485]
'H-NMR (DMSO-d) δ : 0.91-1.19 (m, 4H), 1.18 (t, 3H, J = 7.2 Hz), 1.30-1.45 (m, 6 1H>, 1.76-1.82 (m, 2H), 2.02-2.12 (m, 2H), 2.77-2.83 (m, 2H), 2.98 (q, 2H, J = 7. 2 Hz) 3.10-3.30 (in, 1H), 5.48 (d, 1H, J = 7.8 Hz), 5.80 (d, 1H, J = 2.7 H2), 6.99 (t, 1H, J = 6.0 Hz), 7.15-7.40 (m, 3H), 7.75 (td, 1H, J = 8.4, 1.8 Hz), 7.86 (t, 1H, J = 2.7 Hz). 化合物Ij~113 [化486] -255 - 1376367
化合物Ij-114 [化487]
化合物lj-115 [化488]
'H-NMR (DMSO-d ) δ : 0.92-1.19 (m, 4Η), 1.19 (t, 3H, J = 7.2 Hz), 1.30-1.45 (m, 6 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.74-2.82 (m, 2H), 2.98 (q, 2H, J = 7. 2 Hz) 3.15-3.30 (m, 1H), 5.53 (d, 1H, J = 8.1 Hz), 5.80 (d, 1H, J = 2.4 Hz), 6.92 (t, 1H, J = 8.4 Hz), 7.01 (t, 1H, J = 6.0 Hz), 7.37-7.43 (m, 3H), 8.21 (d, 1H, J = 2.4 Hz). 化合物Ij-116 [化489]
化合物Ij-117 [化 490]
化合物Ij-118 [化 491] -256- 1376367
'H-NMR (DMSO-d ) δ : 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.30-1.45 (ra, 6 1H), 1.75-1.86 (m, 2H), 2.02-2.12 (m, 2H), 2.74-2.83 (m, 2H), 2.97 (q, 2H, J = 7.5 Hz) 3.13-3.30 (m, 1H), 5.38 (d, 1H, J = 8.4 Hz), 5.75 (d, 1H, J = 2.7 Hz), 6.99 (t, 1H, J = 6.3 Hz), 7.18-7.28 (m, 2H), 7.63-7.70 (m. 2H), 8.11 (d, 1H, J = 2.7 Hz). 化合物Ij-119
[化492]
lH-NMR (DMSO-d ) δ : 0.88-1.19 (m, 4H), 1.18 (t, 3H, J = 7.5 Hz), 1.28-1.45 (m, 6 1H), 1.73-1.83 (m, 2H), 2.02-2.13 (m, 2H), 2.73-2.81 (m, 2H), 2.95 (q, 2H, J = 7. 5 Hz) 3.12-3.30 (m, 1H), 5.36 (d, 1H, J = 7.5 Hz), 5.76 (d, 1H, J = 2.4 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.30 (td, 1H, J = 7.5, 1.8 Hz), 7.42 (td, 1H, J = 7.8, 1.5 Hz), 7.53 -7.60 (m, 2H), 7.84 (d, 1H, J = 2.7 Hz). 化合物Ij-120 [化493]
'H-NMR (DMSO-d) 6 : 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.30-1.45 (m, 6 1H), 1.74-1.84 (m, 2H), 2.02-2.10 (m, 2H), 2.75-2.82 (m, 2H), 2.97 (q, 2H, J = 7. 5 Hz) 3.20-3.30 (m, 1H), 5.52 (d, 1H, J = 7.8 Hz), 5.80 (d, 1H, J = 2.4 Hz), 6.99 (t, 1H, J = 6.0 Hz), 7.13 (d, 1H, J = 8.1 Hz), 7.40 (t, 1H, J = 8.1 Hz), 7.62 (d, 1H, J = 8.4 Hz), 7.72 (s, 1H), 8.22 (d, 1H, J = 2.4 Hz). 化合物Ij-121 [化494] -257- 1376367
'H-NMR (DMSO-d ) 8 : 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.30-1.45 (m, 6 1H), 1.74-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.75-2.82 (m, 2H), 2.98 (q, 2H, J = 7. 5 Hz) 3.15-3.30 (m, 1H), 5.47 (d, 1H, J = 8.1 Hz), 5.78 (d, 1H, J = 2.4 Hz), 7.00 (t, 1H, J = 6.0 Hz), 7.43 (d, 2H, J = 7.8 Hz), 7.67 (d, 2H, J = 9.0 Hz), 8.17 (d, 1H, J = 2.4 Hz). 化合物Ij-122 [化495]
'H-NMR (DMS〇-d ) δ : 0.94-1.07 (m, 4H), 1,19 (t, 3H, j = 7.2 Hz), 1.32-1.50 (m, 6 1H), 1.81-1.84 (m, 2H), 1.99-2.07 (m, 2H), 2.77-2.81 (m, 2H), 2.98 (q, 2H, J = 7. 2 Hz), 3.60-3.77 (m, 1H), 7.01-7.05 (m, 1H), 7.22-7.40 (m, 4H), 7.81-7.87 (m, 1H) ,8.02 (s, 1H), 8.36 (s, 1H). 化合物Ij-123 [化496]
'H-NMR (DMSO-d ) δ : 0.95-1.12 (m, 4H), 1.18 (t, 3H, J = 7.2 Hz), 1.32-1.50 (m, 6 1H), 1.77-1.81 (m, 2H), 1.96-1.99 (m, 2H), 2.74-2.78 (m, 2H), 2.97 (q, 2H, J = 7. 2 Hz), 3.54-3.70 (m, 1H), 4.81 (q, 2H, J = 9.0 Hz), 6.50-6.53 (m, 1H), 6.99-7.03 ( m, 1H), 7.50 (d, 1H, J =0.9 Hz) 7.83 (cl, 1H, J = 0.9 Hz). 化合物lj-124 [化497] { c - -258 - 1376367 0 0
H-NMR (DMSO-d ) δ : 0.95-1.23 (m, 4H),1.19 (t, 3H,J = 7.2 Hz), 1.32-1.50 (m, 1H), 1.77-1.81 (m, 2H), 2.03-2.07 (m, 2H), 2.74-2.80 (m, 2H), 2.97 (q, 2H, J = 7. 2 Hz), 3.61-3.73 (m, 1H), 7.00-7.04 (m, 1H), 7.09-7.12 (m, 1H), 7.29-7.37 (m, 2H) ,7.45-7.52 (m, 1H), 7.88-7.94 (m, 2H), 8.04-8.05 (m, 1H). 化合物lj-125 [化498]
'H-NMR (DMSO-d ) δ : 0.94-1.14 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.32-1.50 (m,
B 1H), 1.79-1.83 (m, 2H), 1.97-2.03 (m, 2H), 2.76-2.81 (m, 2H), 2.98 (q, 2H, J = 7. 2 Hz), 3.50-3.63 (m, 1H), 4.43 (q, 2H, J = 9.0 Hz), 7.00-7.04 (m, 1H), 7.13-7.15 ( m, 1H), 7.35 (s, 1H) 7.55 (s, 1H). 化合物【j-126 [化499]
'H-NMR (DMSO-d ) δ : 1.02-1.08 (tn, 2H). 1.17-1.29 (m, 2H), 1.19 (t, 3H, J = 7.5 6
Hz), 1.36-1.43 (m, 1H), 1.79-1.85 (m, 2H), 2.05-2.11 (m, 2H), 2.79 (t, 2H, J = 6.0 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.53-3.62 (m, 1H), 6.98 (t, 1H, J = 7.8 Hz), 7.03 (t, 1H, J = 6.3 Hz), 7.28 (dd, 1H, J = 7.5, 1.2 Hz), 7.63 (dd, 1H, J = 7.5, 1.2 Hz), 8.28 (d, 1H, J = 7.5 Hz). 化合物Ij-127 [化500] -259- 1376367
‘H-NMR (DMSO-d) δ : 0.97-1.05 (m, 2H), 1.18-1.24 (m, 2H),1.16 (t, 3H, J = 7_5 $
Hz), 1.34-1.41 (m, 1H), 1.77-1.81 (m, 2H), 2.02-2.08 (m, 2H), 2.76 (t, 2H, J = 6.0 Hz), 2.96 (q, 2H, J = 7.5 Hz), 3.55-3.64 (m, 1H), 7.00 (t, 1H, J = 7.8 Hz), 7.18 (dd ,1H, J = 8.4, 1.8 Hz), 7.32 (dd, 1H, J = 8.4, 0.6 Hz), 7.74 (d, 1H, J = 1.8 Hz), 8.04 (d, 1H, J = 7.8 Hz). 化合物【j-128
[化 501]
*H-NMR (DMSO-d ) δ : 0.98-1.07 (m, 2H), 1.15-1.26 (m, 8H), 1.32-1.43 (m, 1H), a 1.78-1.84 (m, 2H), 1.98-2.09 (m, 2H), 2.60 (q, 2H, J = 7.5 Hz), 2.78 (t, 2H, J = 6.3 Hz), 2.96 (q, 2H, J = 7.5 Hz), 3.55-3.64 (m, 1H), 6.98-7.05 (m, 2H), 7.27 (dd, 1H, J = 7.8, 1.8 Hz), 7.47 (m, 1H), 7.84 (d, 1H, J =7.5 Hz). 化合物Ij-129 [化502]
'H-NMR (DMSO-d) δ : 0.92-1.15 (m, 2H), 1.15-1.35 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.48 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.78-2.84 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.62-3.80 (m, 1H), 7.02 (t, 1H, J = 6.0 Hz), 7.45 (d, 1H, J = 9.0 Hz), 8.09 (dd, 1H, J = 9.0, 2.4 Hz), 8.68 (d, 1H, J = 2.4 Hz), 8.70 (brs, 1H). 化合物Ij-130 [化503] -260- ' * 1376367 'h-NMR (DMSO-d ) 6 : 0.88-1.10 (m, 2H), 1.15-1.46 (m, 3H), 1.21 (d. 6H, J = 6.6 6
Hz), 1.78-1.88 (m, 2H), 1.98-2.08 (m, 2H), 2.76-2.86 (m, 2H), 3.10-3.20 (m, 1H), 3.46-3.62 (m, 1H), 6.91-6.96 (m, 1H), 7.01 (brs, 1H), 7.64 (d, 1H, J = 7.8 Hz), 8.0 7 (d, 1H, J = 5.1 Hz), 8.35 (d, 1H, J = 7.8 Hz). 化合物丨j-131 [化504]
'H-NMR (DMSO-d ) 5 : 0.92-1.05 (m. 2H), 1.15-1.30 (m, 2H), 1.27 Cs, 9H), 1.30-6 1.43 (m, 1H), 1.77-1.86 (m, 2H), 1.98-2.08 (m, 2H), 2.86-2.92 (m, 2H), 3.35-3.50 (m, 1H)( 3.73 (s, 3H), 6.69 (dd, IH, J = 8.4, 2.0 Hz), 6.86 (t, 1H, J = 6.0 Hz), 7.01 (d, 1H, J = 2.0 Hz), 7.10 (d, 1H, J = 8.4 Hz), 7.62 (d, 1H, J = 7.6 Hz). 化合物Ij-132 [化505]
'H-NMR (DMSO-d ) 8 : 0.92-1.08 (m, 2H), 1.15-1.33 (m, 2H), 1.19 (t, 3H( J = 7.2 6
Hz), 1.33-1.42 (m, 1H), 1.76-1.86 (m, 2H), 1.98-2.08 (m, 2H), 2.76-2.82 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.40-3.58 (rn, 1H), 7.01 (t, 1H, J = 6.0 Hz), 7.13 (d, 1H, J =8.4 Hz), 7.20 (d, 1H, J = 8.4 Hz), 7.49 (s. 1H), 8.01 (d, 1H, J = 7.6 Hz). 化合物lj-133 [化506] -261 - 1376367 'h-NMR (DMSO-d ) δ : 0.96-1.10 (m, 2H), 1.16-1.28 (m, 2H), 1.19 (t, 3H, J = 7.2 6
Hz), 1.33-1.46 (m, 1H), 1.78-1.85 (m, 2H), 2.04-2.12 (m, 2H), 2.76-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.55-3.70 (m, 1H), 7.01 (t, 1H, J = 6.0 Hz), 7.12 (t, 1H, J = 9.6 Hz), 7.48 (d, 1H, J = 7.6 Hz), 8.13 (d, 1H, J = 7.6 Hz). 化合物Ij-134 [化507]
'H-NMR (DMSO-d ) δ : 0.98-1.08 (m, 2H), 1.15-1.26 (m, 2H), 1.21 (d, 6H, J = 6.9 6
Hz), 1.33-1.42 (m, 1H), 1.39-1.84 (m, 2H). 2.05-2.09 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.20 (m, 1H), 3.61-3.75 (m, 1H), 6.98 (t, 1H, J = 6.0 Hz), 7.45 (dd, 1H, J = 7.5, 0.6 Hz), 7.60 (dd, 1H, J = 8.4, 1.5 Hz), 8.17 (d, 1H, J = 1.5 Hz), 8.50 (d, 1 H, J = 7.5 Hz). 化合物U-i35 [化508]
'H-NMR (DMSO-d ) δ : 0.98-1.08 (m, 2H), 1.15-1.25 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.35-1.44 (m, 1H), 1.80-1.84 (m, 2H), 2.05-2.08 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.19 (m, 1H), 3.62-3.78 (m, 1H), 6.98 (t, 1H, J = 6.0 Hz), 7.79 (d, 1H, J =2.1 Hz), 8.10 (d, 1H, J = 2.1, 1.5 Hz), 8.52 (d, 1H, J = 6.9 Hz). 化合物Ij-136 [化509] -262- 1376367
'H-NMR (DMSO-d ) a : 0.97-1.08 (m, 2H), 1.17-1.24 (m, 2H), 1.19 (t, 3H, J = 7.5 6
Hz), 1.33-1.41 (m, 1H), 1.78-1.83 (m, 2H), 2.04-2.08 (m, 2H), 2.78 (t, 2H, J = 6.3 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.56-3.67 (m, 1H), 7.00-7.04 (m, 2H), 7.39 (d, 1H, J = 2.1 Hz), 7.66 (dd, 1H, J = 8.4, 1.8 Hz), 8.14 (d, 1H, J = 7.5 Hz). 化合物丨hi 37 [化 510]
^-NMR (DMS〇-d6) δ : 0.96-1.10 (m, 2H), 1.12-1.28 (m. 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.31 (t, 3H, J = 6.9 Hz), 1.33-1.46 (m, 1H), 1.76-1.85 Cm, 2H), 2.02-2.16 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.22 (m, 1H), 3.50-3.64 (m, 1H), 3.98 (q, 2H, J = 6. 9 Hz), 6.78 (dd, 1H, J = 8.7, 2.7 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.23-7.27 (m, 2H), 7 .68 (d, 1H,J = 7.2 Hz). 化合物【j-138 [化 511]
'H-NMR (DMSO-d ) 6 : 0.94-1.08 (m, 2H), 1.14-1.26 (m, 2H), 1.19 (t, 3H, J = 7.2 6
Hz), 1.33-1.45 (m, 1H), 1.77-1.86 (m, 2H), 2.03-2.12 (m, 2H), 2.76-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.52-3.68 (m, 1H), 6.97-7.06 (m, 2H), 7.34 (dd, 1H, J = 8.4, 4.8 Hz), 7.56 (dd, 1H, J = 8.4, 2.4 Hz), 7.91 (d, 1H, J = 7.6 Hz). 化合物lj-139 [化 512] -263- 1376367
!H-NMR (DMSO-d ) δ : 0.96-1.12 (m, 2H), 1.16-1.32 (m, 2H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.32-1.46 (m, 1H), 1.78-1.86 (m, 2H), 2.02-2.16 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.21 (m, 1H), 3.58-3.76 (m, 1H). 7.00 (t, 1H, J = 6.0 Hz), 8.19-8.23 (m, 2H), 8.52 (d, 1H, J = 6.9 Hz). 化合物Ij-140 [化 513]
'H-NMR (DMSO-d) δ : 0.96-1.12 (m, 2H), 1.12-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6
Hz), 1,32-1.46 (m, 1H), 1.78-1.86 (m, 2H), 2.02-2.16 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.58-3.78 (m, 1H), 7.01 (t, 1H, J = 6.0 Hz), 8.08 (dd, 1H, J = 8 .4, 2.7 Hz), 8.19 (d, 1H, J = 2.7 Hz), 8.38 (d, 1H, J = 7.2 Hz). 化合物Ij-141 [化 514]
*H-NMR (DMSO-d) 5 : 0.97-1.08 (m, 2H), 1.15-1.22 (m, 5H), 1.34-1.42 (m, 1H), 1.78-1.83 (m, 2H), 2.04-2.08 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.53-3.62 (m, 1H), 3.81 (s, 1H), 7.02 (t, 1H, J = 6.3 Hz), 7.41 (s, 1H), 7.53 (s ,1H), 7.88 (d, 1H,J = 7.5 Hz). 化合物丨j-142 [化 515] -264- 1376367
'H-NMR (DMSO-d ) δ : 0.94-1.06 (m, 2H), 1.17-1.30 (m, 2H), 1.18 (t, 3H, J = 7.5 6
Hz), 1.32-1.41 (m, 1H), 1.79-1.84 (m, 2H), 2.01-2.05 (m, 2H), 2.77 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz),.3.41-3.58 (m, 1H), 6.97 (dd, 1H, J = 8.4, 2.4 Hz), 6. 99-7.03 (m, 1H), 7.27 (d, 1H. J = 2.4 Hz), 7.34 (dd, 1H, J = 8.4, 0.3 Hz), 8.07-8.14 (m, 1H).
化合物Ij-143 [化 516]
'H-NMR (DMSO-d ) 5 : 0.94-1.08 (m, 2H), 1.16-1.33 (m, 2H), 1.19 (t, 3H, J = 7.2 6
Hz), 1.33-1.45 (m, 1H), 1.77-1.86 (m, 2H), 2.00-2.08 (m, 2H), 2.74-2.82 (m, 2H), 2_98 (q, 2H, J = 7.2 Hz), 3.38-3.54 (m, 1H), 6.90-7.00 (m, 1H), 7.02 (t, 1H, J = 4. 5 Hz), 7.19 (dd, 1H, J = 8.4, 5.1 Hz), 7.33 (dd, 1H, J. = 8.4, 2.7 Hz), 7.88 (d, 1H, J =7.8 Hz).
化合物I卜144 [化 517]
JH-NMR (DMSO-d ) δ : 0.94-1.06 (m, 2H), 1.19-1.29 (m, 2H), 1.18 (t, 3H, J = 7.2
G
Hz), 1.31-1.41 (m, 1H), 1.79-1.84 (m, 2H), 2.01-2.05 (m, 2H), 2.77 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 6.9 Hz), 3.41-3.57 (m, 1H), 6.71-6.79 (m, 1H), 7.06-7.08 (m ,2H), 7.31 (dd, 1H, J = 8.7, 4.8 Hz), 8.03 (d, 1H, J = 7.8 Hz). 化合物Ij-145 [化 518] -265 - 1376367
'H-NMR (DMSO-d ) δ : 0.95-1.16 (m, 2H), 1.18-1.44 (m, 3H), 1.21 (d, 6H, J = 6.6 6
Hz), 1.78-1.86 (m, 2H), 2.02-2.12 (m, 2H). 2.78-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.40-3.58 (m, 1H), 6.95 (t, 1H, J = 7.8 Hz), 7.01 (brs, 1H), 7.09 (t, 1H, J = 6.9 Hz X 7.22 (d, 1H, J = 6.6 Hz), 7.31 (d, 1H, J = 7.8 Hz), 7.83 (d, 1H, J = 7.8 Hz). 化合物Ij-146 [化 519]
化合物Ij-147 [化520]
化合物Ij-148 [化 521]
試驗例1腦移行性和仲介P-gp之藥物間相互作用 就腦移行性(腦/血漿分配係數;Kp),由小白鼠(Jcl ; C57BL/6J小白鼠,$,7週齡)靜脈內投與(0.5 mg/2 mL/kg)後之血续及腦內濃度來評價。結果,化合物(I-?〗) 之腦 Kp値(Kp C()nt.)爲1.29,呈高腦移行性。 -266- 1376367 GF/C濾過。以50 mM Tris-HCl緩衝液,pH 7.4洗淨後, 以γ計數器求出玻璃濾器上之放射活性。非專一性結合乃 於20 0 ηΜ胜肽ΥΥ之存在下測定,求出對專一性胜肽ΥΥ 結合之被檢化合物之50%抑制濃度(IC5〇値)[參照Inui,a. et al. Endocrinology 131,2090-2096 (1992)] 〇 結果如下表 本發明之化合物抑制對NPY Y5受體之胜肽ΥΥ(與NPY 同屬物質)之結合。也即本化合物對NPY Y5受體呈親和性 .【表1】 化合物編號 結合 IC5〇(nM) Ii-1 0.10 Ii-16 2.5 Ii-34 11 Ii-44 3.4 Ij-1 0.70 Ij-52 0.27 Ij-59 2.5 Ij-66 0.39
試驗例3 CHO細胞中cAMP生成抑制作用 表現人NPY Y5受體之CHO細胞於2.5mM異丁基甲基黄 嘌呤(SIGMA公司)之存在下於37°C培養20分後,添加本 發明化合物而培養5分,其後加50 nMNPY及10 μΜ富科 素(forskolin,Sigma公司)而培養30分.。添加IN HC1而
-268 - 1376367 停止反應後,上清中之 cAMP量用 EIA套組(Amersham LIFE SIENCE公司製)來測定。以對由富科素(forskolin)刺 激之cAMP生成之NPY抑制作用爲10 0%,求出對此NPY 作用之本發明化合物之50%抑制濃度(IC5〇値)。 試驗例4
使用 Y1表現細胞(人神經母細胞瘤,SK-N-MC)膜標品及 Y2表現細胞(人神經母細胞瘤,SMS-ΚΑΝ)膜標品,以與試 驗例2同樣之方法試驗,測定本發明之化合物對NPY Y1 受體及NPY Y2受體之親和性。由其結果確認本發明之化 合物具有NPY Y5受體選擇性。 試驗例5
乙醚麻醉下,由雄性C57BL/6J小白鼠(12-14週齡,25-3 〇g)之外後頭稜至鼻背部沿正中切開皮膚,而露出頭蓋骨 上部。由露出部前頂(bregma)向λ約1 mm後方,由正中 線於左側約1mm之位置用電鑽打開直徑約1mm之穴。於 麻醉覺醒後之小白鼠強制經口投與懸浮於0.5%羥丙基甲基 纖維(信越化學公司製)水溶液或其水溶液之被檢物質,投 與1小時後,由預先開設之頭部開口部用導管注入NPY Y5 受體專一性激動劑([cPph'NPYU’Ala'Aib32, Gln34]-hPancreatic Polypeptide:Tocris 公司製)0.1nmol。注 入2小時後及4小時後測定小白鼠之攝食量,調査0.5 %羥 甲基纖維溶液投與群與被檢物質投與群之間之攝餌量之差 。結果,本發明化合物以6mg/kg之用量投與之場合,與 投與0.5 %羥丙基甲基纖維之場合比較,攝食量顯著地抑制
-269- 1376367 製劑例 如下示製劑例僅爲例示,無任何限定發明之範圍之意圖 製劑例1錠劑 化合物(1-1) 1 5mg 澱粉 1 5mg 乳糖 1 5mg 結晶性纖維 1 9mg 聚乙烯基醇 3mg 蒸飽水 30ml 硬脂酸鈣 3 mg
硬脂酸鈣以外之成分均勻混合,破碎造粒而乾燥,作成 適當大小之顆粒劑。次添加硬脂酸鈣而壓縮成形爲錠劑。 製劑例2膠囊劑 化合物(1-2) 1 0 m g 硬脂酸鎂 1 Omg 乳糖 8 0 m g
均勻混合爲粉末或細粒狀而作成散劑》令其充塡於膠囊 容器而作成膠囊劑。 製劑例3顆粒劑 化合物(1-3) 30g 乳糖 265 g 硬脂酸鎂 5g -270- f ti 、-ta» 1376367 充分混合而壓縮成型後,粉碎、整粒、篩別爲適當大小 之顆粒劑。 【産業上之利用可能性】 由以上之試驗例得知,本發明之化合物呈ΝΡΥ Y5受體 拮抗作用。故本發明之化合物作爲抗肥胖藥及攝食抑制劑 非常有用。 【圖式簡單說明】 無0
C -271
Claims (1)
1376367 I修 修正本 第0961 14901號1具有NPY Y5受體拮抗作用之胺衍生物」 專利案 (2012年7月26曰修正) 十、申請專利範圍: 1.一種如下式⑴化合物、其製藥容許鹽或這些之.溶劑合物, Ri—Y—N—X—N—Z (I) I / R2 R7
[式中R1爲C1-C10烷基, Y 爲-S(0)n-(n 爲 1 或 2), R2爲氫, R7爲氫, X爲 -(CR3R4)p—(^)—(CR5R6)q- (式中R3、R4、R5及R6各自獨立爲氫,
爲C3-C6伸環烷基,ρ及q各自獨立爲0〜2之整數,且ρ 及q不同時爲〇, 但 -0- 不爲
[式中R 14爲可有取代基之苯基]), -nr2-x-可爲 1376367 修正本
爲哌啶二基、哌哜二基、吡啶二基、吡啡二基、吡咯啶二 基或吡咯二基,u爲C1-C10伸烷基或C2-C10伸烯基), Z爲可有取代基之烴環式基或可有取代基之雜環式基(其中 取代基爲選自側氧基、硝基、氰基、鹵素、Cl-CIO烷基、 鹵C1-C10烷基、C1-C10烷氧基C1-C10烷基、C1-C10烷 基雜環cn-cio烷基、芳基、鹵芳基、C1-C10烷基芳基、 鹵C1-C10烷基芳基、C1-C10烷氧基芳基、鹵C1-C10烷 氧基芳基、Cl-C10烷基胺基芳基、雜環基、鹵雜環基、 C1-C10烷基雜環基、經側氧基取代之雜環基、C1-C10烷 氧基、鹵C1-C10烷氧基、芳氧基、鹵芳氧基、C1-C10烷 基芳氧基、C1-C10烷氧基芳氧基、C3-C6環烷氧基、C1-C10烷基胺基、芳基C1-C10烷基胺基、C1-C10烷氧基 C1-C10烷基胺基、C3-C6環烷基胺基 '芳基C1-C10烷基 胺基、雜環羰基、Cl-C10烷基胺甲醯基、及鹵芳基磺醯基 組成之群組中之1個以上的取代基), (但Z不爲3環之稠合雜環式基、可有取代基之噻唑基或可 有取代基之喹唑啉基)] (但X爲 - (CR3R4)p—(^)—(CR5RS)q-其中 -2- 1376367 修正本
爲可有取代基之C3-C6伸環烷基,p爲0,q爲1,且Z爲 可有取代基之嘧啶基之化合物除外)。 2. 如申請專利範圍第1項之化合物、其製藥容許鹽或這些之 溶劑合物,其中Y爲-S(0)2-。 3. 如申請專利範圍第1項之化合物、其製藥容許鹽或這些之 溶劑合物,其中X爲 —(CR3R4)p—(CR5R6)q-
,R1爲碳數2〜10之烷基。 4·如申請專利範圍第3項之化合物、其製藥容許鹽或這些之 I 溶劑合物,其中z爲可有取代基之雜環式基(其中取代基與 申請專利範圍第1項相同)。 5.如申請專利範圍第3項之化合物、其製藥容許鹽或這些之 溶劑合物,其中 -Θ-
爲伸環己基, P及q各自獨立爲0或1,p及q不同時爲0。 6.如申請專利範圍第5項之化合物、其製藥容許鹽或這些之 溶劑合物,其中Z爲可有取代基之苯基、可有取代基之吡 啶基、可有取代基之吡唑基、可有取代基之異噚唑基、可 有取代基之嘮二唑基、可有取代基之嗒啩基、可有取代基 之吡畊基 '可有取代基之嘧啶基或可有取代基之2環之稠 合雜環(其中取代基與申請專利範圍第丨項相同)。 1376367 修正本 7-$D申請專利範圍第1項之化合物、其製藥容許鹽或這些之 溶劑合物,其中X爲 〜(CR3R4)p~~(^)-(CR5R6)q— ’ P + q 爲 1 或 2。 8.如申請專利範圍第7項之化合物、其製藥容許·鹽或這些之 溶劑合物’其中p + q爲1。 9·〜種如下式(I)化合物 '其製藥容許鹽或這些之溶劑合物, R1—Y—N-X—N—Z (I) R2 R7 [式中R1爲Cl -C1 0烷基, Y 爲-s(o)2-, R2爲氫, R7爲氫, X爲 -(CR3R4)p—(^}—(CR5R6)q-(式中R5及R6各自獨立爲氫,其中 爲C3-C6伸環烷基,ρ爲0,q爲1或2), Z爲可有取代基之烴環式基或可有取代基之雜環式基(其中 取代基與申請專利範圍第1項相同)] (但Z爲3環之稠合雜環式基、可有取代基之嘧啶基或可有 取代基之噻唑基之化合物-除外)。 10.如申請專利範圍第9項之化合物、其製藥容許鹽或這些之 溶劑合物,其中Z爲可有取代基之苯基、可有取代基之氫 1376367 修正本 茚基、可有取代基之吡啶基、可有取代基之嗒哜基、可有 取代基之吡唑基、可有取代基之異0f唑基、可有取代基之 噚二唑基或可有取代基之2環之稠合雜環(其中取代基與申 請專利範圍第1項相同)。
11.如申請專利範圍第9項之化合物、其製藥容許鹽或這些之 溶劑合物,其中Z爲可有取代基之異喹啉基、可有取代基 之苯并噻唑基、可有取代基之苯并噚唑基、可有取代基之 苯并吡啶基、可有取代基之苯并嗒哜基、可有取代基之苯 并咪唑基、可有取代基之噻唑并吡啶基、可有取代基之苯 并異嘮唑啉基、可有取代基之苯并噚唑啉基、可有取代基 之苯并噚哜基或可有取代基之苯醯氧基吖庚因基(其中取代 基與申請專利範圍第1項相同)。 12.—種如下式(I)化合物、其製藥容許鹽或這些之溶劑合物 R1 —Y——N-X-N—Z (I) I / R2 R7 [式中R1爲C1-C10烷基, Y 爲-s(o)2-, R2爲氫, R7爲氫, X爲 —(CR3R4)p
(CR5R6)q- (式中R3及R4各自獨立爲氫,其中 -Θ-爲C3-C6伸環烷基,p爲1或2,q爲〇, 1376367 修正本 但 —Qr 不爲
[式中R14爲可有取代基之苯基]), Z爲可有取代基之烴環式基或可有取代基之雜環式基] (但Z爲3環之稠合雜環式基、可有取代基之噻唑基或可有 取代基之喹唑啉基之化合物除外)》 13.如申請專利範圍第12項之化合物、其製藥容許鹽或這些之 溶劑合物,其中Z爲可有取代基之苯基、可有取代基之吡 啶基、可有取代基之嗒哜基、可有取代基之吡哜基、可有 取代基之嘧啶基、可有取代基之喹啉基、可有取代基之異 喹啉基、可有取代基之苯并噻唑基、可有取代基之苯并咪 唑基、可有取代基之苯并噚唑基、可有取代基之噻唑并吡 啶基、可有取代基之嘮唑并吡啶基或可有取代基之吡唑基( 其中取代基與申請專利範圍第1項相同)。 14·~種如下式⑴化合物、其製藥容許鹽或這些之溶劑合物, R1—Υ——Ν-Χ—Ν—Ζ (I) I / R2 R7 [式中R1爲Cl -C1 0烷基, Υ 爲-s(o)2-, 1376367 修正本 - (CR3R4)p-(^}—(CR5R6)q- (式中R3及R4各自獨立爲氫,其中
爲C 3 - C 6伸環烷基.,.p爲1 ·或2,q爲0-), Z爲可有取代基之苯基、可有取代基之吡啶基、可有取代 基之嗒畊基、可有取代基之吡畊基、可有取代基之嘧啶基 、可有取代基之喹啉基、可有取代基之異喹啉基、可有取 φ 代基之苯并噻唑基、可有取代基之苯并咪唑基、可有取代 基之苯并噚唑基、可有取代基之噻唑并吡啶基、可有取代 基之嘮唑并吡啶基或可有取代基之吡唑基(其中取代基與申 請專利範圍第1項相同)]» — 15.如申請專利範圍第14項之化合物、其製藥容許鹽或這些之 溶劑化物,其中Z爲可有取代基之吡啶基、可有取代基之 苯并唾唑基、可有取代基之苯并噚唑基、或可有取代基之 噻唑并吡啶基(其中取代基與申請專利範圍第1項相同)。 φ 16.如申請專利範圍第14項之化合物、其製藥容許鹽或這些之 溶劑化物,其中P爲1。 1 7.如申請專利範圍第1 5或1 6項之化合物、其製藥容許鹽或 這些之溶劑化物,其中Z爲可有取代基之苯并噻唑基或可 有取代基之苯并噚唑基(其中取代基爲(1)鹵素;(3)氰基; (4)硝基;或(6)各自可經鹵素敢代之(i)羥基、(ii)Cl-CIO烷 基或(iv)Cl-ClO烷氧基)。 18.—種醫藥組成物,其係以如申請專利範圍第1至17項中任 一項之化合物、其製藥容許鹽或這些之溶劑合物爲有效成 修正本 &376367 分。 19. 一種ΝΡΥ Y5受體拮抗劑,其係以如申請專利範圍第1至 17項中任一項之化合物、其製藥容許鹽或這些之溶劑合物 爲有效成分。 2 0.—種如下式化合物、其鹽或這些之溶劑合物,
—NH? (式中R1爲乙基或第三丁基)。
21.—種如下式化合物、其鹽或這些之溶劑合物
(式中R1爲乙基、異丙基或第三丁基)。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006124762 | 2006-04-28 | ||
JP2006219606 | 2006-08-11 | ||
JP2007045587 | 2007-02-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200811091A TW200811091A (en) | 2008-03-01 |
TWI376367B true TWI376367B (en) | 2012-11-11 |
Family
ID=38655478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096114901A TWI376367B (en) | 2006-04-28 | 2007-04-27 | An amine derivative as a npy y5 receptor antagonist |
Country Status (14)
Country | Link |
---|---|
US (2) | US9150507B2 (zh) |
EP (1) | EP2017261A4 (zh) |
JP (3) | JP4528901B2 (zh) |
KR (1) | KR101441146B1 (zh) |
AU (1) | AU2007244358B2 (zh) |
BR (1) | BRPI0710950A2 (zh) |
CA (1) | CA2650683A1 (zh) |
MX (1) | MX2008013511A (zh) |
NO (1) | NO20084983L (zh) |
NZ (1) | NZ572381A (zh) |
RU (1) | RU2011129383A (zh) |
TW (1) | TWI376367B (zh) |
WO (1) | WO2007125952A1 (zh) |
ZA (1) | ZA200907457B (zh) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1249233E (pt) | 1999-11-26 | 2008-10-21 | Shionogi & Co | Antagonistas de y5 de npy |
EP2058305A4 (en) | 2006-08-30 | 2010-09-22 | Shionogi & Co | UREA DERIVATIVE |
WO2008026563A1 (fr) | 2006-08-30 | 2008-03-06 | Shionogi & Co., Ltd. | Dérivé d'hydrazine amide |
AU2007292302A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing PARP inhibitors and uses thereof |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
SA08290668B1 (ar) * | 2007-10-25 | 2012-02-12 | شيونوجي آند كو.، ليمتد | مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها |
CL2009000904A1 (es) | 2008-04-21 | 2010-04-30 | Shionogi & Co | Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende. |
WO2010027002A1 (ja) * | 2008-09-05 | 2010-03-11 | 塩野義製薬株式会社 | Pi3k阻害活性を有する縮環モルホリン誘導体 |
US8653125B2 (en) | 2009-03-05 | 2014-02-18 | Shionogi Co., Ltd. | Cyclohexane derivative having NPY Y5 receptor antagonism |
EP2404902A1 (en) | 2009-03-05 | 2012-01-11 | Shionogi&Co., Ltd. | Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
JP5832420B2 (ja) * | 2009-03-25 | 2015-12-16 | アッヴィ・インコーポレイテッド | 抗ウィルス性化合物およびこの使用 |
JP5131783B2 (ja) * | 2009-04-23 | 2013-01-30 | 塩野義製薬株式会社 | Npyy5受容体拮抗作用を有するアミン誘導体およびその用途 |
US8227618B2 (en) | 2009-04-23 | 2012-07-24 | Shionogi & Co., Ltd. | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof |
JPWO2011065351A1 (ja) | 2009-11-25 | 2013-04-11 | 塩野義製薬株式会社 | シクロヘキサン誘導体の製造方法 |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012147765A1 (ja) * | 2011-04-27 | 2012-11-01 | 塩野義製薬株式会社 | Npy y5受容体拮抗作用を有するベンズイミダゾール誘導体 |
KR101893237B1 (ko) * | 2011-04-27 | 2018-08-29 | 시오노기세야쿠 가부시키가이샤 | Npy y5 수용체 길항 작용을 갖는 5원환 방향족 복소환 유도체 |
US9221760B2 (en) | 2011-05-09 | 2015-12-29 | Van Andel Research Institute | Autophagy inhibitors |
US9238625B2 (en) | 2011-12-30 | 2016-01-19 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives |
CN103304555B (zh) * | 2012-03-08 | 2016-03-30 | 中国医学科学院医药生物技术研究所 | 一组苯-噁唑基衍生物及其制备方法和作为impdh抑制剂的相关应用 |
JP5590587B2 (ja) * | 2012-10-26 | 2014-09-17 | 塩野義製薬株式会社 | Npyy5受容体拮抗作用を有する医薬組成物 |
AR096135A1 (es) | 2013-05-02 | 2015-12-09 | Actelion Pharmaceuticals Ltd | Derivados de la quinolona |
US10351449B2 (en) * | 2015-02-20 | 2019-07-16 | Electrolyzed Innovations, Llc | Production of highly ionized alkaline water using a combination of reducing metals and reductive minerals |
US10815135B2 (en) * | 2015-02-20 | 2020-10-27 | Electrolyzed Innovations, Llc | Production of highly ionized alkaline water using a combination of reducing metals and reductive minerals |
WO2021009212A1 (en) | 2019-07-16 | 2021-01-21 | Idorsia Pharmaceuticals Ltd | Antibacterial quinolone derivatives |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZW4194A1 (en) | 1993-03-29 | 1994-12-21 | Zeneca Ltd | Heterocyclic compounds |
US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
RU2219167C2 (ru) * | 1998-04-29 | 2003-12-20 | Орто-Макнейл Фармасьютикал, Инк. | N-замещенные аминотетралины как лиганды для рецептора y5 нейропептида y, полезные при лечении ожирения и других расстройств |
SE9802206D0 (sv) | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
DE60034783T2 (de) * | 1999-04-22 | 2008-01-31 | H. Lundbeck A/S, Valby | Selektive npy(y5)-antagonisten |
EP1177172A1 (en) | 1999-05-05 | 2002-02-06 | Ortho-McNeil Pharmaceutical, Inc. | 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS |
US6214853B1 (en) * | 1999-06-30 | 2001-04-10 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (bicyclics) |
CA2380866A1 (en) | 1999-06-30 | 2001-01-11 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
DE10027514A1 (de) | 2000-06-06 | 2002-01-03 | Basf Ag | Liganden von Integrinrezeptoren |
PT1249233E (pt) * | 1999-11-26 | 2008-10-21 | Shionogi & Co | Antagonistas de y5 de npy |
NZ531153A (en) | 2001-08-09 | 2005-10-28 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
WO2003070244A1 (en) * | 2002-02-22 | 2003-08-28 | Abbott Laboratories | Antagonist of melanin concentrating hormone and their uses |
TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
EP1679309A4 (en) | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
AU2005214225B2 (en) | 2004-02-19 | 2010-05-20 | Banyu Pharmaceutical Co., Ltd. | Novel sulfone amide derivative |
JPWO2005097738A1 (ja) | 2004-04-06 | 2008-02-28 | 大日本住友製薬株式会社 | 新規スルホンアミド誘導体 |
US7405220B2 (en) | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
CA2572135A1 (en) | 2004-06-24 | 2006-01-05 | Shionogi & Co., Ltd. | Sulfonamide compound |
JP2008505088A (ja) * | 2004-06-29 | 2008-02-21 | アムゲン インコーポレイティッド | ACK1およびLCK活性を調節するピロロ[2,3−d]ピリミジン |
EP1765791A1 (en) * | 2004-07-08 | 2007-03-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Pyrimidine derivatives useful as inhibitors of pkc-theta |
US20090286862A1 (en) | 2004-08-06 | 2009-11-19 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for psychoneurotic disease |
JP2006124387A (ja) | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
US20060293341A1 (en) | 2005-06-23 | 2006-12-28 | Vrej Jubian | Alkyl sulfonamide derivatives |
TW200736237A (en) | 2005-06-23 | 2007-10-01 | Lundbeck & Co As H | Alkyl sulfonamide derivatives |
TW200800979A (en) * | 2006-03-07 | 2008-01-01 | Lundbeck & Co As H | Halogenated sulfonamide derivatives |
WO2008026563A1 (fr) | 2006-08-30 | 2008-03-06 | Shionogi & Co., Ltd. | Dérivé d'hydrazine amide |
EP2058305A4 (en) | 2006-08-30 | 2010-09-22 | Shionogi & Co | UREA DERIVATIVE |
WO2008134228A1 (en) | 2007-04-30 | 2008-11-06 | H. Lundbeck A/S | Benzoxazole compounds |
SA08290668B1 (ar) | 2007-10-25 | 2012-02-12 | شيونوجي آند كو.، ليمتد | مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها |
-
2007
- 2007-04-25 MX MX2008013511A patent/MX2008013511A/es active IP Right Grant
- 2007-04-25 AU AU2007244358A patent/AU2007244358B2/en not_active Ceased
- 2007-04-25 WO PCT/JP2007/058938 patent/WO2007125952A1/ja active Application Filing
- 2007-04-25 EP EP07742373.9A patent/EP2017261A4/en not_active Withdrawn
- 2007-04-25 US US12/226,516 patent/US9150507B2/en not_active Expired - Fee Related
- 2007-04-25 BR BRPI0710950-4A patent/BRPI0710950A2/pt not_active IP Right Cessation
- 2007-04-25 CA CA002650683A patent/CA2650683A1/en not_active Abandoned
- 2007-04-25 NZ NZ572381A patent/NZ572381A/en not_active IP Right Cessation
- 2007-04-25 JP JP2008513237A patent/JP4528901B2/ja not_active Expired - Fee Related
- 2007-04-25 KR KR1020087026246A patent/KR101441146B1/ko active Active
- 2007-04-27 TW TW096114901A patent/TWI376367B/zh active
-
2008
- 2008-11-27 NO NO20084983A patent/NO20084983L/no not_active Application Discontinuation
-
2009
- 2009-07-07 JP JP2009160438A patent/JP2009221230A/ja active Pending
- 2009-10-23 ZA ZA2009/07457A patent/ZA200907457B/en unknown
-
2010
- 2010-05-07 JP JP2010107022A patent/JP5392917B2/ja not_active Expired - Fee Related
- 2010-06-25 US US12/823,568 patent/US9139518B2/en not_active Expired - Fee Related
-
2011
- 2011-07-15 RU RU2011129383/04A patent/RU2011129383A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JPWO2007125952A1 (ja) | 2009-09-10 |
MX2008013511A (es) | 2008-10-28 |
US20100267945A1 (en) | 2010-10-21 |
TW200811091A (en) | 2008-03-01 |
US20100063027A1 (en) | 2010-03-11 |
JP2010174038A (ja) | 2010-08-12 |
JP4528901B2 (ja) | 2010-08-25 |
KR20090007571A (ko) | 2009-01-19 |
JP5392917B2 (ja) | 2014-01-22 |
KR101441146B1 (ko) | 2014-09-17 |
BRPI0710950A2 (pt) | 2012-06-26 |
NZ572381A (en) | 2011-01-28 |
AU2007244358B2 (en) | 2012-06-14 |
US9139518B2 (en) | 2015-09-22 |
RU2011129383A (ru) | 2013-01-20 |
JP2009221230A (ja) | 2009-10-01 |
WO2007125952A1 (ja) | 2007-11-08 |
NO20084983L (no) | 2009-01-28 |
AU2007244358A1 (en) | 2007-11-08 |
ZA200907457B (en) | 2011-12-28 |
EP2017261A4 (en) | 2014-04-02 |
US9150507B2 (en) | 2015-10-06 |
EP2017261A1 (en) | 2009-01-21 |
CA2650683A1 (en) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI376367B (en) | An amine derivative as a npy y5 receptor antagonist | |
TWI246514B (en) | NPYY5 antagonist | |
AU2022279504B2 (en) | Substituted 4-Phenyl Pyridine Compounds As Non-Systemic TGR5 Agonists | |
TW200924740A (en) | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof | |
AU2005297799B2 (en) | 3-carbamoyl-2-pyridone derivative | |
AU729320B2 (en) | Novel para-terphenyl compounds | |
EP0742218B1 (en) | Pyrrolopyridazine derivative | |
AU736414B2 (en) | Novel carboxylic acid derivatives, their preparation and use as mixed eta/etb receptor antagonists | |
NZ319595A (en) | Amino acid derivatives as endothelin antagonists | |
CA3114883A1 (en) | Matriptase 2 inhibitors and uses thereof | |
KR101814874B1 (ko) | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 | |
AU2007330190A1 (en) | Aurone derivative-containing composition for diagnosis | |
CZ215690A3 (en) | Derivative of n-acryloylpiperazine or n-acryloylhomopiperazine, process of its preparation and pharmaceutical composition containing thereof | |
JP3143571B2 (ja) | ピロロピリダジン誘導体 | |
AU2012211458A1 (en) | Amine derivative having NPY Y5 receptor antagonist activity | |
WO1999044998A1 (de) | Neue unsymmetrisch substituierte carbonsäurederivate, ihre herstellung und verwendung als gemischte eta/etb-rezeptorantagonisten |